

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (51) International Patent Classification ⁷ : C12N 15/24, C07K 14/54, A61K 38/20, C07K 16/24, G01N 33/68 | A2 | (11) International Publication Number: WO 00/42188 (43) International Publication Date: 20 July 2000 (20.07.00) |
| (21) International Application Number: PCT/US00/00006 (22) International Filing Date: 10 January 2000 (10.01.00) (30) Priority Data: 09/228,822 11 January 1999 (11.01.99) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (72) Inventors: GORMAN, Daniel, M.; 6371 Central Avenue, Newark, CA 94560 (US). BAZAN, J., Fernando; 775 University Drive, Menlo Park, CA 94025 (US). KASTELEIN, Robert, A.; 463 Summit Drive, Redwood City, CA 94062 (US). (74) Agents: THAMPOE, Immac, J. et al.; Schering-Plough Corporation, Patent Department, K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). | | (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i> |
| (54) Title: INTERLEUKIN-17 RELATED MAMMALIAN CYTOKINES. POLYNUCLEOTIDES ENCODING THEM. USES (57) Abstract CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|-------------------------------------------|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

INTERLEUKIN-17 RELATED MAMMALIAN CYTOKINES: POLYNUCLEOTIDES ENCODING THEM. USES

5

FIELD OF THE INVENTION

10 The present invention relates to compositions related to proteins which function in controlling physiology, development, and differentiation of mammalian cells, e.g., cells of a mammalian immune system. In particular, it provides nucleic acids, proteins, antibodies, and mimetics which regulate
15 cellular physiology, development, differentiation, or function of various cell types, including hematopoietic cells.

BACKGROUND OF THE INVENTION

 The immune system of vertebrates consists of a number of
20 organs and several different cell types. Two major cell types include the myeloid and lymphoid lineages. Among the lymphoid cell lineage are B cells, which were originally characterized as differentiating in fetal liver or adult bone marrow, and T cells, which were originally characterized as differentiating
25 in the thymus. See, e.g., Paul (ed. 1998) Fundamental Immunology (4th ed.) Raven Press, New York.

 In many aspects of the development of an immune response or cellular differentiation, soluble proteins known as cytokines play a critical role in regulating cellular
30 interactions. These cytokines apparently mediate cellular activities in many ways. They have been shown, in many cases, to modulate proliferation, growth, and differentiation of hematopoietic stem cells into the vast number of progenitors composing the lineages responsible for an immune response.

35 However, the cellular molecules which are expressed by different developmental stages of cells in these maturation pathways are still incompletely identified. Moreover, the roles and mechanisms of action of signaling molecules which induce, sustain, or modulate the various physiological,

developmental, or proliferative states of these cells is poorly understood. Clearly, the immune system and its response to various stresses had relevance to medicine, e.g., infectious diseases, cancer related responses and treatment, allergic and
5 transplantation rejection responses. See, e.g., Thorn, et al. Harrison's Principles of Internal Medicine McGraw/Hill, New York.

Medical science relies, in large degree, to appropriate recruitment or suppression of the immune system in effecting
10 cures for insufficient or improper physiological responses to environmental factors. However, the lack of understanding of how the immune system is regulated or differentiates has blocked the ability to advantageously modulate the normal defensive mechanisms to biological challenges. Medical
15 conditions characterized by abnormal or inappropriate regulation of the development or physiology of relevant cells thus remain unmanageable. The discovery and characterization of specific cytokines will contribute to the development of therapies for a broad range of degenerative or other conditions
20 which affect the immune system, hematopoietic cells, as well as other cell types. The present invention provides solutions to some of these and many other problems.

SUMMARY OF THE INVENTION

25 The present invention is based, in part, upon the discovery of cDNA clones encoding various cytokine-like proteins which exhibit significant sequence similarity to the cytokine designated CTLA-8.

The invention embraces isolated genes encoding the
30 proteins of the invention, variants of the encoded proteins, e.g., mutations (muteins) of the natural sequences, species and allelic variants, fusion proteins, chemical mimetics, antibodies, and other structural or functional analogs. Various uses of these different nucleic acid or protein
35 compositions are also provided.

In certain nucleic acid embodiments, the invention provides an isolated or recombinant polynucleotide comprising sequence from: a) a mammalian IL-173, which: encodes at least 8 contiguous amino acids of SEQ ID NO: 6, 8, 10, or 12; encodes

at least two distinct segments of at least 5 contiguous amino acids of SEQ ID NO: 6, 8, 10, or 12; or comprises one or more segments at least 21 contiguous nucleotides of SEQ ID NO: 5, 7, 9, or 11; b) a mammalian IL-174, which: encodes at least 8
5 contiguous amino acids of SEQ ID NO: 14, 16, or 18; encodes at least two distinct segments of at least 5 contiguous amino acids of SEQ ID NO: 14, 16, or 18; or comprises one or more segments at least 21 contiguous nucleotides of SEQ ID NO: 14, 16, or 18; c) a mammalian IL-176, which: encodes at least 8
10 contiguous amino acids of SEQ ID NO: 28; encodes at least two distinct segments of at least 5 contiguous amino acids of SEQ ID NO: 28; or comprises one or more segments at least 21 contiguous nucleotides of SEQ ID NO: 27; d) a mammalian IL-177, which: encodes at least 8 contiguous amino acids of SEQ ID NO:
15 30; encodes at least two distinct segments of at least 5 contiguous amino acids of SEQ ID NO: 30; or comprises one or more segments at least 21 contiguous nucleotides of SEQ ID NO: 29. Other embodiments include such a polynucleotide in an expression vector, comprising sequence: a) (IL-173) which:
20 encodes at least 12 contiguous amino acids of SEQ ID NO: 6, 8, 10, or 12; encodes at least two distinct segments of at least 7 and 10 contiguous amino acids of SEQ ID NO: 6, 8, 10, or 12; or comprises at least 27 contiguous nucleotides of SEQ ID NO: 5, 7, 9, 11; b) (IL-174) which: encodes at least 12 contiguous
25 amino acids of SEQ ID NO: 14, 16, or 18; encodes at least two distinct segments of at least 7 and 10 contiguous amino acids of SEQ ID NO: 14, 16, or 18; or comprises at least 27 contiguous nucleotides of SEQ ID NO: 13, 15, or 17; c) (IL-176) which: encodes at least 12 contiguous amino acids of SEQ ID NO:
30 28; encodes at least two distinct segments of at least 7 and 10 contiguous amino acids of SEQ ID NO: 28; or comprises at least 27 contiguous nucleotides of SEQ ID NO: 27; or d) (IL-177) which: encodes at least 12 contiguous amino acids of SEQ ID NO:
35 30; encodes at least two distinct segments of at least 7 and 10 contiguous amino acids of SEQ ID NO: 30; or comprises at least 27 contiguous nucleotides of SEQ ID NO: 29. Certain embodiments will include those polynucleotides: a) (IL-173) which: encode at least 16 contiguous amino acid residues of SEQ ID NO: 6, 8, 10, or 12; encode at least two distinct segments

of at least 10 and 13 contiguous amino acid residues of SEQ ID NO: 6, 8, 10, or 12; comprise at least 33 contiguous nucleotides of SEQ ID NO: 5, 7, 9, or 11; or comprise the entire mature coding portion of SEQ ID NO: 5, 7, 9, or 11; b) (IL-174) which: encode at least 16 contiguous amino acid residues of SEQ ID NO: 14, 16, or 18; encode at least two distinct segments of at least 10 and 13 contiguous amino acid residues of SEQ ID NO: 14, 16, or 18; comprise at least 33 contiguous nucleotides of SEQ ID NO: 13, 15, or 17; or comprise the entire mature coding portion of SEQ ID NO: 13, 15, or 17; c) (IL-176) which: encode at least 16 contiguous amino acids of SEQ ID NO: 28; encode at least two distinct segments of at least 10 and 14 contiguous amino acid residues of SEQ ID NO: 28; comprise at least 33 contiguous nucleotides of SEQ ID NO: 27; or comprise the entire mature coding portion of SEQ ID NO: 27; or d) (IL-177) which: encode at least 16 contiguous amino acids of SEQ ID NO: 30; encode at least two distinct segments of at least 10 and 14 contiguous amino acid residues of SEQ ID NO: 30; comprise at least 33 contiguous nucleotides of SEQ ID NO: 29; or comprise the entire mature coding portion of SEQ ID NO: 29.

Various methods are provided, e.g., making: a) a polypeptide comprising expressing the described expression vector, thereby producing the polypeptide; b) a duplex nucleic acid comprising contacting a described polynucleotide with a complementary nucleic acid, thereby resulting in production of the duplex nucleic acid; or c) a described polynucleotide comprising amplifying using a PCR method.

Alternatively, the invention provides an isolated or recombinant polynucleotide which hybridizes under stringent wash conditions of at least 55° C and less than 400 mM salt to: a) the described (IL-173) polynucleotide which consists of the coding portion of SEQ ID NO: 5, 7, 9, or 11; b) the described (IL-174) polynucleotide which consists of the coding portion of SEQ ID NO: 13, 15, or 17; the described (IL-176) polynucleotide which consists of the coding portion of SEQ ID NO: 27; or d) the described (IL-177) polynucleotide which consists of the coding portion of SEQ ID NO: 29. Other embodiments include such described polynucleotide: a) wherein the wash conditions

are at least 65° C and less than 300 mM salt; or b) which comprises at least 50 contiguous nucleotides of the coding portion of: SEQ ID NO: 5, 7, 9, or 11 (IL-173); SEQ ID NO: 13, 15, or 17 (IL-174); SEQ ID NO: 27 (IL-176); or SEQ ID NO: 29 (IL-177).

Certain kits are provided, e.g., comprising a described polynucleotide, and: a) instructions for the use of the polynucleotide for detection; b) instructions for the disposal of the polynucleotide or other reagents of the kit; or c) both a and b.

Various cells are provided also, e.g., a cell containing the described expression vector, wherein the cell is: a prokaryotic cell; a eukaryotic cell; a bacterial cell; a yeast cell; an insect cell; a mammalian cell; a mouse cell; a primate cell; or a human cell.

Polypeptide embodiments include, e.g., an isolated or recombinant antigenic polypeptide: a) (IL-173) comprising at least: i) one segment of 8 identical contiguous amino acids from SEQ ID NO: 6, 8, 10, or 12; or ii) two distinct segments of at least 5 contiguous amino acids from SEQ ID NO: 6, 8, 10, or 12; c) (IL-174) comprising at least: i) one segment of 8 identical contiguous amino acids from SEQ ID NO: 14, 16, or 18; or ii) two distinct segments of at least 5 contiguous amino acids from SEQ ID NO: 14, 16, or 18; c) (IL-176) comprising at least: i) one segment of 8 identical contiguous amino acids from SEQ ID NO: 28; or ii) two distinct segments of at least 5 contiguous amino acids from SEQ ID NO: 28; or d) (IL-177) comprising at least: i) one segment of 8 identical contiguous amino acids from SEQ ID NO: 30; or ii) two distinct segments of at least 5 contiguous amino acids from SEQ ID NO: 30.

Additional embodiments include such a described polypeptide, wherein: a) the segment of 8 identical contiguous amino acids is at least 14 contiguous amino acids; or b) one of the segments of at least 5 contiguous amino acids comprises at least 7 contiguous amino acids. Other embodiments include a described polypeptide, wherein: A) (IL-173) the polypeptide: a) comprises a mature sequence of SEQ ID NO: 6, 8, 10, or 12; b) binds with selectivity to a polyclonal antibody generated against an immunogen of a mature SEQ ID NO: 6, 8, 10, or 12; c)

comprises a plurality of distinct polypeptide segments of 10 contiguous amino acids of SEQ ID NO: 6, 8, 10, or 12; d) is a natural allelic variant of SEQ ID NO: 6, 8, 10, or 12; e) has a length at least 30 amino acids; or f) exhibits at least two non-overlapping epitopes which are selective for the mature SEQ ID NO: 6, 8, 10, or 12; B) (IL-174) the polypeptide: a) comprises mature SEQ ID NO: 14, 16, or 18; b) binds with selectivity to a polyclonal antibody generated against an immunogen of mature SEQ ID NO: 14, 16, or 18; c) comprises a plurality of distinct polypeptide segments of 10 contiguous amino acids of SEQ ID NO: 14, 16, or 18; d) has a length at least 30 amino acids; or e) exhibits at least two non-overlapping epitopes which are selective for mature SEQ ID NO: 14, 16, or 18; or D) (IL-176) the polypeptide: a) comprises SEQ ID NO: 28; b) binds with selectivity to a polyclonal antibody generated against an immunogen of SEQ ID NO: 28; c) comprises a plurality of distinct polypeptide segments of 10 contiguous amino acids of SEQ ID NO: 28; d) has a length at least 30 amino acids; or e) exhibits at least two non-overlapping epitopes which are selective for primate protein of SEQ ID NO: 28; or D) (IL-177) the polypeptide: a) comprises SEQ ID NO: 30; b) binds with selectivity to a polyclonal antibody generated against an immunogen of SEQ ID NO: 30; c) comprises a plurality of distinct polypeptide segments of 10 contiguous amino acids of SEQ ID NO: 30; d) has a length at least 30 amino acids; or e) exhibits at least two non-overlapping epitopes which are selective for primate protein of SEQ ID NO: 30. Various other embodiments include such a described polypeptide, which: a) is in a sterile composition; b) is not glycosylated; c) is denatured; d) is a synthetic polypeptide; e) is attached to a solid substrate; f) is a fusion protein with a detection or purification tag; g) is a 5-fold or less substitution from a natural sequence; or h) is a deletion or insertion variant from a natural sequence.

Methods of using described polypeptides are also provided, e.g.,: a) to label the polypeptide, comprising labeling the polypeptide with a radioactive label; b) to separate the polypeptide from another polypeptide in a mixture, comprising running the mixture on a chromatography matrix, thereby

separating the polypeptides; c) to identify a compound that binds selectively to the polypeptide, comprising incubating the compound with the polypeptide under appropriate conditions; thereby causing the compound to bind to the polypeptide; or d) to conjugate the polypeptide to a matrix, comprising derivatizing the polypeptide with a reactive reagent, and conjugating the polypeptide to the matrix.

Antibodies are also provided, including a binding compound comprising an antigen binding portion from an antibody which binds with selectivity to such a described polypeptide, wherein the polypeptide: a) (IL-173) comprises the mature polypeptide of SEQ ID NO: 6, 8, 10, or 12; b) (IL-174) comprises SEQ ID NO: 14, 16, or 18; c) (IL-176) comprises SEQ ID NO: 28; or d) (IL-177) comprises SEQ ID NO: 30. Certain embodiments embrace such a binding compound, wherein the antibody is a polyclonal antibody which is raised against the polypeptide of: a) (IL-173) SEQ ID NO: 6, 8, 10, or 12; b) (IL-174) SEQ ID NO: 14, 16, or 18; c) (IL-176) SEQ ID NO: 28; or d) (IL-177) SEQ ID NO: 30. Other embodiments include such a described binding compound, wherein the: a) antibody: i) is immunoselected; ii) binds to a denatured protein; or iii) exhibits a K_d to the polypeptide of at least 30 mM; or b) the binding compound: i) is attached to a solid substrate, including a bead or plastic membrane; ii) is in a sterile composition; or iii) is detectably labeled, including a radioactive or fluorescent label.

Methods are provided, e.g., producing an antigen:antibody complex, comprising contacting a polypeptide comprising sequence from SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 28, or 30 with a described binding compound under conditions which allow the complex to form. Preferably, the binding compound is an antibody, and the polypeptide is in a biological sample.

Kits are provided, e.g., comprising a described binding compound and: a) a polypeptide of SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 28, or 30; b) instructions for the use of the binding compound for detection; or c) instructions for the disposal of the binding compound or other reagents of the kit.

And a method is provided of evaluating the selectivity of binding of an antibody to a protein of SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 28, or 30, comprising contacting a described

antibody to the protein and to another cytokine; and comparing binding of the antibody to the protein and the cytokine.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

5

I. General

The present invention provides DNA sequence encoding various mammalian proteins which exhibit structural features characteristic of cytokines, particularly related to the cytokine designated CTLA-8 (also referred to as IL-17). Rat, mouse, human forms and a viral homolog of the CTLA-8 have been described and their sequences available from GenBank. See Rouvier, et al. (1993) J. Immunol. 150:5445-5456; Yao, et al. (1995) Immunity 3:811-821; Yao, et al. (1995) J. Immunol. 155:5483-5486; and Kennedy, et al. (1996) J. Interferon and Cytokine Res. 16:611-617. The CTLA-8 has activities implicated in arthritis, kidney graft rejection, tumorigenicity, virus-host interactions, and innate immunity; and appears to exhibit certain regulatory functions similar to IL-6. See PubMed (search for IL-17); Chabaud, et al. (1998) J. Immunol. 63:139-148; Amin, et al. (1998) Curr. Opin. Rheumatol. 10:263-268; Van Kooten, et al. (1998) J. Am. Soc. Nephrol. 9:1526-1534; Fossiez, et al. (1998) Int. Rev. Immunol. 16:541-551; Knappe, et al. (1998) J. Virol. 72:5797-5801; Seow (1998) Vet. Immunol. Immunopathol. 63:139-48; and Teunissen, et al. (1998) J. Invest. Dermatol. 111:645-649. A report on the signaling through the NF κ B transcription factor implicates a signal pathway which is used in innate immunity. Shalom-Barak, et al. (1998) J. Biol. Chem. 273:27467-27473.

The newly presented cDNA sequences exhibit various features which are characteristic of mRNAs encoding cytokines, growth factors, and oncogenes. Because the IL-17 is the first member of this newly recognized family of cytokines related to TGF- β , Applicants have designated the family IL-170, with the new members IL-172, IL-173, IL-174, IL-176, IL-177; and IL-171 and IL-175. The fold for this family is predicted to be that of the TGF- β family of cytokines. The TGF- β family of cytokines, and the IL-170 family share the common feature of a cystine knot motif, characterized by a particular spacing of

cysteine residues. See, e.g., Sun and Davies (1995) Ann. Rev. Biophys. Biomolec. Struct. 24:269-291; McDonald, et al. (1993) Cell 73:421-424; and Isaacs (1995) Curr. Op. Struct. Biol. 5:391-395. In particular, the structures suggest a number of conserved cysteines, which correspond to, and are numbered, in human IL-172 (SEQ ID NO: 2), cysteines at 101, 103, 143, 156, and 158. The first cysteine corresponds to the position in Table 7 of human IL-172 (SEQ ID NO: 2) val19. The fourth cysteine corresponds to that at mouse IL-172 (SEQ ID NO: 4) cys141; at human IL-173 (SEQ ID NO: 6) cys119; at mouse IL-174 (SEQ ID NO: 16) cys104; and at human IL-171 (SEQ ID NO: 21) cys50. The disulfide linkages should be cysteines 2 with 5; and 3 with 6; and 1 with 4. Functional significance of the fold similarity suggests formation of dimers for the IL-170 family. As a consequence, IL-170 dimers would bring together two cell surface receptors, through which signal transduction will occur.

These new proteins are designated CTLA-8 related, or generally IL-170, proteins. The natural proteins should be capable of mediating various physiological responses which would lead to biological or physiological responses in target cells, e.g., those responses characteristic of cytokine signaling. Initial studies had localized the message encoding this protein to various cell lines of hematopoietic cells. Genes encoding the original CTLA-8 (IL-17) antigen have been mapped to mouse chromosome 1A and human chromosome 2q31. Murine CTLA-8 was originally cloned by Rouvier, et al. (1993) J. Immunol. 150:5445-5456. The human IL-173 has been mapped to chromosome 13q11. Similar sequences for proteins in other mammalian species should also be available.

Purified CTLA-8, when cultured with synoviocytes, is able to induce the secretion of IL-6 from these cells. This induction is reversed upon the addition of a neutralizing antibody raised against human CTLA-8. Endothelial, epithelial, fibroblast and carcinoma cells also exhibit responses to treatment with CTLA-8. This data suggests that CTLA-8 may be implicated in inflammatory fibrosis, e.g., psoriasis, sclerodermia, lung fibrosis, or cirrhosis. CTLA-8 may also cause proliferation of carcinomas or other cancer cells

inasmuch as IL-6 often acts as a growth factor for such cells. As such, the newly discovered other related family members are likely to have similar or related biological activities.

The descriptions below are directed, for exemplary purposes, to a murine or human IL-170 proteins, but are likewise applicable to related embodiments from other species.

II. Nucleic Acids

Tables 1-6 disclose the nucleotide and amino acid sequences of various new IL-170 family member sequences. The described nucleotide sequences and the related reagents are useful in constructing DNA clones useful for extending the clones in both directions for full length or flanking sequence determination, expressing IL-170 polypeptides, or, e.g., isolating a homologous gene from another natural source. Typically, the sequences will be useful in isolating other genes, e.g., allelic variants, from mouse, and similar procedures will be applied to isolate genes from other species, e.g., warm blooded animals, such as birds and mammals. Cross hybridization will allow isolation of genes from other species. A number of different approaches should be available to successfully isolate a suitable nucleic acid clone from other sources.

Table 1: Nucleotide sequence encoding a primate, e.g., human, IL-172 polypeptide and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. Predicted signal cleavage site indicated, but may be a few residues on either side; putative glycosylation site at residues 55-57. SEQ ID NO: 1 and 2.

| | | |
|----|-----------------------------------------------------------------|-----|
| 35 | ATG GAC TGG CCT CAC AAC CTG CTG TTT CTT CTT ACC ATT TCC ATC TTC | 48 |
| | Met Asp Trp Pro His Asn Leu Leu Phe Leu Leu Thr Ile Ser Ile Phe | |
| | -20 -15 -10 -5 | |
| 40 | CTG GGG CTG GGC CAG CCC AGG AGC CCC AAA AGC AAG AGG AAG GGG CAA | 96 |
| | Leu Gly Leu Gly Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln | |
| | 1 5 10 | |
| 45 | GGG CGG CCT GGG CCC CTG GTC CCT GGC CCT CAC CAG GTG CCA CTG GAC | 144 |
| | Gly Arg Pro Gly Pro Leu Val Pro Gly Pro His Gln Val Pro Leu Asp | |
| | 15 20 25 | |
| | CTG GTG TCA CGG ATG AAA CCG TAT GCC CGC ATG GAG GAG TAT GAG AGG | 192 |
| | Leu Val Ser Arg Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg | |
| | 30 35 40 | |

| | | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | AAC | ATC | GAG | GAG | ATG | GTG | GCC | CAG | CTG | AGG | AAC | AGC | TCA | GAG | CTG | GCC | 240 |
| | Asn | Ile | Glu | Glu | Met | Val | Ala | Gln | Leu | Arg | Asn | Ser | Ser | Glu | Leu | Ala | |
| | 45 | | | | | 50 | | | | | 55 | | | | | 60 | |
| 5 | CAG | AGA | AAG | TGT | GAG | GTC | AAC | TTG | CAG | CTG | TGG | ATG | TCC | AAC | AAG | AGG | 288 |
| | Gln | Arg | Lys | Cys | Glu | Val | Asn | Leu | Gln | Leu | Trp | Met | Ser | Asn | Lys | Arg | |
| | | | | | 65 | | | | | 70 | | | | | 75 | | |
| 10 | AGC | CTG | TCT | CCC | TGG | GGC | TAC | AGC | ATC | AAC | CAC | GAC | CCC | AGC | CGT | ATC | 336 |
| | Ser | Leu | Ser | Pro | Trp | Gly | Tyr | Ser | Ile | Asn | His | Asp | Pro | Ser | Arg | Ile | |
| | | | | 80 | | | | | 85 | | | | | 90 | | | |
| 15 | CCC | GTG | GAC | CTG | CCG | GAG | GCA | CGG | TGC | CTG | TGT | CTG | GGC | TGT | GTG | AAC | 384 |
| | Pro | Val | Asp | Leu | Pro | Glu | Ala | Arg | Cys | Leu | Cys | Leu | Gly | Cys | Val | Asn | |
| | | | 95 | | | | | 100 | | | | | 105 | | | | |
| 20 | CCC | TTC | ACC | ATG | CAG | GAG | GAC | CGC | AGC | ATG | GTG | AGC | GTG | CCG | GTG | TTC | 432 |
| | Pro | Phe | Thr | Met | Gln | Glu | Asp | Arg | Ser | Met | Val | Ser | Val | Pro | Val | Phe | |
| | | 110 | | | | | 115 | | | | | 120 | | | | | |
| | AGC | CAG | GTT | CCT | GTG | CGC | CGC | CGC | CTC | TGC | CCG | CCA | CCG | CCC | CGC | ACA | 480 |
| | Ser | Gln | Val | Pro | Val | Arg | Arg | Arg | Leu | Cys | Pro | Pro | Pro | Pro | Arg | Thr | |
| | 125 | | | | | 130 | | | | | 135 | | | | | 140 | |
| 25 | GGG | CCT | TGC | CGC | CAG | CGC | GCA | GTC | ATG | GAG | ACC | ATC | GCT | GTG | GGC | TGC | 528 |
| | Gly | Pro | Cys | Arg | Gln | Arg | Ala | Val | Met | Glu | Thr | Ile | Ala | Val | Gly | Cys | |
| | | | | 145 | | | | | | 150 | | | | | 155 | | |
| 30 | ACC | TGC | ATC | TTC | TGA | | | | | | | | | | | | 543 |
| | Thr | Cys | Ile | Phe | | | | | | | | | | | | | |
| | | | | 160 | | | | | | | | | | | | | |

35 MDWPHNLLFLLTISIFLGLG QPRSPKSKRKGGQGRPGPLVFGPHQVPLDLVSRMKPYARMEEYERN
 IEEMVAQLRNSSELAQRKCEVNLQLWMSNKRSLSPWGYSINHDPSRIPVDLPEARCLCLGCVNPF
 MQEDRSMVSVEVFSQVPVRRRLCPPPPRTGPCRQRAVMTIAGVCTCIF

40 Particularly interesting segments include, e.g., those
 which begin or end with gln1; val19; pro20; pro22; lys34;
 pro35; leu78; ser79; glu98; ala99; phe110; thr111; cys143; or
 arg144.

45 Nucleotide sequence encoding a rodent, e.g., mouse, IL-172
 polypeptide and predicted amino acid sequence. Also can use
 complementary nucleic acid sequences for many purposes.
 Predicted signal cleavage site indicated, but may be a few
 residues on either side; putative glycosylation site at
 50 residues 53-55. SEQ ID NO: 3 and 4.

| | | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | ATG | GAC | TGG | CCG | CAC | AGC | CTG | CTC | TTC | CTC | CTG | GCC | ATC | TCC | ATC | TTC | 48 |
| | Met | Asp | Trp | Pro | His | Ser | Leu | Leu | Phe | Leu | Leu | Ala | Ile | Ser | Ile | Phe | |
| 55 | -22 | | -20 | | | | -15 | | | | | -10 | | | | | |
| | CTG | GCG | CCA | AGC | CAC | CCC | CGG | AAC | ACC | AAA | GGC | AAA | AGA | AAA | GGG | CAA | 96 |
| | Leu | Ala | Pro | Ser | His | Pro | Arg | Asn | Thr | Lys | Gly | Lys | Arg | Lys | Gly | Gln | |
| | | -5 | | | | | 1 | | | | 5 | | | | 10 | | |
| 60 | GGG | AGG | CCC | AGT | CCC | TTG | GCC | CCT | GGG | CCT | CAT | CAG | GTG | CCG | CTG | GAC | 144 |
| | Gly | Arg | Pro | Ser | Pro | Leu | Ala | Pro | Gly | Pro | His | Gln | Val | Pro | Leu | Asp | |
| | | | | | 15 | | | | 20 | | | | | 25 | | | |
| 65 | CTG | GTG | TCT | CGA | GTA | AAG | CCC | TAC | GCT | CGA | ATG | GAA | GAG | TAT | GAG | CGG | 192 |
| | Leu | Val | Ser | Arg | Val | Lys | Pro | Tyr | Ala | Arg | Met | Glu | Glu | Tyr | Glu | Arg | |
| | | | | 30 | | | | | 35 | | | | | 40 | | | |

| | | |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 5 | AAC CTT GGG GAG ATG GTG GCC CAG CTG AGG AAC AGC TCC GAG CCA GCC Asn Leu Gly Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Pro Ala 45 50 55 | 240 |
| 10 | AAG AAG AAA TGT GAA GTC AAT CTA CAG CTG TGG TTG TCC AAC AAG AGG Lys Lys Lys Cys Glu Val Asn Leu Gln Leu Trp Leu Ser Asn Lys Arg 60 65 70 | 288 |
| 15 | AGC CTG TCC CCA TGG GGC TAC AGC ATC AAC CAC GAC CCC AGC CGC ATC Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile 75 80 85 90 | 336 |
| 20 | CCT GCG GAC TTG CCC GAG GCG CGG TGC CTA TGT TTG GGT TGC GTG AAT Pro Ala Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn 95 100 105 | 384 |
| 25 | CCC TTC ACC ATG CAG GAG GAC CGT AGC ATG GTG AGC GTG CCA GTG TTC Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe 110 115 120 | 432 |
| 30 | AGC CAG GTG CCG GTG CGC CGC CGC CTC TGT CCT CAA CCT CCT CGC CCT Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro Gln Pro Pro Arg Pro 125 130 135 | 480 |
| 35 | GGG CCC TGC CGC CAG CGT GTC GTC ATG GAG ACC ATC GCT GTG GGT TGC Gly Pro Cys Arg Gln Arg Val Val Met Glu Thr Ile Ala Val Gly Cys 140 145 150 | 528 |
| 40 | ACC TGC ATC TTC TGA Thr Cys Ile Phe 155 | 543 |
| 45 | MDWPHSLFLLAISIFLAPSHP RNTKGKRKGQGRPSPLAPGPHQVPLDLVSRVKPYARMEEYERN LGEMVAQLRNSSEPAKKKCEVNLQLWLSNKRSLSPWGYSINHDPSPRIADLPEARCLCLGCVNPF MQEDRSMVSVPVFSQVPVRRRLCPQPPRPGPCRQRVVMETIAVGCTCIF | |

Particularly interesting segments include, e.g., those which begin or end with arg1; ala17; pro18; pro20; his21; lys32; pro33; leu76; ser77; glu96; ala97; phe108; thr109; cys141; or arg142.

| | | |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 50 | TGC GCG GAC CGG CCG GAG GAG CTA CTG GAG CAG CTG TAC GGG CGC CTG Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu 1 5 10 15 | 48 |
| 55 | GCG GCC GGC GTG CTC AGT GCC TTC CAC CAC ACG CTG CAG CTG GGG CCG Ala Ala Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro 20 25 30 | 96 |
| 60 | CGT GAG CAG GCG CGC AAC GCG AGC TGC CCG GCA GGG GGC AGG CCC GCC Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Arg Pro Ala 35 40 45 | 144 |
| 65 | GAC CGC CGC TTC CGG ACG CCC ACC AAC CTG CGC AGC GTG TCG CCC TGG Asp Arg Arg Phe Arg Thr Pro Thr Asn Leu Arg Ser Val Ser Pro Trp 50 55 60 | 192 |
| 70 | GCC TAC AGA ATC TCC TAC GAC CCG GCG AGG TAC CCC AGG TAC CTG CCT Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro 65 70 75 80 | 240 |

| | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| | GAA GCC TAC TGC CTG TGC CGG GGC TGC CTG ACC GGG CTG TTC GGC GAG | 288 |
| | Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu | |
| 5 | GAG GAC GTG CGC TTC CGC AGC GCC CCT GTC TAC ATG CCC ACC GTC GTC | 336 |
| | Glu Asp Val Arg Phe Arg Ser Ala Pro Val Tyr Met Pro Thr Val Val | |
| 10 | CTG CGC CGC ACC CCC GCC TGC GCC GGC GGC CGT TCC GTC TAC ACC GAG | 384 |
| | Leu Arg Arg Thr Pro Ala Cys Ala Gly Gly Arg Ser Val Tyr Thr Glu | |
| 15 | GCC TAC GTC ACC ATC CCC GTG GGC TGC ACC TGC GTC CCC GAG CCG GAG | 432 |
| | Ala Tyr Val Thr Ile Pro Val Gly Cys Thr Cys Val Pro Glu Pro Glu | |
| 20 | AAG GAC GCA GAC AGC ATC AAC T | 454 |
| | Lys Asp Ala Asp Ser Ile Asn | |
| 25 | CADRPEELLEQLYGRLLAAGVLSAFHHTLQLGPREQARNASCPAGGRPADDRFRFTPTNLR | |
| | VSPWAYRISYDPARYPRYLPEAYCLCRGCLTGLFGEEDVRFRSAPVYMPTVVLRRTPACA | |
| | GGRSVYTEAYVTIPVGCTCVPEPEKADDSIN | |
| 30 | Supplementary nucleotide sequence encoding a primate, e.g., human, IL-173 polypeptide and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 7 and 8. | |
| | gcccgggagcag gtggcgacct dgctcagtcg gcttctcggt ccaagtcccc gggctctgg | 58 |
| 35 | atg ctg gta gcc ggc ttc ctg ctg gcg ctg ccg ccg agc tgg gcc gcg | 106 |
| | Met Leu Val Ala Gly Phe Leu Leu Ala Leu Pro Pro Ser Trp Ala Ala | |
| 40 | ggc gcc ccg agg gcg ggc agg cgc ccc gcg ccg ccg ggc tgc gcg | 154 |
| | Gly Ala Pro Arg Ala Gly Arg Arg Pro Ala Arg Pro Arg Gly Cys Ala | |
| 45 | gac ccg ccg gag gag cta ctg gag cag ctg tac ggg cgc ctg gcg gcc | 202 |
| | Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu Ala Ala | |
| 50 | ggc gtg ctc agt gcc ttc cac cac acg ctg cag ctg ggg ccg cgt gag | 250 |
| | Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro Arg Glu | |
| 55 | cag gcg cgc aac gcg agc tgc ccg gca ggg ggc agg ccc gcc gac cgc | 298 |
| | Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Gly Arg Pro Ala Asp Arg | |
| 60 | cgc ttc ccg ccg ccc acc aac ctg cgc agc gtg tgc ccc tgg gcc tac | 346 |
| | Arg Phe Arg Pro Pro Thr Asn Leu Arg Ser Val Ser Pro Trp Ala Tyr | |
| 65 | aga atc tcc tac gac ccg gcg agg tac ccc agg tac ctg cct gaa gcc | 394 |
| | Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro Glu Ala | |
| | tac tgc ctg tgc ccg ggc tgc ctg acc ggg ctg ttc ggc gag gag gac | 442 |
| | Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu Glu Asp | |
| | gtg cgc ttc ccg agc gcc cct gtc tac atg ccc acc gtc gtc ctg cgc | 490 |
| | Val Arg Phe Arg Ser Ala Pro Val Tyr Met Pro Thr Val Val Leu Arg | |

cgc acc ccc gcc tgc gcc ggc ggc cgt tcc gtc tac acc gag gcc tac 538
 Arg Thr Pro Ala Cys Ala Gly Gly Arg Ser Val Tyr Thr Glu Ala Tyr
 130 135 140

5 gtc acc atc ccc gtg gcc tgc acc tgc gtc ccc gag ccg gag aag gac 586
 Val Thr Ile Pro Val Gly Cys Thr Cys Val Pro Glu Pro Glu Lys Asp
 145 150 155

10 gca gac agc atc aac tcc agc atc gac aaa cag ggc gcc aag ctc ctg 634
 Ala Asp Ser Ile Asn Ser Ser Ile Asp Lys Gln Gly Ala Lys Leu Leu
 160 165 170 175

15 ctg ggc ccc aac gac gcg ccc gct ggc ccc tgaggccggg cctgccccgg 684
 Leu Gly Pro Asn Asp Ala Pro Ala Gly Pro
 180 185

gaggtctccc cgccccgcat cccgagggcg ccaagctgga gccgcctgga gggctcggtc 744
 20 ggcgacctct gaagagagtg caccgagcaa accaagtgcc ggagcaccag cgccgccttt 804
 ccattggagac tcgtaagcag cttcatctga cacgggcatc cctggcttgc ttttagctac 864
 aagcaagcag cgtggctgga agctgatggg aaacgaccgc gcacgggcat cctgtgtgag 924
 25 gcccgcatgg agggtttgga aaagttcacg gaggtccctt gaggagcctc tcagatcggc 984
 tgctgcgggt gcaggcgctg actcacgcgt ggggtcctgc caaagagata gggacgcata 1044
 tgctttttta agcaatctaa aaataataat aagtatagcg actatatacc tactttttaa 1104
 30 atcaactgtt ttgaatagag gcagagctat tttatattat caaatgagag ctactctgtt 1164
 acatttctta acatataaac atcgtttttt acttcttctg gtagaatttt ttaaagcata 1224
 35 attggaatcc ttggataaat tttgtagctg gtacactctg gcctgggtct ctgaattcag 1284
 cctgtcaccg atggctgact gatgaaatgg acacgtctca tctgaccac tcttccttcc 1344
 actgaaggtc ttcacgggcc tccaggcctc gtgccgaatt c 1385
 40

MLVAGFLLALPPSWAAGAPRAGRRPARPRGCADRPEELLEQLYGRLAAGVLSAFHHTLQLGPREQARNA
 SCPAGGRPADRRFRPPTNLRVSPWAYRISYDPARYPRYLPEAYCLCRGCLTGFLGEEDVFRFRSAPVYM
 PTVVLRRTACAGGRSVYTEAYVTIPVGCTCVPEPEKADDSINSSIDKQAKLLLPNDAPAGP

45 Important predicted motifs include, e.g., cAMP PK at 50-53, 66-
 69, 72-75, and 113-116; Ca Phos at 82-84 and 166-168; myristoly
 sites at 57-61 and 164-166; phosphorylation sites at 50, 53,
 72, 75, 80, 82, 113, and 116.

50 Nucleotide sequence encoding a rodent, e.g., rat, IL-173
 polypeptide and predicted amino acid sequence. Also can use
 complementary nucleic acid sequences for many purposes. SEQ ID
 NO: 9 and 10.

55 TTT CCG AGA TAC CTG CCC GAA GCC TAC TGC CTG TGC CGA GGC TGT CTG 48
 Phe Pro Arg Tyr Leu Pro Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu
 1 5 10 15

60 ACC GGG CTC TAC GGT GAG GAG GAC TTC CGC TTT CGC AGC GCA CCC GTC 96
 Thr Gly Leu Tyr Gly Glu Glu Asp Phe Arg Phe Arg Ser Ala Pro Val
 20 25 30

65 TTC TCT CCG GCG GTG GTG CTG CGG CGC ACG GCG GCC T 133
 Phe Ser Pro Ala Val Val Leu Arg Arg Thr Ala Ala
 35 40

FPRYLPEAYCLCRGCLTGFLYGEEDFRFRSAPVFSAPVLRRTAA

Supplementary nucleotide sequence encoding a rodent, e.g., mouse, IL-173 polypeptide and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 11 and 12.

| | | |
|----|--------------------------------------------------------------------|------|
| 5 | atg ttg ggg aca ctg gtc tgg atg ctc ctc gtc ggc ttc ctg ctg gca | 48 |
| | Met Leu Gly Thr Leu Val Trp Met Leu Leu Val Gly Phe Leu Leu Ala | |
| | -20 -15 -10 | |
| 10 | ctg gcg ccg ggc cgc gcg gcg gcc gcg ctg agg acc ggg agg cgc ccg | 96 |
| | Leu Ala Pro Gly Arg Ala Ala Gly Ala Leu Arg Thr Gly Arg Arg Pro | |
| | -5 -1 1 5 | |
| 15 | gcg ccg ccg ccg gac tgc gcg gac ccg cca gag gag ctc ctg gag cag | 144 |
| | Ala Arg Pro Arg Asp Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln | |
| | 10 15 20 | |
| 20 | ctg tac ggg ccg ctg gcg gcc gcc gtg ctc agc gcc ttc cac cac acg | 192 |
| | Leu Tyr Gly Arg Leu Ala Ala Gly Val Leu Ser Ala Phe His His Thr | |
| | 25 30 35 40 | |
| 25 | ctg cag ctc ggg ccg cgc gag cag gcg cgc aat gcc agc tgc ccg gcc | 240 |
| | Leu Gln Leu Gly Pro Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala | |
| | 45 50 55 | |
| 30 | ggg gcc agg gcc gcc gac cgc cgc ttc ccg cca ccc acc aac ctg cgc | 288 |
| | Gly Gly Arg Ala Ala Asp Arg Arg Phe Arg Pro Pro Thr Asn Leu Arg | |
| | 60 65 70 | |
| 35 | agc gtg tgc ccc tgg gcg tac agg att tcc tac gac cct gct cgc ttt | 336 |
| | Ser Val Ser Pro Trp Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Phe | |
| | 75 80 85 | |
| 40 | ccg agg tac ctg ccc gaa gcc tac tgc ctg tgc cga ggc tgc ctg acc | 384 |
| | Pro Arg Tyr Leu Pro Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr | |
| | 90 95 100 | |
| 45 | ggg ctc tac ggg gag gag gac ttc cgc ttt cgc agc aca ccc gtc ttc | 432 |
| | Gly Leu Tyr Gly Glu Glu Asp Phe Arg Phe Arg Ser Thr Pro Val Phe | |
| | 105 110 115 120 | |
| 50 | tct cca gcc gtg gtg ctg ccg cgc aca gcg gcc tgc gcg gcc gcc cgc | 480 |
| | Ser Pro Ala Val Val Leu Arg Arg Thr Ala Ala Cys Ala Gly Gly Arg | |
| | 125 130 135 | |
| 55 | tct gtg tac gcc gaa cac tac atc acc atc ccg gtg ggc tgc acc tgc | 528 |
| | Ser Val Tyr Ala Glu His Tyr Ile Thr Ile Pro Val Gly Cys Thr Cys | |
| | 140 145 150 | |
| 60 | gtg ccc gag ccg gac aag tcc gcg gac agt gcg aac tcc agc atg gac | 576 |
| | Val Pro Glu Pro Asp Lys Ser Ala Asp Ser Ala Asn Ser Ser Met Asp | |
| | 155 160 165 | |
| 65 | aag ctg ctg ctg ggg ccc gcc gac agg cct gcg ggg cgc tgatgccggg | 625 |
| | Lys Leu Leu Leu Gly Pro Ala Asp Arg Pro Ala Gly Arg | |
| | 170 175 180 | |
| 70 | gactgccgc catggcccag cttcctgcat gcatcaggtc ccctggccct gacaaaacc | 685 |
| | accccatgat ccctggccgc tgcctaattt ttccaaaagg acagctacat aagctttaaa | 745 |
| | tatatatttc aaagtagaca ctacatatct acaactattt tgaatagtgg cagaaactat | 805 |
| | tttcatatta gtaatttaga gcaagcatgt tgttttttaa cttctttgat atacaagcac | 865 |
| | atcacacaca tcccgttttc ctctagtagg attcttgagt gcataattgt agtgctcaga | 925 |
| | tgaacttcc tctgctgcac tgtgccctgt ccctgagttc ctcctgtggc ccaagcttac | 985 |
| | taagggtgata atgagtgctc cggatctggg cacctaaggt ctccagggtc ctggagaggg | 1045 |

agggatgtgg gggggctagg aaccaagcgc ccctttgttc ttttagcttat ggatggtctt 1105
aactttataa agattaaagt ttttggtggt attctttc 1143

5

MLGTLVWMLLVGFLALAPGRAAGALRTGRRPARPRDCADRPEELLEQLYGRLAAGVLSAFHHTLQLGP
QARNASCPAGGRAADRRFRPPTNLRVSPWAYRISYDPARFPRYLPEAYCLCRGCLTGLYGEEDFRFRSTP
VFSPAVVLRRTAACAGGRSVYAEHYITIPVGCTCVPEPKSADSANSSMDKLLLPADRPAGR.

- 10 Important predicted motifs include, e.g., cAMP PK sites at 50-53, 66-69, 72-75, and 113-116; Ca phosphorylation sites at 82-84, 159-161, and 166-168; myristoly sites at 57-61 and 101-105; N-glycosyl sites at 51-53 and 164-166; phosphorylation sites at 50, 53, 72, 75, 80, 82, 113, and 116; and PKC phosphorylation sites at 4-6

15

Table 3: Nucleotide sequence encoding a primate, e.g., human, IL-174 polypeptide and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 13 and 14.

20

| | | | | | | | | | | | | | |
|------------|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| tgagtgtgca | gtgccagc | atg | tac | cag | gtg | gtt | gca | ttc | ttg | gca | atg | gtc | 51 |
| | | Met | Tyr | Gln | Val | Val | Ala | Phe | Leu | Ala | Met | Val | |
| | | -15 | | | | | | -10 | | | | | |

25

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| atg | gga | acc | cac | acc | tac | agc | cac | tgg | ccc | agc | tgc | tgc | ccc | agc | aaa | 99 |
| Met | Gly | Thr | His | Thr | Tyr | Ser | His | Trp | Pro | Ser | Cys | Cys | Pro | Ser | Lys | |
| -5 | | | -1 | 1 | | | | 5 | | | | | 10 | | | |

30

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| ggg | cag | gac | acc | tct | gag | gag | ctg | ctg | agg | tgg | agc | act | gtg | cct | gtg | 147 |
| Gly | Gln | Asp | Thr | Ser | Glu | Glu | Leu | Leu | Arg | Trp | Ser | Thr | Val | Pro | Val | |
| | | 15 | | | | | 20 | | | | | 25 | | | | |

35

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| cct | ccc | cta | gag | cct | gct | agg | ccc | aac | cgc | cac | cca | gag | tcc | tgt | agg | 195 |
| Pro | Pro | Leu | Glu | Pro | Ala | Arg | Pro | Asn | Arg | His | Pro | Glu | Ser | Cys | Arg | |
| | | 30 | | | | | 35 | | | | | 40 | | | | |

40

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| gcc | agt | gaa | gat | gga | ccc | ctc | aac | agc | agg | gcc | atc | tcc | ccc | tgg | aga | 243 |
| Ala | Ser | Glu | Asp | Gly | Pro | Leu | Asn | Ser | Arg | Ala | Ile | Ser | Pro | Trp | Arg | |
| 45 | | | | | | 50 | | | | 55 | | | | | | |

45

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| tat | gag | ttg | gac | aga | gac | ttg | aac | cgg | ctc | ccc | cag | gac | ctg | tac | cac | 291 |
| Tyr | Glu | Leu | Asp | Arg | Asp | Leu | Asn | Arg | Leu | Pro | Gln | Asp | Leu | Tyr | His | |
| 60 | | | | | 65 | | | | 70 | | | | 75 | | | |

50

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| gcc | cgt | tgc | ctg | tgc | ccg | cac | tgc | gtc | agc | cta | cag | aca | ggc | tcc | cac | 339 |
| Ala | Arg | Cys | Leu | Cys | Pro | His | Cys | Val | Ser | Leu | Gln | Thr | Gly | Ser | His | |
| | | | 80 | | | | | 85 | | | | | 90 | | | |

55

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| atg | gac | ccc | cgg | ggc | aac | tcg | gag | ctg | ctc | tac | cac | aac | cag | act | gtc | 387 |
| Met | Asp | Pro | Arg | Gly | Asn | Ser | Glu | Leu | Leu | Tyr | His | Asn | Gln | Thr | Val | |
| | | 95 | | | | | 100 | | | | | 105 | | | | |

60

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| ttc | tac | cgg | cgg | cca | tgc | cat | ggc | gag | aag | ggc | acc | cac | aag | ggc | tac | 435 |
| Phe | Tyr | Arg | Arg | Pro | Cys | His | Gly | Glu | Lys | Gly | Thr | His | Lys | Gly | Tyr | |
| | | 110 | | | | | 115 | | | | | 120 | | | | |

65

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| tgc | ctg | gag | cgc | agg | ctg | tac | cgt | gtt | tcc | tta | gct | tgt | gtg | tgt | gtg | 483 |
| Cys | Leu | Glu | Arg | Arg | Leu | Tyr | Arg | Val | Ser | Leu | Ala | Cys | Val | Cys | Val | |
| 125 | | | | | 130 | | | | | | 135 | | | | | |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|--|--|--|--|--|--|--|--|--|-----|
| cgg | ccc | cgt | gtg | atg | ggc | tag | | | | | | | | | | 504 |
| Arg | Pro | Arg | Val | Met | Gly | | | | | | | | | | | |
| 140 | | | | | 145 | | | | | | | | | | | |

MYQVVAFLAMVMGTHTYSHWPSCCPKSGQDTSEELLRWSTVPVPPLEPARPNRHPESCRASEDGPL
NSRAISPWRVYELDRDLNRLPDQLYHARCLCPHCVSLQTGSHMDPRGNSELLYHNQTVFYRRPCHGE
KGTHKGICYLERRLYRVSLACVCVRPRVMG

5 Important predicted motifs include, e.g., cAMP PK sites at 21-24, 53-56, and 95-98; Ca phosphorylation sites at 15-17, 16-18, and 45-47; myristoyl sites at 12-16, 115-119, and 118-122; N-glycosyl site at 104-107; phosphorylation sites at 21, 23, 43, 53, 56, 95, 98, and 131; PKC phosphorylation sites at 41-43 and 119-121; and tyrosine kinase site at 95-102.

10 Nucleotide sequence encoding a rodent, e.g., mouse, IL-174 polypeptide and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 15 and 16.

| | | |
|----|-----------------------------------------------------------------------|-----|
| 15 | CGG CAC AGG CGG CAC AAA GCC CGG AGA GTG GCT GAA GTG GAG CTC TGC | 48 |
| | Arg His Arg Arg His Lys Ala Arg Arg Val Ala Glu Val Glu Leu Cys | |
| | 1 5 10 15 | |
| 20 | ATC TGT ATC CCC CCC AGA GCC TCT GAG CCA CAC CCA CCA CGC AGA ATC | 96 |
| | Ile Cys Ile Pro Pro Arg Ala Ser Glu Pro His Pro Pro Arg Arg Ile | |
| | 20 25 30 | |
| 25 | CTG CAG GGC CAG CAA GGA TGG CCT CTC AAC AGC AGG GCC ATC TCT CCT | 144 |
| | Leu Gln Gly Gln Gln Gly Trp Pro Leu Asn Ser Arg Ala Ile Ser Pro | |
| | 35 40 45 | |
| 30 | TGG AGC TAT GAG TTG GAC AGG GAC TTG AAT CGG GTC CCC CAG GAC TGG | 192 |
| | Trp Ser Tyr Glu Leu Asp Arg Asp Leu Asn Arg Val Pro Gln Asp Trp | |
| | 50 55 60 | |
| 35 | TAC CAC GCT CGA TGC CTG TGC CCA CAC TGC GTC ACG CTA CAG ACA GGC | 240 |
| | Tyr His Ala Arg Cys Leu Cys Pro His Cys Val Thr Leu Gln Thr Gly | |
| | 65 70 75 80 | |
| 40 | TCC CAC ATG GAC CCG CTG GGC AAC TCC GTC CCA CTT TAC CAC AAC CAG | 288 |
| | Ser His Met Asp Pro Leu Gly Asn Ser Val Pro Leu Tyr His Asn Gln | |
| | 85 90 95 | |
| 45 | ACG GTC TTC TAC CGG CGG CCA TGC ATG GCG AGG AAG GTA CCC ATC GCC | 336 |
| | Thr Val Phe Tyr Arg Arg Pro Cys Met Ala Arg Lys Val Pro Ile Ala | |
| | 100 105 110 | |
| 50 | GCT ACT GCT TGG AGC GCA GGT CTA CCG AGT CTC CTT GGC TTG TGT GTG | 384 |
| | Ala Thr Ala Trp Ser Ala Gly Leu Pro Ser Leu Leu Gly Leu Cys Val | |
| | 115 120 125 | |
| 55 | TGT GCG GCC CCG GGT CAT GGC TTA GTC ATG CTC ACC ATC TGC CTG AGG | 432 |
| | Cys Ala Ala Pro Gly His Gly Leu Val Met Leu Thr Ile Cys Leu Arg | |
| | 130 135 140 | |
| 60 | TGAATGCCGG GTGGGAGAGA GGGCCAGGTG TACATCACCTGCCAATGCCGG GCCGGGTTCA | 492 |
| | AGCCTGCAAA GCCTACCTGA AGCAGCAGGT CCCGGGACAG GATGGAGACT TGGGGAGAAA | 552 |
| | TCTGACTTTT GCACCTTTTGT GAGCATTTTGT GGAAGAGCAG GTTCGCTTGT GCTGTAGAGA | 612 |
| | TGCTGTTG | 620 |
| | RHRRHKARRVAEVELCICIPPRASEPHPPRRILQGQGWPLNSRAISPWSYELDRDLNRVPQDWYHARC | |
| | LCPHCVTLQTGSHMDPLGNSVPLYHNQTVFYRRPCMARKVPPIATAWSAGLPSSLGLCVCAAPGHGLVM | |
| | LTICLR | |

Supplementary nucleotide sequence encoding a rodent, e.g., mouse, IL-174 polypeptide and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 17 and 18.

5
atg tac cag gct gtt gca ttc ttg gca atg atc gtg gga acc cac acc 48
Met Tyr Gln Ala Val Ala Phe Leu Ala Met Ile Val Gly Thr His Thr
-15 -10 -5 -1

10
gtc agc ttg cgg atc cag gag ggc tgc agt cac ttg ccc agc tgc tgc 96
Val Ser Leu Arg Ile Gln Glu Gly Cys Ser His Leu Pro Ser Cys Cys
1 5 10 15

15
ccc agc aaa gag caa gaa ccc ccg gag gag tgg ctg aag tgg agc tct 144
Pro Ser Lys Glu Gln Glu Pro Pro Glu Glu Trp Leu Lys Trp Ser Ser
20 25 30

20
gca tct gtg tcc ccc cca gag cct ctg agc cac acc cac cac gca gaa 192
Ala Ser Val Ser Pro Pro Glu Pro Leu Ser His Thr His His Ala Glu
35 40 45

25
tcc tgc agg gcc agc aag gat ggc ccc ctc aac agc agg gcc atc tct 240
Ser Cys Arg Ala Ser Lys Asp Gly Pro Leu Asn Ser Arg Ala Ile Ser
50 55 60

30
cct tgg agc tat gag ttg gac agg gac ttg aat cgg gtc ccc cag gac 288
Pro Trp Ser Tyr Glu Leu Asp Arg Asp Leu Asn Arg Val Pro Gln Asp
65 70 75 80

35
ctg tac cac gct cga tgc ctg tgc cca cac tgc gtc agc cta cag aca 336
Leu Tyr His Ala Arg Cys Leu Cys Pro His Cys Val Ser Leu Gln Thr
85 90 95

40
ggc tcc cac atg gac ccg ctg ggc aac tcc gtc cca ctt tac cac aac 384
Gly Ser His Met Asp Pro Leu Gly Asn Ser Val Pro Leu Tyr His Asn
100 105 110

45
cag acg gtc ttc tac cgg cgg cca tgc cat ggt gag gaa ggt acc cat 432
Gln Thr Val Phe Tyr Arg Arg Pro Cys His Gly Glu Glu Gly Thr His
115 120 125

50
cgc cgc tac tgc ttg gag cgc agg ctc tac cga gtc tcc ttg gct tgt 480
Arg Arg Tyr Cys Leu Glu Arg Arg Leu Tyr Arg Val Ser Leu Ala Cys
130 135 140

55
gtg tgt gtg cgg ccc cgg gtc atg gct tagtcatgct caccacctgc 527
Val Cys Val Arg Pro Arg Val Met Ala
145 150

60
ctgaggctga tgcccgggttg ggagagaggg ccagggtgtac aatcaccttg ccaatgctggg 587
ccgggttcaa gccctccaaa gccctacctg aagcagcagg ctcccggggac aagatggagg 647
acttggggag aaactctgac ttttgcactt tttggaagca cttttgggaa ggagcaggtt 707
ccgcttgtgc tgctagagga tgctgtgtgtg gcattttctac tcaggaacgg actccaaagg 767
cctgctgacc ctggaagcca tactcctggc tcttttcccc tgaatcccc aactcctggc 827
acaggcactt tctccacctc tccccctttg ccttttgttg tgtttgtttg tgcattgcaa 887
ctctgcgtgc agccaggtgt aattgccttg aaggatgggt ctgaggtgaa agctgttatc 947
gaaagtgaag agatttatcc aaataaacat ctgtgttt 985

65
MYQAVAFAMIVGTHTVSLRIQEGCSHLPSCCPSKEQEPPEWLKSSASVSPPEPLSHTHAESCRAS
KDGPLNSRAISFWSYELDRDLNRVPQDLYHARCLCPHCVSLQTGSHMDPLGNSVPLYHNQTVFYRRPCH
GEEGTHRRYCLERRLYRVSILACVCVRPRVMA

Important predicted motifs include, e.g., cAMP PK sites at 29-32 and 61-64; Ca phosphorylation sites at 18-20, 53-55, and 67-69; myristoly site at 123-127; N-glycosylation site at 112-114; and phosphorylation sites at 29, 31, 51, 53, 61, 64, 139, and 141; and PKC phosphorylation sites at 2-4, 49-51, and 127-129.

Table 4: Nucleotide sequence encoding a primate, e.g., human, IL-171 under IUPAC code. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 19:

| | | |
|----|-------------------------------------------------------------------|-----|
| | GACACGGATG AGGACCGCTA TCCACAGAAG CTGGCCTTCG CCGAGTGCCT GTGCAGAGGC | 60 |
| 15 | TGTATCGATG CACGGACGGG CCGCGAGACA GCTGCGCTCA ACTCCGTGCG GCTGCTCCAG | 120 |
| | AGCCTGCTGG TGCTGCGCCG CCGGCCCTGC TCCGCGACG GCTCGGGGCT CCCCACACCT | 180 |
| 20 | GGGGCCTTTG CCTTCCACAC CGAGTTCATC CACGTCCCCG TCGGCTGCAC CTGCGTGCTG | 240 |
| | CCCCGTTCAA GTGTGACCGC CAAGGCCGTG GGGCCCTTAG NTGACACCGT GTGCTCCCCA | 300 |
| | GAGGGACCCC TATTTATGGG AATTATGGTA TTATATGCTT CCCACATACT TGGGGTGGC | 360 |
| 25 | ATCCCGNGCT GAGACAGCCC CCTGTTCTAT TCAGCTATAT GGGGAGAAGA GTAGACTTTC | 420 |
| | AGCTAAGTGA AAAGTGNAAC GTGCTGACTG TCTGCTGTCG TNCTACTNAT GCTAGCCCGA | 480 |
| 30 | GTGTTCACTC TGAGCCTGTT AAATATAGGC GGTATGTAC C | 521 |

SEQ ID NO: 20 and 21 are PATENTIN translatable cDNA and polypeptide sequences:

| | | |
|----|-------------------------------------------------------------------|-----|
| 35 | GAC ACG GAT GAG GAC CGC TAT CCA CAG AAG CTG GCC TTC GCC GAG TGC | 48 |
| | Asp Thr Asp Glu Asp Arg Tyr Pro Gln Lys Leu Ala Phe Ala Glu Cys | |
| | 1 5 10 15 | |
| 40 | CTG TGC AGA GGC TGT ATC GAT GCA CGG ACG GGC CGC GAG ACA GCT GCG | 96 |
| | Leu Cys Arg Gly Cys Ile Asp Ala Arg Thr Gly Arg Glu Thr Ala Ala | |
| | 20 25 30 | |
| 45 | CTC AAC TCC GTG CGG CTG CTC CAG AGC CTG CTG GTG CTG CGC CGC CGG | 144 |
| | Leu Asn Ser Val Arg Leu Leu Gln Ser Leu Leu Val Leu Arg Arg Arg | |
| | 35 40 45 | |
| 50 | CCC TGC TCC CGC GAC GGC TCG GGG CTC CCC ACA CCT GGG GCC TTT GCC | 192 |
| | Pro Cys Ser Arg Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala | |
| | 50 55 60 | |
| 55 | TTC CAC ACC GAG TTC ATC CAC GTC CCC GTC GGC TGC ACC TGC GTG CTG | 240 |
| | Phe His Thr Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val Leu | |
| | 65 70 75 80 | |
| 60 | CCC CGT TCA AGT GTG ACC GCC AAG GCC GTG GGG CCC TTA GAT ACC | 288 |
| | Pro Arg Ser Ser Val Thr Ala Lys Ala Val Gly Pro Leu Xaa Asp Thr | |
| | 85 90 95 | |
| 65 | GTG TGC TCC CCA GAG GGA CCC CTA TTT ATG GGA ATT ATG GTA TTA TAT | 336 |
| | Val Cys Ser Pro Glu Gly Pro Leu Phe Met Gly Ile Met Val Leu Tyr | |
| | 100 105 110 | |
| | GCT TCC CAC ATA CTT GGG GCT GGC ATC CCG nGC TGAGACAGCC CCCTGTTCTA | 389 |
| | Ala Ser His Ile Leu Gly Ala Gly Ile Pro Xaa | |
| | 115 120 | |
| | TTCAGCTATA TGGGAGAAG AGTAGACTTT CAGCTAAGTG AAAAGTGCAA CGTGCTGACT | 449 |

| | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| | GTCTGCTGTC GTCCTACTCA TGCTAGCCCG AGTGTTCACT CTGAGCCTGT TAAATATAGG | 509 |
| | CGGTTATGTA CC | 521 |
| 5 | DTDED RYPQKLAF AECLCRGCIDARTGRETAALNSVRLQLSLVLRRRPCSRDGSGLPTPGAF AFHTEFI HVPVGCTCVLPRSSVTAKAVGPLXDTVCSPEGPLFMGIMVLYASHILGAGIPX | |
| 10 | Supplementary nucleotide sequence encoding a primate, e.g., human, IL-171. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 22 and 23: | |
| 15 | gtgtggcctc aggtataaga gcggctgctg ccaggtgcat ggccaggtgc acctgtggga 60 ttgccgccag gtgtgcaggc cgctccaagc ccagcctgcc ccgctgccgc cacc atg 117 Met | |
| 20 | acg ctc ctc ccc ggc ctc ctg ttt ctg acc tgg ctg cac aca tgc ctg 165 Thr Leu Leu Pro Gly Leu Leu Phe Leu Thr Trp Leu His Thr Cys Leu -15 -10 -5 -1 | |
| 25 | gcc cac cat gac ccc tcc ctc agg ggg cac ccc cac agt cac ggt acc 213 Ala His His Asp Pro Ser Leu Arg Gly His Pro His Ser His Gly Thr 1 5 10 15 | |
| 30 | cca cac tgc tac tgc gct gag gaa ctg ccc ctc ggc cag gcc ccc cca 261 Pro His Cys Tyr Ser Ala Glu Glu Leu Pro Leu Gly Gln Ala Pro Pro 20 25 30 | |
| 35 | cac ctg ctg gct cga ggt gcc aag tgg ggg cag gct ttg cct gta gcc 309 His Leu Leu Ala Arg Gly Ala Lys Trp Gly Gln Ala Leu Pro Val Ala 35 40 45 | |
| 40 | ctg gtg tcc agc ctg gag gca gca agc cac agg ggg agg cac gag agg 357 Leu Val Ser Ser Leu Glu Ala Ala Ser His Arg Gly Arg His Glu Arg 50 55 60 | |
| 45 | ccc tca gct acg acc cag tgc ccg gtg ctg cgg ccg gag gag gtg ttg 405 Pro Ser Ala Thr Thr Gln Cys Pro Val Leu Arg Pro Glu Glu Val Leu 65 70 75 80 | |
| 50 | gag gca gac acc cac cag cgc tcc atc tca ccc tgg aga tac cgt gtg 453 Glu Ala Asp Thr His Gln Arg Ser Ile Ser Pro Trp Arg Tyr Arg Val 85 90 95 | |
| 55 | gac acg gat gag gac cgc tat cca cag aag ctg gcc ttc gcc gag tgc 501 Asp Thr Asp Glu Asp Arg Tyr Pro Gln Lys Leu Ala Phe Ala Glu Cys 100 105 110 | |
| 60 | ctg tgc aga ggc tgt atc gat gca cgg acg ggc cgc gag aca gct gcg 549 Leu Cys Arg Gly Cys Ile Asp Ala Arg Thr Gly Arg Glu Thr Ala Ala 115 120 125 | |
| 65 | ctc aac tcc gtg cgg ctg ctc cag agc ctg ctg gtg ctg cgc cgc cgg 597 Leu Asn Ser Val Arg Leu Leu Gln Ser Leu Leu Val Leu Arg Arg Arg 130 135 140 | |
| 70 | ccc tgc tcc cgc gac ggc tgc ggg ctc ccc aca cct ggg gcc ttt gcc 645 Pro Cys Ser Arg Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala 145 150 155 160 | |
| | ttc cac acc gag ttc atc cac gtc ccc gtc ggc tgc acc tgc gtg ctg 693 Phe His Thr Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val Leu 165 170 175 | |
| | ccc cgt tca gtg tgaccgccga ggccgtgggg cccttagact ggacacgtgt 745 Pro Arg Ser Val 180 | |

| | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| | gctccccaga gggcaccccc tatttatgtg tatttattgg tatttatatg cctcccccaa | 805 |
| | cactaccctt ggggtctggg cattccccgt gtctggagga cagcccccca ctgttctcct | 865 |
| 5 | catctccagc ctcagtagtt gggggtagaa ggagctcagc acctcttcca gcccttaaag | 925 |
| | ctgcagaaaa ggtgtcacac ggctgcctgt accttggtc cctgtcctgc tccccgcttc | 985 |
| 10 | ccttacccta tcaactggcct caggcccccg caggctgcct cttcccaacc tccttggaag | 1045 |
| | taccctgtt tcttaaacia ttatttaagt gtacgtgtat tattaaactg atgaacacat | 1105 |
| | cc | 1107 |
| 15 | MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGOALPVALVSS LEAASHRGRHERPSATTQCPVLRPEEVLEADTHORSISPWRYRVDTDDEDRYPQKLAFACLCRCGIDAR TGRETAALNSVRLQLSLLVLRRLRRPCSRDGSGLPTPGAFAFHTEFIHVPVGCTCVLPRSV | |
| 20 | Table 5: Nucleotide sequence encoding a primate, e.g., human, IL-175 sequence under IUPAC code. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 24: | |
| 25 | GAGAAAGAGC TTCCTGCACA AAGTAAGCCA CCAGCGCAAC ATGACAGTGA AGACCCTGCA | 60 |
| | TGGCCCAGCC ATGGTCAAGT ACTTGCTGCT GTCGATATTG GGGCTTGCCT TTCTGAGTGA | 120 |
| 30 | GGCGGCAGCT CGGAAATCC CCAAAGTAGG ACATACTTTT TTCCAAAAGC CTGAGAGTTG | 180 |
| | CCCGCCTGTG CCAGGAGGTA GTATGAAGCT TGACATTGGC ATCATCAATG AAAACCAGCG | 240 |
| | CGTTTCCATG TCACGTAACA TCGAGAGCCG CTCCACCTCC CCCTGGAATT AACTGTAC | 300 |
| 35 | TTGGGACCCC AACCGGTACC CCTCGAAGTT GTACAGGCC AAGTGTAGGA ACTTGGGCTG | 360 |
| | TATCAATGCT CAAGGAAAGG AAGACATCTN CATGAATTCC GTC | 403 |
| 40 | SEQ ID NO: 25 and 26 are PATENTIN translatable cDNA and polypeptide sequences. Predicted signal cleavage site indicated, but may be a few residues on either side; putative glycosylation site at residues 53-55: | |
| 45 | GAGAAAGAGC TTCCTGCACA AAGTAAGCCA CCAGCGCAAC ATGACAGTGA AGACCCTGCA | 60 |
| | TGGCCCAGCC ATG GTC AAG TAC TTG CTG CTG TCG ATA TTG GGG CTT GCC | 109 |
| | Met Val Lys Tyr Leu Leu Leu Ser Ile Leu Gly Leu Ala | |
| | -20 -15 -10 | |
| 50 | TTT CTG AGT GAG GCG GCA GCT CGG AAA ATC CCC AAA GTA GGA CAT ACT | 157 |
| | Phe Leu Ser Glu Ala Ala Ala Arg Lys Ile Pro Lys Val Gly His Thr | |
| | -5 1 5 | |
| 55 | TTT TTC CAA AAG CCT GAG AGT TGC CCG CCT GTG CCA GGA GGT AGT ATG | 205 |
| | Phe Phe Gln Lys Pro Glu Ser Cys Pro Pro Val Pro Gly Gly Ser Met | |
| | 10 15 20 25 | |
| 60 | AAG CTT GAC ATT GGC ATC ATC AAT GAA AAC CAG CGC GTT TCC ATG TCA | 253 |
| | Lys Leu Asp Ile Gly Ile Ile Asn Glu Asn Gln Arg Val Ser Met Ser | |
| | 30 35 40 | |
| | CGT AAC ATC GAG AGC CGC TCC ACC TCC CCC TGG AAT TAC ACT GTC ACT | 301 |
| 65 | Arg Asn Ile Glu Ser Arg Ser Thr Ser Pro Trp Asn Tyr Thr Val Thr | |
| | 45 50 55 | |
| | TGG GAC CCC AAC CGG TAC CCC TCG AAG TTG TAC AGG CCC AAG TGT AGG | 349 |
| | Trp Asp Pro Asn Arg Tyr Pro Ser Lys Leu Tyr Arg Pro Lys Cys Arg | |
| | 60 65 70 | |

```
TCC GTC
Ser Val
90
```

Particularly interesting segments include, e.g., those which begin or end with arg1; cys17; pro18, pro19; val20; thr49; ser50; arg69; pro70; and the end of the sequence available.

20 Table 6: Nucleotide sequence encoding a primate, e.g., human, IL-176. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 27 and 28:

tat tac ttg tta ggg aga ccc aat ggt agt ttt att cct tgg gga tac 95
Tyr Tyr Leu Leu Gly Arg Pro Asn Gly Ser Phe Ile Pro Trp Gly Tyr
20 25 30

gga tgt gtg gga tgt act gcc gcc ttc aga agt cca cac act gcc tgg 191
Gly Cys Val Gly Cys Thr Ala Ala Phe Arg Ser Pro His Thr Ala Trp
50 55 60

aac tac ttt tca tgt ctt atc tta att ctc ata aca gtc att 281
Asn Tyr Phe Ser Cys Leu Ile Leu Ile Leu Ile Thr Val Ile
80 85 90

tgatatttta aaaaacccca gaaatctgag aaagagataa agtggtttgc tcaaggttat 341
agaacagact accatgtggt gtatttcaga ttttaattca tgtttgtctg attttaagtt 401

gagatacctg aaatgacagg gtagcatcac acctgagagg ggtaaaagcat qaaaaacctac 521

ccgaggctct gagaattaac tgcttaaaga actgccttct ggagggagaa gaggacaaga 641

ttataacattt tagcaactat cttcaaaacc tgagggtatg ttatatattg agcaatttact 761

ctgggcaaaa gtgtaaaagt ttg 784

65 VPYLFKKIILHFFASYLLGRPNGSFIPWGYIVNTSLKSSTEFDEKCGCVGCTAAFRSPHTAWRR
TAVYSLIKHLLCTNYFSCILILITVI

Nucleotide sequence encoding a primate, e.g., human, IL-177. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 29 and 30:

```

5  gtg act gta ttg tgg gga cag gaa gca caa att ccc atg tgg atc act 48
   Val Thr Val Leu Trp Gly Gln Glu Ala Gln Ile Pro Met Trp Ile Thr
     1           5           10           15

10  agg aga gat aat aag tgg ggt cat ttc acc cct tgg tcc cct gct tcc 96
   Arg Arg Asp Asn Lys Trp Gly His Phe Thr Pro Trp Ser Pro Ala Ser
     20           25           30

15  aga ccc aaa gag gcc tac atg gca ttg tgc ttc ctt ctt agt tgt agg 144
   Arg Pro Lys Glu Ala Tyr Met Ala Leu Cys Phe Leu Leu Ser Cys Arg
     35           40           45

20  agg tgt gag ata caa tca ttt gcc tct gac ttt gag ggt tgg tcc 189
   Arg Cys Glu Ile Gln Ser Phe Ala Ser Asp Phe Glu Gly Trp Ser
     50           55           60

25  tagcatgccc ctgaccagta gcccttaaa tacttcattg atatggaagg tctctgaatc 249
   ttctgtgggct taatctacca ctctctgaag ttcttatgtc tttcaaaggc ctctaaaatc 309

30  tctgccatgt cttgctcatc cagttgtag catgatgtca ttgatacagt ggacttttga 369
   atctaagtgg ggagacactg gtaagtgacc aattacttca cctgtggtgt gcaagccaga 429
   tcaggaagcc tctacctgca cgacaacaca t 460
   VTVLWGQEAQIPMWITRRDNKNGHFTPWSPASRPKEAYMALCFLLSRRCEIQSFASDFEGWS

```

Table 7: Alignment of various CTLA-8/IL-170 family members. The rat CTLA-8 sequence is SEQ ID NO: 31 (see GB L13839; 293329/30); mouse CTLA-8 sequence is SEQ ID NO: 32 (see GB 1469917/8); human CTLA-8 is SEQ ID NO: 33 (see GB U32659; 115222/3); and Herpes Saimiri virus ORF13 is SEQ ID NO: 34 (see GB Y13183; 2370235). CLUSTAL X (1.64b) multiple sequence alignment

```

40  IL-74_Mu  -----MYQAVAFLAMIVGHTVSLRI-----QEGCSHLPPSCCPSKEQEPPEEWLKWS
   IL-74_Hu  -----MYQVVAFLAMVMGHTY-----S---HWPPSCCPSKQDTSSELLRWS
   IL-72_Hu  -----MDWPHNLLFLLTISIFLGLGQPRSPKSKRKQGGRPGPLVPGPHQVPLDLVSRMK
   IL-72_Mu  -----MDWPHSLFLLAISIFLAPSHPRNTKGKRGQGRPSPLAPGPHQVPLDLVSRVK
45  IL-73_Mu  --MLGTLVWMLLVGFLLALAPGRAAGALRT--GRRP--ARPRCADRPEELLEQLYGRLA
   IL-73_Hu  -----MLVAGFLLALPPSWAAGAPRA--GRRP--ARPRCADRPEELLEQLYGRLA
   IL-17_Hu  --MTPGKTSLSVLLLLLSLEAIVKAGITIP-----RNPCCPNSDKNFPRTVMVNL
   IL-17_Hs  --MTFRKTSLV-LLLLLSIDCIVKSEITSA-----QTPRCLAANN-SFPRSVMTL
50  IL-17_Rt  -----MCLMLLLLLNLEATVKA AVLIP-----QSSVCPNAEANNFLQNVKVN
   IL-17_Mu  -----MLLLLLLSLAATVKA AAIIP-----QSSACPNTAKDFLQNVKVN
   IL-75_Hu  -----MVKYLLLSILGLAFLSEAAARKIPKVGHTFFQKPESCPVPVPGSGMKLDIGIIN
   IL-71_Hu  MTLPLGLLFLTWLHTCLAHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ
   *

55  IL-74_Mu  S-----ASVSP-EP LSHTHAES---CRASKD-GPLNSRAISPWSYELDRDLNRLV
   IL-74_Hu  T-----VPVPPL-EPARPNRHPES---CRASED-GPLNSRAISPWRYELDRDLNRL
   IL-72_Hu  P-YARMEEYERNIEEMVAQLRNSSELAQ-RKCEVNLQLWMSNKRSLSPWGYSINHDP SRI
   IL-72_Mu  P-YARMEEYERNLGEMVAQLRNSSEPAK-KKCEVNLQLWLSNKRSLSPWGYSINHDP SRI
60  IL-73_Mu  AGVLSAFHHTLQLGPR-EQARNASCPAGGRAADRFR-PPTNLRVSPWAYRISYDPARF
   IL-73_Hu  AGVLSAFHHTLQLGPR-EQARNASCPAGGRPADRFR-PPTNLRVSPWAYRISYDPARY
   IL-17_Hu  N-----IHNRTNTN-----P-KRSSDYNRSTSPWNLRNEDPDY
   IL-17_Hs  S-----IRNWTSS-----KRASDYNRSTSPWTLHRNEDQDRY
   IL-17_Rt  K-----VINSLSKA-----SSRRPSDYLNRSTSPWTLRNEDPDY
   IL-17_Mu  K-----VFNSLGAKV-----SSRRPSDYLNRSTSPWTLHRNEDPDY
65  IL-75_Hu  E-----N--QRVMS-----R--NIESRSTSPWNYTVTWDPNRY
   IL-71_Hu  ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTD ERY
   * * *

```

| | |
|-------------|---------------------------------------------------------------|
| IL-74_Mu | PQDLYHARCLCPHCVSLQTGSHMDPLGNSVPLYHNQTVFYRR--PCHGEEGTHRRYCLER |
| IL-74_Hu | PQDLYHARCLCPHCVSLQTGSHMDPRGNSSELLYHNQTVFYRR--PCHGEKGTHKGYCLER |
| IL-72_Hu | PVDLPEARCLCLGCVNPFTM-QEDRSMVSVPVFS-QVPVRRR--LCPPPP--RTGPCRQR |
| 5 IL-72_Mu | PADLPEARCLCLGCVNPFTM-QEDRSMVSVPVFS-QVPVRRR--LCPQPP--RPGPCRQR |
| IL-73_Mu | PRYLPEAYCLCRGCLTGLYG-EEDFRFRSTPVFS-PAVVLRRRTAACAG-----GRSVYA |
| IL-73_Hu | PRYLPEAYCLCRGCLTGLFG-EEDVRFRSAPVYM-PTVVLRRTPACAG-----GRSVYT |
| IL-17_Hu | PSVIWEAKCRHLGCINADGN--VDYHMNSVPIQQEILVLRREPPHCPN-----SFR |
| IL-17_Hs | PSVIWEAKCRYLGCVNADGN--VDYHMNSVPIQQEILVVRKGHQPCPN-----SFR |
| 10 IL-17_Rt | PSVIWEAQCRHQRCVNAEGK--LDHHMNSVLIQQEILVLKREPEKCPF-----TFR |
| IL-17_Mu | PSVIWEAQCRHQRCVNAEGK--LDHHMNSVLIQQEILVLKREPESCPF-----TFR |
| IL-75_Hu | PSEVVQAQCRNLGCINAQGG--EDISMNSVPIQQETLVVRRKHQGC SV-----SFQ |
| IL-71_Hu | PQKLAFAECLCRGCIDARTG-RETAALNSVRLQLSLLVLRRRRPSRDSGLPTPGAFAPH |
| | * : * * * : |
| 15 IL-74_Mu | RLYR-VSLACVCVRPRVMA----- |
| IL-74_Hu | RLYR-VSLACVCVRPRVMG----- |
| IL-72_Hu | AVMETIavgctcIF----- |
| IL-72_Mu | VVMETIavgctcIF----- |
| 20 IL-73_Mu | EHYITIPVGCTCVPEPKSADSANSSMDK----LLLPADRPAWR |
| IL-73_Hu | EAYVTIPVGCTCVPEPEKDADSINSSIDKQAKLLLPNDAPAGP |
| IL-17_Hu | LEKILVSGCTCVTPIVHHVA----- |
| IL-17_Hs | LEKMLVTVGCTCVTPIVHNV----- |
| IL-17_Rt | VEKMLVGVGCTCVSSIVRHAS----- |
| 25 IL-17_Mu | VEKMLVGVGCTCVASIVRQAA----- |
| IL-75_Hu | LEKVLVTVGCTCVTPVHHVQ----- |
| IL-71_Hu | TEFIHVPVGCTCVLPRSV----- |
| | : : * * : |

30 Particularly interesting segments include, e.g., those corresponding to the segments of IL-172 or IL-175, indicated above, with the other family members.

35 Purified protein or polypeptides are useful for generating antibodies by standard methods, as described above. Synthetic peptides or purified protein can be presented to an immune system to generate a specific binding composition, e.g., monoclonal or polyclonal antibodies. See, e.g., Coligan (1991)

40 Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press.

For example, the specific binding composition could be used for screening of an expression library made from a cell

45 line which expresses an IL-170 protein. The screening can be standard staining of surface expressed protein, or by panning. Screening of intracellular expression can also be performed by various staining or immunofluorescence procedures. The binding compositions could be used to affinity purify or sort out cells

50 expressing the protein.

This invention contemplates use of isolated DNA or fragments to encode a biologically active corresponding IL-170 protein or polypeptide. In addition, this invention covers

isolated or recombinant DNA which encodes a biologically active protein or polypeptide and which is capable of hybridizing under appropriate conditions with the DNA sequences described herein. Said biologically active protein or polypeptide can be
5 an intact antigen, or fragment, and have an amino acid sequence as disclosed in Tables 1-6. Further, this invention covers the use of isolated or recombinant DNA, or fragments thereof, which encode proteins which are homologous to an IL-170 protein or which were isolated using cDNA encoding an IL-170 protein as a
10 probe. The isolated DNA can have the respective regulatory sequences in the 5' and 3' flanks, e.g., promoters, enhancers, poly-A addition signals, and others.

An "isolated" nucleic acid is a nucleic acid, e.g., an
15 RNA, DNA, or a mixed polymer, which is substantially separated from other components which naturally accompany a native sequence, e.g., ribosomes, polymerases, and flanking genomic sequences from the originating species. The term embraces a nucleic acid sequence which has been removed from its naturally
20 occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biologically synthesized by heterologous systems. A substantially pure molecule includes isolated forms of the molecule. Alternatively, a purified species may be separated
25 from host components from a recombinant expression system. The size of homology of such a nucleic acid will typically be less than large vectors, e.g., less than tens of kB, typically less than several kB, and preferably in the 2-6 kB range.

An isolated nucleic acid will generally be a homogeneous
30 composition of molecules, but will, in some embodiments, contain minor heterogeneity. This heterogeneity is typically found at the polymer ends or portions not critical to a desired biological function or activity.

A "recombinant" nucleic acid is defined either by its
35 method of production or its structure. In reference to its method of production, e.g., a product made by a process, the process is use of recombinant nucleic acid techniques, e.g., involving human intervention in the nucleotide sequence, typically selection or production. Alternatively, it can be a

nucleic acid made by generating a sequence comprising fusion of two fragments which are not naturally contiguous to each other, but is meant to exclude products of nature, e.g., naturally occurring mutants. Thus, for example, products made by transforming cells with any unnaturally occurring vector is encompassed, as are nucleic acids comprising sequence derived using any synthetic oligonucleotide process. Such is often done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions not found in the commonly available natural forms. Restriction enzyme recognition sites are often the target of such artificial manipulations, but other site specific targets, e.g., promoters, DNA replication sites, regulation sequences, control sequences, or other useful features may be incorporated by design. A similar concept is intended for a recombinant, e.g., fusion, polypeptide. Specifically included are synthetic nucleic acids which, by genetic code redundancy, encode polypeptides similar to fragments of these antigens, and fusions of sequences from various different species variants.

A significant "fragment" in a nucleic acid context is a contiguous segment of at least about 17 nucleotides, generally at least 20 nucleotides, more generally at least 23 nucleotides, ordinarily at least 26 nucleotides, more ordinarily at least 29 nucleotides, often at least 32 nucleotides, more often at least 35 nucleotides, typically at least 38 nucleotides, more typically at least 41 nucleotides, usually at least 44 nucleotides, more usually at least 47 nucleotides, preferably at least 50 nucleotides, more preferably at least 53 nucleotides, and in particularly preferred embodiments will be at least 56 or more nucleotides. Said fragments may have termini at any location, but especially at boundaries between structural domains.

In other embodiments, the invention provides polynucleotides (or polypeptides) which comprise a plurality of distinct, e.g., nonoverlapping, segments of the specified

length. Typically, the plurality will be at least two, more usually at least three, and preferably 5, 7, or even more. While the length minima are provided, longer lengths, of various sizes, may be appropriate, e.g., one of length 7, and
5 two of length 12.

A DNA which codes for an IL-170 protein will be particularly useful to identify genes, mRNA, and cDNA species which code for related or homologous proteins, as well as DNAs which code for homologous proteins from different species.
10 There are likely homologues in other species, including primates. Various CTLA-8 proteins should be homologous and are encompassed herein. However, even proteins that have a more distant evolutionary relationship to the antigen can readily be isolated under appropriate conditions using these sequences if
15 they are sufficiently homologous. Primate CTLA-8 protein proteins are of particular interest.

This invention further covers recombinant DNA molecules and fragments having a DNA sequence identical to or highly homologous to the isolated DNAs set forth herein. In
20 particular, the sequences will often be operably linked to DNA segments which control transcription, translation, and DNA replication. Alternatively, recombinant clones derived from the genomic sequences, e.g., containing introns, will be useful for transgenic studies, including, e.g., transgenic cells and
25 organisms, and for gene therapy. See, e.g., Goodnow (1992) "Transgenic Animals" in Roitt (ed.) Encyclopedia of Immunology Academic Press, San Diego, pp. 1502-1504; Travis (1992) Science 256:1392-1394; Kuhn, et al. (1991) Science 254:707-710; Capecchi (1989) Science 244:1288; Robertson (ed. 1987)
30 Teratocarcinomas and Embryonic Stem Cells: A Practical Approach IRL Press, Oxford; Rosenberg (1992) J. Clinical Oncology 10:180-199; and Cournoyer and Caskey (1993) Ann. Rev. Immunol. 11:297-329.

Homologous nucleic acid sequences, when compared, exhibit
35 significant similarity. The standards for homology in nucleic acids are either measures for homology generally used in the art by sequence comparison or based upon hybridization conditions. The hybridization conditions are described in greater detail below.

Substantial homology in the nucleic acid sequence comparison context means either that the segments, or their complementary strands, when compared, are identical when optimally aligned, with appropriate nucleotide insertions or deletions, in at least about 50% of the nucleotides, generally at least 56%, more generally at least 59%, ordinarily at least 62%, more ordinarily at least 65%, often at least 68%, more often at least 71%, typically at least 74%, more typically at least 77%, usually at least 80%, more usually at least about 85%, preferably at least about 90%, more preferably at least about 95 to 98% or more, and in particular embodiments, as high at about 99% or more of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to a strand, or its complement, typically using a sequence derived from Table 2, 3, or 6. Typically, selective hybridization will occur when there is at least about 55% homology over a stretch of at least about 14 nucleotides, preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90%.

See, Kanehisa (1984) Nuc. Acids Res. 12:203-213. The length of homology comparison, as described, may be over longer stretches, and in certain embodiments will be over a stretch of at least about 17 nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 40 nucleotides, preferably at least about 50 nucleotides, and more preferably at least about 75 to 100 or more nucleotides.

Stringent conditions, in referring to homology in the hybridization context, will be stringent combined conditions of salt, temperature, organic solvents, and other parameters, typically those controlled in hybridization reactions. Stringent temperature conditions will usually include temperatures in excess of about 30° C, more usually in excess of about 37° C, typically in excess of about 45° C, more typically in excess of about 55° C, preferably in excess of about 65° C, and more preferably in excess of about 70° C. Stringent salt conditions will ordinarily be less than about 1000 mM, usually less than about 500 mM, more usually less than

about 400 mM, typically less than about 300 mM, preferably less than about 200 mM, and more preferably less than about 150 mM. However, the combination of parameters is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson (1968) J. Mol. Biol. 31:349-370. Hybridization under stringent conditions should give a background of at least 2-fold over background, preferably at least 3-5 or more.

Alternatively, for sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

Optical alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally Ausubel, et al., supra).

One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle (1987) J. Mol. Evol. 35:351-360. The method used is similar to the method described by Higgins and Sharp (1989) CABIOS 5:151-153. The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned

sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps.

Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described Altschul, et al. (1990) J. Mol. Biol. 215:403-410. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul, et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Nat'l Acad. Sci. USA

89:10915) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Nat'l Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

A further indication that two nucleic acid sequences of polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions, as described below.

CTLA-8-like proteins from other mammalian species can be cloned and isolated by cross-species hybridization of closely related species, e.g., human, as disclosed in Tables 1-7. Homology may be relatively low between distantly related species, and thus hybridization of relatively closely related species is advisable. Alternatively, preparation of an antibody preparation which exhibits less species specificity may be useful in expression cloning approaches.

III. Purified IL-170 protein

The predicted sequence of primate, e.g., human, and rodent, e.g., mouse, IL-173 polypeptide sequence is shown in Table 2. Similarly, in Table 3, is provided primate, e.g.,

human, IL-174 sequence, and is assigned SEQ ID NO: 14. A rodent, e.g., murine, IL-174 is also described in Table 3. The peptide sequences allow preparation of peptides to generate antibodies to recognize such segments.

5 As used herein, the terms "primate IL-170 protein" and "rodent IL-170 protein" shall encompass, when used in a protein context, a protein having designated amino acid sequences shown in Tables 1-7, or a significant fragment of such a protein. It also refers to a primate or rodent derived polypeptide which
10 exhibits similar biological function or interacts with IL-170 protein specific binding components. These binding components, e.g., antibodies, typically bind to an IL-170 protein with high affinity, e.g., at least about 100 nM, usually better than about 30 nM, preferably better than about 10 nM, and more
15 preferably at better than about 3 nM. Homologous proteins would be found in mammalian species other than rat or humans, e.g., mouse, primates, and in the herpes virus genome, e.g., ORF13. Non-mammalian species should also possess structurally or functionally related genes and proteins.

20 The term "polypeptide" as used herein includes a significant fragment or segment, and encompasses a stretch of amino acid residues of at least about 8 amino acids, generally at least 10 amino acids, more generally at least 12 amino acids, often at least 14 amino acids, more often at least 16
25 amino acids, typically at least 18 amino acids, more typically at least 20 amino acids, usually at least 22 amino acids, more usually at least 24 amino acids, preferably at least 26 amino acids, more preferably at least 28 amino acids, and, in particularly preferred embodiments, at least about 30 or more
30 amino acids. The specific ends of such a segment will be at any combinations within the protein, preferably encompassing structural domains.

The term "binding composition" refers to molecules that bind with specificity to IL-170 protein, e.g., in a ligand-receptor type fashion, an antibody-antigen interaction, or
35 compounds, e.g., proteins which specifically associate with IL-170 protein, e.g., in a natural physiologically relevant protein-protein interaction, either covalent or non-covalent. The molecule may be a polymer, or chemical reagent. No

implication as to whether IL-170 protein is either the ligand or the receptor of a ligand-receptor interaction is represented, other than the interaction exhibit similar specificity, e.g., specific affinity. A functional analog may
5 be a protein with structural modifications, or may be a wholly unrelated molecule, e.g., which has a molecular shape which interacts with the appropriate binding determinants. The proteins may serve as agonists or antagonists of a receptor, see, e.g., Goodman, et al. (eds. 1990) Goodman & Gilman's: The
10 Pharmacological Bases of Therapeutics (8th ed.), Pergamon Press.

Solubility of a polypeptide or fragment depends upon the environment and the polypeptide. Many parameters affect polypeptide solubility, including temperature, electrolyte
15 environment, size and molecular characteristics of the polypeptide, and nature of the solvent. Typically, the temperature at which the polypeptide is used ranges from about 4° C to about 65° C. Usually the temperature at use is greater than about 18° C and more usually greater than about 22° C.
20 For diagnostic purposes, the temperature will usually be about room temperature or warmer, but less than the denaturation temperature of components in the assay. For therapeutic purposes, the temperature will usually be body temperature, typically about 37° C for humans, though under certain
25 situations the temperature may be raised or lowered in situ or in vitro.

The electrolytes will usually approximate in situ physiological conditions, but may be modified to higher or lower ionic strength where advantageous. The actual ions may
30 be modified, e.g., to conform to standard buffers used in physiological or analytical contexts.

The size and structure of the polypeptide should generally be in a substantially stable state, and usually not in a denatured state. The polypeptide may be associated with other
35 polypeptides in a quaternary structure, e.g., to confer solubility, or associated with lipids or detergents in a manner which approximates natural lipid bilayer interactions.

The solvent will usually be a biologically compatible buffer, of a type used for preservation of biological

activities, and will usually approximate a physiological solvent. Usually the solvent will have a neutral pH, typically between about 5 and 10, and preferably about 7.5. On some occasions, a detergent will be added, typically a mild non-denaturing one, e.g., CHS or CHAPS, or a low enough concentration as to avoid significant disruption of structural or physiological properties of the antigen.

Solubility is reflected by sedimentation measured in Svedberg units, which are a measure of the sedimentation velocity of a molecule under particular conditions. The determination of the sedimentation velocity was classically performed in an analytical ultracentrifuge, but is typically now performed in a standard ultracentrifuge. See, Freifelder (1982) Physical Biochemistry (2d ed.), W.H. Freeman; and Cantor and Schimmel (1980) Biophysical Chemistry, parts 1-3, W.H. Freeman & Co., San Francisco. As a crude determination, a sample containing a putatively soluble polypeptide is spun in a standard full sized ultracentrifuge at about 50K rpm for about 10 minutes, and soluble molecules will remain in the supernatant. A soluble particle or polypeptide will typically be less than about 30S, more typically less than about 15S, usually less than about 10S, more usually less than about 6S, and, in particular embodiments, preferably less than about 4S, and more preferably less than about 3S.

IV. Making IL-170 protein; Mimetics

DNA which encodes the IL-170 protein or fragments thereof can be obtained by chemical synthesis, screening cDNA libraries, or by screening genomic libraries prepared from a wide variety of cell lines or tissue samples.

This DNA can be expressed in a wide variety of host cells for the synthesis of a full-length protein or fragments which can in turn, for example, be used to generate polyclonal or monoclonal antibodies; for binding studies; for construction and expression of modified molecules; and for structure/function studies. Each antigen or its fragments can be expressed in host cells that are transformed or transfected with appropriate expression vectors. These molecules can be substantially purified to be free of protein or cellular

contaminants, other than those derived from the recombinant host, and therefore are particularly useful in pharmaceutical compositions when combined with a pharmaceutically acceptable carrier and/or diluent. The antigen, or portions thereof, may
5 be expressed as fusions with other proteins.

Expression vectors are typically self-replicating DNA or RNA constructs containing the desired antigen gene or its fragments, usually operably linked to suitable genetic control elements that are recognized in a suitable host cell. These
10 control elements are capable of effecting expression within a suitable host. The specific type of control elements necessary to effect expression will depend upon the eventual host cell used. Generally, the genetic control elements can include a prokaryotic promoter system or a eukaryotic promoter expression
15 control system, and typically include a transcriptional promoter, an optional operator to control the onset of transcription, transcription enhancers to elevate the level of mRNA expression, a sequence that encodes a suitable ribosome binding site, and sequences that terminate transcription and
20 translation. Expression vectors also usually contain an origin of replication that allows the vector to replicate independently of the host cell. Methods for amplifying vector copy number are also known, see, e.g., Kaufman, et al. (1985) Molec. and Cell. Biol. 5:1750-1759.

The vectors of this invention contain DNA which encodes an
25 IL-170 protein, or a fragment thereof, typically encoding a biologically active polypeptide. The DNA can be under the control of a viral promoter and can encode a selection marker. This invention further contemplates use of such expression
30 vectors which are capable of expressing eukaryotic cDNA coding for an IL-170 protein in a prokaryotic or eukaryotic host, where the vector is compatible with the host and where the eukaryotic cDNA coding for the antigen is inserted into the vector such that growth of the host containing the vector
35 expresses the cDNA in question. Usually, expression vectors are designed for stable replication in their host cells or for amplification to greatly increase the total number of copies of the desirable gene per cell. It is not always necessary to require that an expression vector replicate in a host cell,

e.g., it is possible to effect transient expression of the antigen or its fragments in various hosts using vectors that do not contain a replication origin that is recognized by the host cell. It is also possible to use vectors that cause
5 integration of an IL-170 protein gene or its fragments into the host DNA by recombination, or to integrate a promoter which controls expression of an endogenous gene.

Vectors, as used herein, comprise plasmids, viruses, bacteriophage, integratable DNA fragments, and other vehicles
10 which enable the integration of DNA fragments into the genome of the host. Expression vectors are specialized vectors which contain genetic control elements that effect expression of operably linked genes. Plasmids are the most commonly used form of vector but all other forms of vectors which serve an
15 equivalent function and which are, or become, known in the art are suitable for use herein. See, e.g., Pouwels, et al. (1985 and Supplements) Cloning Vectors: A Laboratory Manual, Elsevier, N.Y., and Rodriguez, et al. (eds. 1988) Vectors: A Survey of Molecular Cloning Vectors and Their Uses,
20 Buttersworth, Boston, MA.

Transformed cells include cells, preferably mammalian, that have been transformed or transfected with vectors containing an IL-170 gene, typically constructed using recombinant DNA techniques. Transformed host cells usually
25 express the antigen or its fragments, but for purposes of cloning, amplifying, and manipulating its DNA, do not need to express the protein. This invention further contemplates culturing transformed cells in a nutrient medium, thus permitting the protein to accumulate in the culture. The
30 protein can be recovered, either from the culture or from the culture medium.

For purposes of this invention, DNA sequences are operably linked when they are functionally related to each other. For example, DNA for a presequence or secretory leader is operably
35 linked to a polypeptide if it is expressed as a preprotein or participates in directing the polypeptide to the cell membrane or in secretion of the polypeptide. A promoter is operably linked to a coding sequence if it controls the transcription of the polypeptide; a ribosome binding site is operably linked to

a coding sequence if it is positioned to permit translation. Usually, operably linked means contiguous and in reading frame, however, certain genetic elements such as repressor genes are not contiguously linked but still bind to operator sequences that in turn control expression.

Suitable host cells include prokaryotes, lower eukaryotes, and higher eukaryotes. Prokaryotes include both gram negative and gram positive organisms, e.g., *E. coli* and *B. subtilis*. Lower eukaryotes include yeasts, e.g., *S. cerevisiae* and *Pichia*, and species of the genus *Dictyostelium*. Higher eukaryotes include established tissue culture cell lines from animal cells, both of non-mammalian origin, e.g., insect cells, and birds, and of mammalian origin, e.g., human, primates, and rodents.

Prokaryotic host-vector systems include a wide variety of vectors for many different species. As used herein, *E. coli* and its vectors will be used generically to include equivalent vectors used in other prokaryotes. A representative vector for amplifying DNA is pBR322 or many of its derivatives. Vectors that can be used to express the IL-170 proteins or its fragments include, but are not limited to, such vectors as those containing the lac promoter (pUC-series); trp promoter (pBR322-trp); Ipp promoter (the pIN-series); lambda-pP or pR promoters (pOTS); or hybrid promoters such as ptac (pDR540). See Brosius, et al. (1988) "Expression Vectors Employing Lambda-, trp-, lac-, and Ipp-derived Promoters", in Rodriguez and Denhardt (eds.) Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworth, Boston, Chapter 10, pp. 205-236.

Lower eukaryotes, e.g., yeasts and *Dictyostelium*, may be transformed with vectors encoding IL-170 proteins. For purposes of this invention, the most common lower eukaryotic host is the baker's yeast, *Saccharomyces cerevisiae*. It will be used to generically represent lower eukaryotes although a number of other strains and species are also available. Yeast vectors typically consist of a replication origin (unless of the integrating type), a selection gene, a promoter, DNA encoding the desired protein or its fragments, and sequences for translation termination, polyadenylation, and transcription

- termination. Suitable expression vectors for yeast include such constitutive promoters as 3-phosphoglycerate kinase and various other glycolytic enzyme gene promoters or such inducible promoters as the alcohol dehydrogenase 2 promoter or metallothionine promoter. Suitable vectors include derivatives of the following types: self-replicating low copy number (such as the YRp-series), self-replicating high copy number (such as the YEp-series); integrating types (such as the YIp-series), or mini-chromosomes (such as the YCp-series).
- Higher eukaryotic tissue culture cells are the preferred host cells for expression of the functionally active IL-170 protein. In principle, many higher eukaryotic tissue culture cell lines are workable, e.g., insect baculovirus expression systems, whether from an invertebrate or vertebrate source. However, mammalian cells are preferred, in that the processing, both cotranslationally and posttranslationally. Transformation or transfection and propagation of such cells has become a routine procedure. Examples of useful cell lines include HeLa cells, Chinese hamster ovary (CHO) cell lines, baby rat kidney (BRK) cell lines, insect cell lines, bird cell lines, and monkey (COS) cell lines. Expression vectors for such cell lines usually include an origin of replication, a promoter, a translation initiation site, RNA splice sites (if genomic DNA is used), a polyadenylation site, and a transcription termination site. These vectors also usually contain a selection gene or amplification gene. Suitable expression vectors may be plasmids, viruses, or retroviruses carrying promoters derived, e.g., from such sources as from adenovirus, SV40, parvoviruses, vaccinia virus, or cytomegalovirus.
- Representative examples of suitable expression vectors include pCDNA1; pCD, see Okayama, et al. (1985) Mol. Cell Biol. 5:1136-1142; pMC1neo Poly-A, see Thomas, et al. (1987) Cell 51:503-512; and a baculovirus vector such as pAC 373 or pAC 610, see O'Reilly, et al. (1992) Baculovirus Expression Vectors: A Laboratory Manual Freeman and Co., CRC Press, Boca Raton, Fla.

It will often be desired to express an IL-170 protein polypeptide in a system which provides a specific or defined glycosylation pattern. In this case, the usual pattern will be that provided naturally by the expression system. However, the

pattern will be modifiable by exposing the polypeptide, e.g., an unglycosylated form, to appropriate glycosylating proteins introduced into a heterologous expression system. For example, the IL-170 protein gene may be co-transformed with one or more
5 genes encoding mammalian or other glycosylating enzymes. Using this approach, certain mammalian glycosylation patterns will be achievable or approximated in prokaryote or other cells.

The IL-170 protein, or a fragment thereof, may be engineered to be phosphatidyl inositol (PI) linked to a cell
10 membrane, but can be removed from membranes by treatment with a phosphatidyl inositol cleaving enzyme, e.g., phosphatidyl inositol phospholipase-C. This releases the antigen in a biologically active form, and allows purification by standard procedures of protein chemistry. See, e.g., Low (1989)
15 Biochim. Biophys. Acta 988:427-454; Tse, et al. (1985) Science 230:1003-1008; and Brunner, et al. (1991) J. Cell Biol. 114:1275-1283.

Now that the IL-170 protein has been characterized, fragments or derivatives thereof can be prepared by
20 conventional processes for synthesizing peptides. These include processes such as are described in Stewart and Young (1984) Solid Phase Peptide Synthesis, Pierce Chemical Co., Rockford, IL; Bodanszky and Bodanszky (1984) The Practice of Peptide Synthesis, Springer-Verlag, New York; and Bodanszky
25 (1984) The Principles of Peptide Synthesis, Springer-Verlag, New York. For example, an azide process, an acid chloride process, an acid anhydride process, a mixed anhydride process, an active ester process (for example, p-nitrophenyl ester, N-hydroxysuccinimide ester, or cyanomethyl ester), a
30 carbodiimidazole process, an oxidative-reductive process, or a dicyclohexylcarbodiimide (DCCD)/additive process can be used. Solid phase and solution phase syntheses are both applicable to the foregoing processes.

The IL-170 protein, fragments, or derivatives are suitably
35 prepared in accordance with the above processes as typically employed in peptide synthesis, generally either by a so-called stepwise process which comprises condensing an amino acid to the terminal amino acid, one by one in sequence, or by coupling peptide fragments to the terminal amino acid. Amino groups

that are not being used in the coupling reaction are typically protected to prevent coupling at an incorrect location.

If a solid phase synthesis is adopted, the C-terminal amino acid is bound to an insoluble carrier or support through its carboxyl group. The insoluble carrier is not particularly limited as long as it has a binding capability to a reactive carboxyl group. Examples of such insoluble carriers include halomethyl resins, such as chloromethyl resin or bromomethyl resin, hydroxymethyl resins, phenol resins, tert-alkyloxycarbonyl-hydrazidated resins, and the like.

An amino group-protected amino acid is bound in sequence through condensation of its activated carboxyl group and the reactive amino group of the previously formed peptide or chain, to synthesize the peptide step by step. After synthesizing the complete sequence, the peptide is split off from the insoluble carrier to produce the peptide. This solid-phase approach is generally described by Merrifield, et al. (1963) in J. Am. Chem. Soc. 85:2149-2156.

The prepared protein and fragments thereof can be isolated and purified from the reaction mixture by means of peptide separation, for example, by extraction, precipitation, electrophoresis and various forms of chromatography, and the like. The IL-170 proteins of this invention can be obtained in varying degrees of purity depending upon its desired use. Purification can be accomplished by use of the protein purification techniques disclosed herein or by the use of the antibodies herein described in immunoabsorbant affinity chromatography. This immunoabsorbant affinity chromatography is carried out by first linking the antibodies to a solid support and then contacting the linked antibodies with solubilized lysates of appropriate source cells, lysates of other cells expressing the protein, or lysates or supernatants of cells producing the IL-170 protein as a result of DNA techniques, see below.

V. Physical Variants

This invention also encompasses proteins or peptides having substantial amino acid sequence homology with the amino

acid sequence of the IL-170 protein. The variants include species or allelic variants.

Amino acid sequence homology, or sequence identity, is determined by optimizing residue matches, if necessary, by introducing gaps as required. This changes when considering conservative substitutions as matches. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Homologous amino acid sequences are typically intended to include natural allelic and interspecies variations in each respective protein sequence. Typical homologous proteins or peptides will have from 25-100% homology (if gaps can be introduced), to 50-100% homology (if conservative substitutions are included) with the amino acid sequence of the IL-170 protein. Homology measures will be at least about 35%, generally at least 40%, more generally at least 45%, often at least 50%, more often at least 55%, typically at least 60%, more typically at least 65%, usually at least 70%, more usually at least 75%, preferably at least 80%, and more preferably at least 80%, and in particularly preferred embodiments, at least 85% or more. See also Needleham, et al. (1970) J. Mol. Biol. 48:443-453; Sankoff, et al. (1983) Chapter One in Time Warps, String Edits, and Macromolecules: The Theory and Practice of Sequence Comparison Addison-Wesley, Reading, MA; and software packages from IntelliGenetics, Mountain View, CA; and the University of Wisconsin Genetics Computer Group, Madison, WI.

The isolated DNA encoding an IL-170 protein can be readily modified by nucleotide substitutions, nucleotide deletions, nucleotide insertions, and inversions of nucleotide stretches. These modifications result in novel DNA sequences which encode these antigens, their derivatives, or proteins having similar physiological, immunogenic, or antigenic activity. These modified sequences can be used to produce mutant antigens or to enhance expression. Enhanced expression may involve gene amplification, increased transcription, increased translation, and other mechanisms. Such mutant IL-170 protein derivatives include predetermined or site-specific mutations of the

respective protein or its fragments. "Mutant IL-170 protein" encompasses a polypeptide otherwise falling within the homology definition of the murine IL-170 or human IL-170 protein as set forth above, but having an amino acid sequence which differs
5 from that of IL-170 protein as found in nature, whether by way of deletion, substitution, or insertion. In particular, "site specific mutant IL-170 protein" generally includes proteins having significant homology with the corresponding protein having sequences from Tables 1-6, and as sharing various
10 biological activities, e.g., antigenic or immunogenic, with those sequences, and in preferred embodiments contain most of the disclosed sequences. Similar concepts apply to different IL-170 proteins, particularly those found in various warm blooded animals, e.g., mammals and birds. As stated before, it
15 is emphasized that descriptions are generally meant to encompass all IL-170 proteins, not limited to the mouse embodiment specifically discussed.

Although site specific mutation sites are predetermined, mutants need not be site specific. IL-170 protein mutagenesis
20 can be conducted by making amino acid insertions or deletions. Substitutions, deletions, insertions, or any combinations may be generated to arrive at a final construct. Insertions include amino- or carboxy- terminal fusions. Random mutagenesis can be conducted at a target codon and the
25 expressed mutants can then be screened for the desired activity. Methods for making substitution mutations at predetermined sites in DNA having a known sequence are well known in the art, e.g., by M13 primer mutagenesis or polymerase chain reaction (PCR) techniques. See also Sambrook, et al.
30 (1989) and Ausubel, et al. (1987 and Supplements).

The mutations in the DNA normally should not place coding sequences out of reading frames and preferably will not create complementary regions that could hybridize to produce secondary mRNA structure such as loops or hairpins.

35 The present invention also provides recombinant proteins, e.g., heterologous fusion proteins using segments from these proteins. A heterologous fusion protein is a fusion of proteins or segments which are naturally not normally fused in the same manner. Thus, the fusion product of an immunoglobulin

with an IL-170 polypeptide is a continuous protein molecule having sequences fused in a typical peptide linkage, typically made as a single translation product and exhibiting properties derived from each source peptide. A similar concept applies to
5 heterologous nucleic acid sequences.

In addition, new constructs may be made from combining similar functional domains from other proteins. For example, antigen-binding or other segments may be "swapped" between different new fusion polypeptides or fragments. See, e.g.,
10 Cunningham, et al. (1989) Science 243:1330-1336; and O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992. Thus, new chimeric polypeptides exhibiting new combinations of specificities will result from the functional linkage of biologically relevant domains and other functional domains.

15 The phosphoramidite method described by Beaucage and Carruthers (1981) Tetra. Letts. 22:1859-1862, will produce suitable synthetic DNA fragments. A double stranded fragment will often be obtained either by synthesizing the complementary strand and annealing the strand together under appropriate
20 conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence, e.g., PCR techniques.

VI. Functional Variants

25 The blocking of physiological response to IL-170 proteins may result from the inhibition of binding of the antigen to its natural binding partner, e.g., through competitive inhibition. Thus, in vitro assays of the present invention will often use isolated protein, membranes from cells expressing a recombinant
30 membrane associated IL-170 protein, soluble fragments comprising binding segments, or fragments attached to solid phase substrates. These assays will also allow for the diagnostic determination of the effects of either binding segment mutations and modifications, or protein mutations and
35 modifications, e.g., analogs.

This invention also contemplates the use of competitive drug screening assays, e.g., where neutralizing antibodies to antigen or binding partner fragments compete with a test compound for binding to the protein. In this manner, the

antibodies can be used to detect the presence of any polypeptide which shares one or more antigenic binding sites of the protein and can also be used to occupy binding sites on the protein that might otherwise interact with a binding partner.

5 Additionally, neutralizing antibodies against the IL-170 protein and soluble fragments of the antigen which contain a high affinity receptor binding site, can be used to inhibit antigen function in tissues, e.g., tissues experiencing abnormal physiology.

10 "Derivatives" of the IL-170 antigens include amino acid sequence mutants, glycosylation variants, and covalent or aggregate conjugates with other chemical moieties. Covalent derivatives can be prepared by linkage of functionalities to groups which are found in the IL-170 amino acid side chains or
15 at the N- or C- termini, by means which are well known in the art. These derivatives can include, without limitation, aliphatic esters or amides of the carboxyl terminus, or of residues containing carboxyl side chains, O-acyl derivatives of hydroxyl group-containing residues, and N-acyl derivatives of
20 the amino terminal amino acid or amino-group containing residues, e.g., lysine or arginine. Acyl groups are selected from the group of alkyl-moieties including C3 to C18 normal alkyl, thereby forming alkanoyl aroyl species. Covalent attachment to carrier proteins may be important when
25 immunogenic moieties are haptens.

 In particular, glycosylation alterations are included, e.g., made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing, or in further processing steps. Particularly preferred means for
30 accomplishing this are by exposing the polypeptide to glycosylating enzymes derived from cells which normally provide such processing, e.g., mammalian glycosylation enzymes. Deglycosylation enzymes are also contemplated. Also embraced are versions of the same primary amino acid sequence which have
35 other minor modifications, including phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.

 A major group of derivatives are covalent conjugates of the IL-170 protein or fragments thereof with other proteins or

polypeptides. These derivatives can be synthesized in recombinant culture such as N- or C-terminal fusions or by the use of agents known in the art for their usefulness in cross-linking proteins through reactive side groups. Preferred
5 antigen derivatization sites with cross-linking agents are at free amino groups, carbohydrate moieties, and cysteine residues.

Fusion polypeptides between the IL-170 proteins and other homologous or heterologous proteins are also provided.
10 Homologous polypeptides may be fusions between different surface markers, resulting in, e.g., a hybrid protein exhibiting receptor binding specificity. Likewise, heterologous fusions may be constructed which would exhibit a combination of properties or activities of the derivative
15 proteins. Typical examples are fusions of a reporter polypeptide, e.g., luciferase, with a segment or domain of an antigen, e.g., a receptor-binding segment, so that the presence or location of the fused antigen may be easily determined. See, e.g., Dull, et al., U.S. Patent No. 4,859,609. Other gene
20 fusion partners include bacterial β -galactosidase, trpE, Protein A, β -lactamase, alpha amylase, alcohol dehydrogenase, and yeast alpha mating factor. See, e.g., Godowski, et al. (1988) Science 241:812-816.

The phosphoramidite method described by Beaucage and
25 Carruthers (1981) Tetra. Letts. 22:1859-1862, will produce suitable synthetic DNA fragments. A double stranded fragment will often be obtained either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA
30 polymerase with an appropriate primer sequence.

Such polypeptides may also have amino acid residues which have been chemically modified by phosphorylation, sulfonation, biotinylation, or the addition or removal of other moieties, particularly those which have molecular shapes similar to
35 phosphate groups. In some embodiments, the modifications will be useful labeling reagents, or serve as purification targets, e.g., affinity ligands.

Fusion proteins will typically be made by either recombinant nucleic acid methods or by synthetic polypeptide

methods. Techniques for nucleic acid manipulation and expression are described generally, for example, in Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), Vols. 1-3, Cold Spring Harbor Laboratory. Techniques for synthesis of polypeptides are described, for example, in Merrifield (1963) J. Amer. Chem. Soc. 85:2149-2156; Merrifield (1986) Science 232: 341-347; and Atherton, et al. (1989) Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford.

10 This invention also contemplates the use of derivatives of the IL-170 proteins other than variations in amino acid sequence or glycosylation. Such derivatives may involve covalent or aggregative association with chemical moieties. These derivatives generally fall into the three classes: (1)
15 salts, (2) side chain and terminal residue covalent modifications, and (3) adsorption complexes, for example with cell membranes. Such covalent or aggregative derivatives are useful as immunogens, as reagents in immunoassays, or in purification methods such as for affinity purification of
20 antigens or other binding proteins. For example, an IL-170 antigen can be immobilized by covalent bonding to a solid support such as cyanogen bromide-activated Sepharose, by methods which are well known in the art, or adsorbed onto polyolefin surfaces, with or without glutaraldehyde cross-
25 linking, for use in the assay or purification of anti-IL-170 protein antibodies or its receptor or other binding partner. The IL-170 antigens can also be labeled with a detectable group, for example radioiodinated by the chloramine T procedure, covalently bound to rare earth chelates, or
30 conjugated to another fluorescent moiety for use in diagnostic assays. Purification of IL-170 protein may be effected by immobilized antibodies or binding partners.

A solubilized IL-170 antigen or fragment of this invention can be used as an immunogen for the production of antisera or
35 antibodies specific for the protein or fragments thereof. The purified antigen can be used to screen monoclonal antibodies or binding fragments prepared by immunization with various forms of impure preparations containing the protein. In particular, the term "antibodies" also encompasses antigen binding

fragments of natural antibodies. The purified IL-170 proteins can also be used as a reagent to detect any antibodies generated in response to the presence of elevated levels of the protein or cell fragments containing the antigen, both of which
5 may be diagnostic of an abnormal or specific physiological or disease condition. Additionally, antigen fragments may also serve as immunogens to produce the antibodies of the present invention, as described immediately below. For example, this invention contemplates antibodies raised against amino acid
10 sequences encoded by nucleotide sequences shown in Tables 1-6, or fragments of proteins containing them. In particular, this invention contemplates antibodies having binding affinity to or being raised against specific fragments which are predicted to lie outside of the lipid bilayer.

15 The present invention contemplates the isolation of additional closely related species variants. Southern blot analysis established that similar genetic entities exist in other mammals, e.g., rat and human. It is likely that the IL-170 proteins are widespread in species variants, e.g., rodents,
20 lagomorphs, carnivores, artiodactyla, perissodactyla, and primates.

The invention also provides means to isolate a group of related antigens displaying both distinctness and similarities in structure, expression, and function. Elucidation of many of
25 the physiological effects of the antigens will be greatly accelerated by the isolation and characterization of distinct species variants. In particular, the present invention provides useful probes for identifying additional homologous genetic entities in different species.

30 The isolated genes will allow transformation of cells lacking expression of a corresponding IL-170 protein, e.g., either species types or cells which lack corresponding antigens and should exhibit negative background activity. Expression of transformed genes will allow isolation of antigenically pure
35 cell lines, with defined or single specie variants. This approach will allow for more sensitive detection and discrimination of the physiological effects of IL-170 proteins. Subcellular fragments, e.g., cytoplasts or membrane fragments, can be isolated and used.

Dissection of the critical structural elements which effect the various physiological or differentiation functions provided by the proteins is possible using standard techniques of modern molecular biology, particularly in comparing members of the related class. See, e.g., the homolog-scanning mutagenesis technique described in Cunningham, et al. (1989) Science 243:1339-1336; and approaches used in O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992; and Lechleiter, et al. (1990) EMBO J. 9:4381-4390.

In particular, functional domains or segments can be substituted between species variants to determine what structural features are important in both binding partner affinity and specificity, as well as signal transduction. An array of different variants will be used to screen for molecules exhibiting combined properties of interaction with different species variants of binding partners.

Antigen internalization may occur under certain circumstances, and interaction between intracellular components and "extracellular" segments of proteins involved in interactions may occur. The specific segments of interaction of IL-170 protein with other intracellular components may be identified by mutagenesis or direct biochemical means, e.g., cross-linking or affinity methods. Structural analysis by crystallographic or other physical methods will also be applicable. Further investigation of the mechanism of biological function will include study of associated components which may be isolatable by affinity methods or by genetic means, e.g., complementation analysis of mutants.

Further study of the expression and control of IL-170 protein will be pursued. The controlling elements associated with the antigens may exhibit differential developmental, tissue specific, or other expression patterns. Upstream or downstream genetic regions, e.g., control elements, are of interest.

Structural studies of the antigen will lead to design of new variants, particularly analogs exhibiting agonist or antagonist properties on binding partners. This can be combined with previously described screening methods to isolate variants exhibiting desired spectra of activities.

Expression in other cell types will often result in glycosylation differences in a particular antigen. Various species variants may exhibit distinct functions based upon structural differences other than amino acid sequence.

- 5 Differential modifications may be responsible for differential function, and elucidation of the effects are now made possible.

Thus, the present invention provides important reagents related to antigen-binding partner interaction. Although the foregoing description has focused primarily upon the murine IL-
10 170 and human IL-170 protein, those of skill in the art will immediately recognize that the invention encompasses other antigens, e.g., mouse and other mammalian species or allelic variants, as well as variants thereof.

15 VII. Antibodies

Antibodies can be raised to the various IL-170 proteins, including species or allelic variants, and fragments thereof, both in their naturally occurring forms and in their recombinant forms. Additionally, antibodies can be raised to
20 IL-170 proteins in either their active forms or in their inactive forms. Anti-idiotypic antibodies are also contemplated.

Antibodies, including binding fragments and single chain versions, against predetermined fragments of the antigens can
25 be raised by immunization of animals with conjugates of the fragments with immunogenic proteins. Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies can be screened for binding to normal or defective IL-170 proteins, or screened for agonistic or antagonistic
30 activity, e.g., mediated through a binding partner. These monoclonal antibodies will usually bind with at least a K_D of about 1 mM, more usually at least about 300 μ M, typically at least about 10 μ M, more typically at least about 30 μ M, preferably at least about 10 μ M, and more preferably at least
35 about 3 μ M or better.

An IL-170 polypeptide that specifically binds to or that is specifically immunoreactive with an antibody, e.g., such as a polyclonal antibody, generated against a defined immunogen, e.g., such as an immunogen consisting of an amino acid sequence

of mature SEQ ID NO: 8 or fragments thereof or a polypeptide generated from the nucleic acid of SEQ ID NO: 7 is typically determined in an immunoassay. Included within the metes and bounds of the present invention are those nucleic acid sequences described herein, including functional variants, that encode polypeptides that selectively bind to polyclonal antibodies generated against the prototypical IL-173, IL-174, IL-176, or IL-177 polypeptide as structurally and functionally defined herein. The immunoassay typically uses a polyclonal antiserum which was raised, e.g., to a protein of SEQ ID NO: 8. This antiserum is selected to have low crossreactivity against appropriate other IL-170 family members, preferably from the same species, and any such crossreactivity is removed by immunoabsorption prior to use in the immunoassay. Appropriate selective serum preparations can be isolated, and characterized.

In order to produce antisera for use in an immunoassay, the protein, e.g., of SEQ ID NO: 8, is isolated as described herein. For example, recombinant protein may be produced in a mammalian cell line. An appropriate host, e.g., an inbred strain of mice such as Balb/c, is immunized with the protein of SEQ ID NO: 8 using a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol (see Harlow and Lane). Alternatively, a substantially full length synthetic peptide derived from the sequences disclosed herein can be used as an immunogen. Polyclonal sera are collected and titered against the immunogen protein in an immunoassay, e.g., a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of 10^4 or greater are selected and tested for their cross reactivity against other IL-170 family members, e.g., IL-171, IL-172, or IL-175, using a competitive binding immunoassay such as the one described in Harlow and Lane, supra, at pages 570-573. Preferably at least two IL-170 family members are used in this determination in conjunction with the target. These IL-170 family members can be produced as recombinant proteins and isolated using standard molecular biology and protein chemistry techniques as described herein. Thus, antibody preparations

can be identified or produced having desired selectivity or specificity for subsets of IL-170 family members.

Immunoassays in the competitive binding format can be used for the crossreactivity determinations. For example, the protein of mature SEQ ID NO: 8 can be immobilized to a solid support. Proteins added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the above proteins to compete with the binding of the antisera to the immobilized protein is compared to the protein of SEQ ID NO: 8. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with each of the proteins listed above are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorption with the above-listed proteins.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein to the immunogen protein. In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required is less than twice the amount of the protein of, e.g., SEQ ID NO: 8 that is required, then the second protein is said to specifically bind to an antibody generated to the immunogen.

The antibodies, including antigen binding fragments, of this invention can have significant diagnostic or therapeutic value. They can be potent antagonists that bind to a binding partner and inhibit antigen binding or inhibit the ability of an antigen to elicit a biological response. They also can be useful as non-neutralizing antibodies and can be coupled to toxins or radionuclides so that when the antibody binds to the antigen, a cell expressing it, e.g., on its surface, is killed. Further, these antibodies can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker, and may effect drug targeting.

The antibodies of this invention can also be useful in diagnostic applications. As capture or non-neutralizing antibodies, they can be screened for ability to bind to the

antigens without inhibiting binding by a partner. As neutralizing antibodies, they can be useful in competitive binding assays. They will also be useful in detecting or quantifying IL-170 protein or its binding partners. See, e.g.,

- 5 Chan (ed. 1987) Immunoassay: A Practical Guide Academic Press, Orlando, Fla.; Ngo (ed. 1988) Nonisotopic Immunoassay Plenum Press, NY; and Price and Newman (eds. 1991) Principles and Practice of Immunoassay Stockton Press, NY.

- Antigen fragments may be joined to other materials, particularly polypeptides, as fused or covalently joined polypeptides to be used as immunogens. An antigen and its fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc. See Microbiology, Hoeber Medical Division, Harper and Row, 1969; Landsteiner (1962) Specificity of Serological Reactions, Dover Publications, New York, and Williams, et al. (1967) Methods in Immunology and Immunochemistry, Vol. 1, Academic Press, New York, for descriptions of methods of preparing polyclonal antisera. A typical method involves hyperimmunization of an animal with an antigen. The blood of the animal is then collected shortly after the repeated immunizations and the gamma globulin is isolated.
- 10
15
20

- In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be found in, e.g., Stites, et al. (eds.) Basic and Clinical Immunology (4th ed.), Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press, New York; and particularly in Kohler and Milstein (1975) in Nature 256: 495-497, which discusses one method of generating monoclonal antibodies. Summarized briefly, this method involves injecting an animal with an immunogen. The animal is then sacrificed and cells taken from its spleen, which are then fused with myeloma cells. The result is a hybrid cell or "hybridoma" that is capable of reproducing in vitro. The population of hybridomas
- 25
30
35

is then screened to isolate individual clones, each of which secrete a single antibody species to the immunogen. In this manner, the individual antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated in response to a specific site recognized on the immunogenic substance.

Other suitable techniques involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors. See, Huse, et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281; and Ward, et al. (1989) Nature 341:544-546. The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents, teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see Cabilly, U.S. Patent No. 4,816,567.

The antibodies of this invention can also be used for affinity chromatography in isolating the protein. Columns can be prepared where the antibodies are linked to a solid support, e.g., particles, such as agarose, Sephadex, or the like, where a cell lysate may be passed through the column, the column washed, followed by increasing concentrations of a mild denaturant, whereby the purified IL-170 protein will be released.

The antibodies may also be used to screen expression libraries for particular expression products. Usually the antibodies used in such a procedure will be labeled with a

moiety allowing easy detection of presence of antigen by antibody binding.

Antibodies raised against each IL-170 protein will also be useful to raise anti-idiotypic antibodies. These will be
5 useful in detecting or diagnosing various immunological conditions related to expression of the respective antigens.

VIII. Uses

The present invention provides reagents which will find
10 use in diagnostic applications as described elsewhere herein, e.g., in the general description for physiological or developmental abnormalities, or below in the description of kits for diagnosis.

This invention also provides reagents with significant
15 therapeutic value. The IL-170 protein (naturally occurring or recombinant), fragments thereof, and antibodies thereto, along with compounds identified as having binding affinity to IL-170 protein, should be useful in the treatment of conditions associated with abnormal physiology or development, including
20 abnormal proliferation, e.g., cancerous conditions, or degenerative conditions. Abnormal proliferation, regeneration, degeneration, and atrophy may be modulated by appropriate therapeutic treatment using the compositions provided herein. For example, a disease or disorder associated with abnormal
25 expression or abnormal signaling by an IL-170 antigen should be a likely target for an agonist or antagonist of the protein.

Other abnormal developmental conditions are known in the cell types shown to possess IL-170 antigen mRNA by Northern blot analysis. See Berkow (ed.) The Merck Manual of Diagnosis
30 and Therapy, Merck & Co., Rahway, N.J.; and Thorn, et al. Harrison's Principles of Internal Medicine, McGraw-Hill, N.Y. These problems may be susceptible to prevention or treatment using compositions provided herein.

Recombinant antibodies which bind to IL-170 can be
35 purified and then administered to a patient. These reagents can be combined for therapeutic use with additional active or inert ingredients, e.g., in conventional pharmaceutically acceptable carriers or diluents, e.g., immunogenic adjuvants, along with physiologically innocuous stabilizers and

excipients. These combinations can be sterile filtered and placed into dosage forms as by lyophilization in dosage vials or storage in stabilized aqueous preparations. This invention also contemplates use of antibodies or binding fragments thereof, including forms which are not complement binding.

Screening using IL-170 for binding partners or compounds having binding affinity to IL-170 antigen can be performed, including isolation of associated components. Subsequent biological assays can then be utilized to determine if the compound has intrinsic biological activity and is therefore an agonist or antagonist in that it blocks an activity of the antigen. This invention further contemplates the therapeutic use of antibodies to IL-170 protein as antagonists. This approach should be particularly useful with other IL-170 protein species variants.

The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Various considerations are described, e.g., in Gilman, et al. (eds. 1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn. Methods for administration are discussed therein and below, e.g., for oral, intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others. See also Langer (1990) Science 249:1527-1533. Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, e.g., in the Merck Index, Merck & Co., Rahway, New Jersey. Dosage ranges would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about 10 μ M concentrations, usually less than about 100 nM, preferably less than about 10 pM (picomolar), and most preferably less than

about 1 fM (femtomolar), with an appropriate carrier. Slow release formulations, or a slow release apparatus will often be utilized for continuous administration.

IL-170 protein, fragments thereof, and antibodies to it or its fragments, antagonists, and agonists, may be administered directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration. Therapeutic formulations may be administered in any conventional dosage formulation. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation. Formulations typically comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient. Formulations include those suitable for oral, rectal, nasal, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman, et al. (eds. 1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press, Parrytown, NY; Remington's Pharmaceutical Sciences, 17th ed. (1990) Mack Publishing Co., Easton, Penn.; Avis, et al. (eds. 1993) Pharmaceutical Dosage Forms: Parenteral Medications 2d ed., Dekker, NY; Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Tablets 2d ed., Dekker, NY; and Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Disperse Systems Dekker, NY. The therapy of this invention may be combined with or used in association with other therapeutic, including cytokine, reagents.

Both the naturally occurring and the recombinant forms of the IL-170 proteins of this invention are particularly useful in kits and assay methods which are capable of screening compounds for binding activity to the proteins. Several methods of automating assays have been developed in recent years so as to permit screening of tens of thousands of

compounds in a short period. See, e.g., Fodor, et al. (1991) Science 251:767-773, which describes means for testing of binding affinity by a plurality of defined polymers synthesized on a solid substrate. The development of suitable assays can
5 be greatly facilitated by the availability of large amounts of purified, soluble IL-170 protein as provided by this invention.

This invention is particularly useful for screening compounds by using recombinant antigen in any of a variety of drug screening techniques. The advantages of using a
10 recombinant protein in screening for specific ligands include: (a) improved renewable source of the antigen from a specific source; (b) potentially greater number of antigen molecules per cell giving better signal to noise ratio in assays; and (c) species variant specificity (theoretically giving greater
15 biological and disease specificity). The purified protein may be tested in numerous assays, typically in vitro assays, which evaluate biologically relevant responses. See, e.g., Coligan Current Protocols in Immunology; Hood, et al. Immunology Benjamin/Cummings; Paul (ed.) Fundamental Immunology; and
20 Methods in Enzymology Academic Press.

One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant DNA molecules expressing the IL-170 antigens. Cells may be isolated which express an antigen in isolation
25 from other functionally equivalent antigens. Such cells, either in viable or fixed form, can be used for standard protein-protein binding assays. See also, Parce, et al. (1989) Science 246:243-247; and Owicki, et al. (1990) Proc. Nat'l Acad. Sci. USA 87:4007-4011, which describe sensitive methods
30 to detect cellular responses. Competitive assays are particularly useful, where the cells (source of IL-170 protein) are contacted and incubated with a labeled binding partner or antibody having known binding affinity to the ligand, such as ¹²⁵I-antibody, and a test sample whose binding affinity to the
35 binding composition is being measured. The bound and free labeled binding compositions are then separated to assess the degree of antigen binding. The amount of test compound bound is inversely proportional to the amount of labeled receptor binding to the known source. Any one of numerous techniques

can be used to separate bound from free antigen to assess the degree of binding. This separation step could typically involve a procedure such as adhesion to filters followed by washing, adhesion to plastic followed by washing, or
5 centrifugation of the cell membranes. Viable cells could also be used to screen for the effects of drugs on IL-170 protein mediated functions, e.g., second messenger levels, i.e., Ca^{++} ; cell proliferation; inositol phosphate pool changes; and others. Some detection methods allow for elimination of a
10 separation step, e.g., a proximity sensitive detection system. Calcium sensitive dyes will be useful for detecting Ca^{++} levels, with a fluorimeter or a fluorescence cell sorting apparatus.

Another method utilizes membranes from transformed
15 eukaryotic or prokaryotic host cells as the source of the IL-170 protein. These cells are stably transformed with DNA vectors directing the expression of a membrane associated IL-170 protein, e.g., an engineered membrane bound form. Essentially, the membranes would be prepared from the cells and
20 used in any receptor/ligand type binding assay such as the competitive assay set forth above.

Still another approach is to use solubilized, unpurified or solubilized, purified IL-170 protein from transformed eukaryotic or prokaryotic host cells. This allows for a
25 "molecular" binding assay with the advantages of increased specificity, the ability to automate, and high drug test throughput.

Another technique for drug screening involves an approach which provides high throughput screening for compounds having
30 suitable binding affinity to IL-170 and is described in detail in Geysen, European Patent Application 84/03564, published on September 13, 1984. First, large numbers of different small peptide test compounds are synthesized on a solid substrate, e.g., plastic pins or some other appropriate surface, see
35 Fodor, et al. (1991). Then all the pins are reacted with solubilized, unpurified or solubilized, purified IL-170 binding composition, and washed. The next step involves detecting bound binding composition.

Rational drug design may also be based upon structural studies of the molecular shapes of the IL-170 protein and other effectors or analogs. Effectors may be other proteins which mediate other functions in response to antigen binding, or
5 other proteins which normally interact with the antigen. One means for determining which sites interact with specific other proteins is a physical structure determination, e.g., x-ray crystallography or 2 dimensional NMR techniques. These will provide guidance as to which amino acid residues form molecular
10 contact regions. For a detailed description of protein structural determination, see, e.g., Blundell and Johnson (1976) Protein Crystallography, Academic Press, New York.

Purified IL-170 protein can be coated directly onto plates for use in the aforementioned drug screening techniques.
15 However, non-neutralizing antibodies to these ligands can be used as capture antibodies to immobilize the respective ligand on the solid phase.

IX. Kits

20 This invention also contemplates use of IL-170 proteins, fragments thereof, peptides, and their fusion products in a variety of diagnostic kits and methods for detecting the presence of a binding composition. Typically the kit will have a compartment containing either a defined IL-170 peptide or
25 gene segment or a reagent which recognizes one or the other, e.g., antigen fragments or antibodies.

A kit for determining the binding affinity of a test compound to an IL-170 protein would typically comprise a test compound; a labeled compound, for example an antibody having
30 known binding affinity for the antigen; a source of IL-170 protein (naturally occurring or recombinant); and a means for separating bound from free labeled compound, such as a solid phase for immobilizing the antigen. Once compounds are screened, those having suitable binding affinity to the antigen
35 can be evaluated in suitable biological assays, as are well known in the art, to determine whether they exhibit similar biological activities to the natural antigen. The availability of recombinant IL-170 protein polypeptides also provide well defined standards for calibrating such assays.

A preferred kit for determining the concentration of, for example, an IL-170 protein in a sample would typically comprise a labeled compound, e.g., antibody, having known binding affinity for the antigen, a source of antigen (naturally occurring or recombinant) and a means for separating the bound from free labeled compound, for example, a solid phase for immobilizing the IL-170 protein. Compartments containing reagents, and instructions, will normally be provided.

One method for determining the concentration of IL-170 protein in a sample would typically comprise the steps of: (1) preparing membranes from a sample comprised of a membrane bound IL-170 protein source; (2) washing the membranes and suspending them in a buffer; (3) solubilizing the antigen by incubating the membranes in a culture medium to which a suitable detergent has been added; (4) adjusting the detergent concentration of the solubilized antigen; (5) contacting and incubating said dilution with radiolabeled antibody to form complexes; (6) recovering the complexes such as by filtration through polyethyleneimine treated filters; and (7) measuring the radioactivity of the recovered complexes.

Antibodies, including antigen binding fragments, specific for the IL-170 protein or fragments are useful in diagnostic applications to detect the presence of elevated levels of IL-170 protein and/or its fragments. Such diagnostic assays can employ lysates, live cells, fixed cells, immunofluorescence, cell cultures, body fluids, and further can involve the detection of antigens related to the protein in serum, or the like. Diagnostic assays may be homogeneous (without a separation step between free reagent and protein-protein complex) or heterogeneous (with a separation step). Various commercial assays exist, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), enzyme-multiplied immunoassay technique (EMIT), substrate-labeled fluorescent immunoassay (SLFIA), and the like. For example, unlabeled antibodies can be employed by using a second antibody which is labeled and which recognizes the antibody to an IL-170 protein or to a particular fragment thereof. Similar assays have also been extensively discussed

in the literature. See, e.g., Harlow and Lane (1988)

Antibodies: A Laboratory Manual, CSH.

Anti-idiotypic antibodies may have similar use to diagnose presence of antibodies against an IL-170 protein, as such may be diagnostic of various abnormal states. For example, overproduction of IL-170 protein may result in production of various immunological reactions which may be diagnostic of abnormal physiological states, particularly in proliferative cell conditions such as cancer or abnormal differentiation.

Frequently, the reagents for diagnostic assays are supplied in kits, so as to optimize the sensitivity of the assay. For the subject invention, depending upon the nature of the assay, the protocol, and the label, either labeled or unlabeled antibody, or labeled IL-170 protein is provided. This is usually in conjunction with other additives, such as buffers, stabilizers, materials necessary for signal production such as substrates for enzymes, and the like. Preferably, the kit will also contain instructions for proper use and disposal of the contents after use. Typically the kit has compartments for each useful reagent. Desirably, the reagents are provided as a dry lyophilized powder, where the reagents may be reconstituted in an aqueous medium providing appropriate concentrations of reagents for performing the assay.

Any of the aforementioned constituents of the drug screening and the diagnostic assays may be used without modification or may be modified in a variety of ways. For example, labeling may be achieved by covalently or non-covalently joining a moiety which directly or indirectly provides a detectable signal. In any of these assays, the antigen, test compound, IL-170 protein, or antibodies thereto can be labeled either directly or indirectly. Possibilities for direct labeling include label groups: radiolabels such as ^{125}I , enzymes (U.S. Pat. No. 3,645,090) such as peroxidase and alkaline phosphatase, and fluorescent labels (U.S. Pat. No. 3,940,475) capable of monitoring the change in fluorescence intensity, wavelength shift, or fluorescence polarization. Possibilities for indirect labeling include biotinylation of one constituent followed by binding to avidin coupled to one of the above label groups.

There are also numerous methods of separating the bound from the free antigen, or alternatively the bound from the free test compound. The IL-170 protein can be immobilized on various matrixes followed by washing. Suitable matrixes include plastic such as an ELISA plate, filters, and beads. Methods of immobilizing the IL-170 protein to a matrix include, without limitation, direct adhesion to plastic, use of a capture antibody, chemical coupling, and biotin-avidin. The last step in this approach involves the precipitation of protein-protein complex by any of several methods including those utilizing, e.g., an organic solvent such as polyethylene glycol or a salt such as ammonium sulfate. Other suitable separation techniques include, without limitation, the fluorescein antibody magnetizable particle method described in Rattle, et al. (1984) Clin. Chem. 30:1457-1461, and the double antibody magnetic particle separation as described in U.S. Pat. No. 4,659,678.

The methods for linking proteins or their fragments to the various labels have been extensively reported in the literature and do not require detailed discussion here. Many of the techniques involve the use of activated carboxyl groups either through the use of carbodiimide or active esters to form peptide bonds, the formation of thioethers by reaction of a mercapto group with an activated halogen such as chloroacetyl, or an activated olefin such as maleimide, for linkage, or the like. Fusion proteins will also find use in these applications.

Another diagnostic aspect of this invention involves use of oligonucleotide or polynucleotide sequences taken from the sequence of an IL-170 protein. These sequences can be used as probes for detecting levels of antigen message in samples from patients suspected of having an abnormal condition, e.g., cancer or developmental problem. The preparation of both RNA and DNA nucleotide sequences, the labeling of the sequences, and the preferred size of the sequences has received ample description and discussion in the literature. Normally an oligonucleotide probe should have at least about 14 nucleotides, usually at least about 18 nucleotides, and the polynucleotide probes may be up to several kilobases. Various

labels may be employed, most commonly radionuclides, particularly ^{32}P . However, other techniques may also be employed, such as using biotin modified nucleotides for introduction into a polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, which may be labeled with a wide variety of labels, such as radionuclides, fluorescers, enzymes, or the like. Alternatively, antibodies may be employed which can recognize specific duplexes, including DNA duplexes, RNA duplexes, DNA-RNA hybrid duplexes, or DNA-protein duplexes. The antibodies in turn may be labeled and the assay carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected. The use of probes to the novel anti-sense RNA may be carried out in any conventional techniques such as nucleic acid hybridization, plus and minus screening, recombinational probing, hybrid released translation (HRT), and hybrid arrested translation (HART). This also includes amplification techniques such as polymerase chain reaction (PCR). Another approach utilizes, e.g., antisense nucleic acid, including the introduction of double stranded RNA (dsRNA) to genetically interfere with gene function as described, e.g., in Misquitta, et al. (1999) Proc. Nat'l Acad. Sci. USA 96:1451-1456, and/or ribozymes to block translation of a specific IL-70 mRNA. The use of antisense methods to inhibit the in vitro translation of genes is well known in the art. Marcus-Sakura (1988) Anal. Biochem. 172:289; Akhtar (ed. 1995) Delivery Strategies for Antisense Oligonucleotide Therapeutics CRC Press, Inc.

Diagnostic kits which also test for the qualitative or quantitative presence of other markers are also contemplated. Diagnosis or prognosis may depend on the combination of multiple indications used as markers. Thus, kits may test for combinations of markers. See, e.g., Viallet, et al. (1989) Progress in Growth Factor Res. 1:89-97.

The broad scope of this invention is best understood with reference to the following examples, which are not intended to limit the invention to specific embodiments.

EXAMPLES

I. General Methods

- Some of the standard methods are described or referenced, e.g., in Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press; Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual, (2d ed.), vols. 1-3, CSH Press, NY; Ausubel, et al., Biology, Greene Publishing Associates, Brooklyn, NY; or Ausubel, et al. (1987 and Supplements) Current Protocols in Molecular Biology, Greene/Wiley, New York; Innis, et al. (eds. 1990) PCR Protocols: A Guide to Methods and Applications Academic Press, N.Y.; and Kohler, et al. (1995) Quantitation of mRNA by Polymerase Chain Reaction Springer-Verlag, Berlin.
- Methods for protein purification include such methods as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, e.g., Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) "Guide to Protein Purification" in Methods in Enzymology, vol. 182, and other volumes in this series; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway, N.J., or Bio-Rad, Richmond, CA. Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence. See, e.g., Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, N.Y.; and Crowe, et al. (1992) QIAexpress: The High Level Expression & Protein Purification System QUIAGEN, Inc., Chatsworth, CA.

Also incorporated herein by reference is a similar patent application directed to the IL-171 and IL-175 cytokines, Attorney Docket Number DX0918P, filed on the same date as this.

- Standard immunological techniques are described, e.g., in Hertenzenberg, et al. (eds. 1996) Weir's Handbook of Experimental Immunology vols. 1-4, Blackwell Science; Coligan (1991) Current Protocols in Immunology Wiley/Greene, NY; and Methods in Enzymology vols. 70, 73, 74, 84, 92, 93, 108, 116, 121, 132, 150, 162, and 163. Cytokine assays are described, e.g., in

- Thomson (ed. 1998) The Cytokine Handbook (3d ed.) Academic Press, San Diego; Mire-Sluis and Thorpe (1998) Cytokines Academic Press, San Diego; Metcalf and Nicola (1995) The Hematopoietic Colony Stimulating Factors Cambridge University Press; and Aggarwal and Gutterman (1991) Human Cytokines Blackwell Pub.

- Assays for vascular biological activities are well known in the art. They will cover angiogenic and angiostatic activities in tumor, or other tissues, e.g., arterial smooth muscle proliferation (see, e.g., Koyoma, et al. (1996) Cell 87:1069-1078), monocyte adhesion to vascular epithelium (see McEvoy, et al. (1997) J. Exp. Med. 185:2069-2077), etc. See also Ross (1993) Nature 362:801-809; Rekhter and Gordon (1995) Am. J. Pathol. 147:668-677; Thyberg, et al. (1990) Atherosclerosis 10:966-990; and Gumbiner (1996) Cell 84:345-357.

- Assays for neural cell biological activities are described, e.g., in Wouterlood (ed. 1995) Neuroscience Protocols modules 10, Elsevier; Methods in Neurosciences Academic Press; and Neuromethods Humana Press, Totowa, NJ. Methodology of developmental systems is described, e.g., in Meisami (ed.) Handbook of Human Growth and Developmental Biology CRC Press; and Chrispeels (ed.) Molecular Techniques and Approaches in Developmental Biology Interscience.

- Computer sequence analysis is performed, e.g., using available software programs, including those from the GCG (U. Wisconsin) and GenBank sources. Public sequence databases were also used, e.g., from GenBank and others.

- Many techniques applicable to IL-170 may be applied to these new entities, as described, e.g., in USSN, each of which is incorporated herein by reference for all purposes.

- FACS analyses are described in Melamed, et al. (1990) Flow Cytometry and Sorting Wiley-Liss, Inc., New York, NY; Shapiro (1988) Practical Flow Cytometry Liss, New York, NY; and Robinson, et al. (1993) Handbook of Flow Cytometry Methods Wiley-Liss, New York, NY.

II. Isolation of a DNA clone encoding IL-170 protein

Isolation of murine CTLA-8 is described in Rouvier, et al. (1993) J. Immunol. 150:5445-5456. Similar methods are available for isolating species counterparts of the IL-173, IL-174, IL-176, and IL-177, along with the IL-171, IL-172, and IL-175.

Source of the IL-170 messages

Various cell lines are screened using an appropriate probe for high level message expression. Appropriate cell lines are selected based upon expression levels of the appropriate IL-170 message.

Isolation of an IL-170 encoding clone

Standard PCR techniques are used to amplify an IL-170 gene sequence from a genomic or cDNA library, or from mRNA. A human genomic or cDNA library is obtained and screened with an appropriate cDNA or synthetic probe. PCR primers may be prepared. Appropriate primers are selected, e.g., from the sequences provided, and a full length clone is isolated. Various combinations of primers, of various lengths and possibly with differences in sequence, may be prepared. The full length clone can be used as a hybridization probe to screen for other homologous genes using stringent or less stringent hybridization conditions.

In another method, oligonucleotides are used to screen a library. In combination with polymerase chain reaction (PCR) techniques, synthetic oligonucleotides in appropriate orientations are used as primers to select correct clones from a library.

III. Biochemical Characterization of IL-170 proteins

An IL-170 protein is expressed in heterologous cells, e.g., the native form or a recombinant form displaying the FLAG peptide at the carboxy terminus. See, e.g., Crowe, et al. (1992) QIAexpress: The High Level Expression and Protein Purification System QIAGEN, Inc. Chatsworth, CA; and Hopp, et al. (1988) Bio/Technology 6:1204-1210. These two forms are

introduced into expression vectors, e.g., pME18S or pEE12, and subsequently transfected into appropriate cells, e.g., COS-7 or NSO cells, respectively. Electroporated cells are cultivated, e.g., for 48 hours in RPMI medium supplemented with 10% Fetal Calf Serum. Cells are then incubated with ^{35}S -Met and ^{35}S -Cys in order to label cellular proteins. Comparison of the proteins under reducing conditions on SDS-PAGE should show that cells transfected with full length clones should secrete a polypeptide of the appropriate size, e.g., about 15,000 daltons. Treatment with endoglycosidases will demonstrate whether there are N-glycosylated forms.

IV. Large Scale Production, Purification of IL-170s

For biological assays, mammalian IL-170 is produced in large amounts, e.g., with transfected COS-7 cells grown in RPMI medium supplemented with 1% Nutridoma HU (Boehringer Mannheim, Mannheim, Germany) and subsequently purified. Purification may use affinity chromatography using antibodies, or protein purification techniques, e.g., using antibodies to determine separation properties.

In order to produce larger quantities of native proteins, stable transformants of NSO cells can be prepared according to the methodology developed by Celltech (Slough, Berkshire, UK; International Patent Applications WO86/05807, WO87/04462, WO89/01036, and WO89/10404).

Typically, 1 liter of supernatant containing human IL-173 or IL-173-FLAG is passed, e.g., on a 60 ml column of Zn^{++} ions grafted to a Chelating Sepharose Fast Flow matrix (Pharmacia, Upsalla, Sweden). After washing with 10 volumes of binding buffer (His-Bind Buffer kit, Novagen, Madison, WI), the proteins retained by the metal ions are eluted with a gradient of 20-100 mM Imidazole. The content of human IL-173-FLAG in the eluted fractions is determined by dot blot using the anti-FLAG monoclonal antibody M2 (Eastman Kodak, New Haven, CT), whereas the content of human IL-173 is assessed, e.g., by silver staining of non-reducing SDS-PAGE. The IL-170 containing fractions are then pooled and dialyzed against PBS, and are either used in biological assays or further purified, e.g., by anion exchange HPLC on a DEAE column. A third step of

gel filtration chromatography may be performed on a SUPERDEX G-75 HRD30 column (Pharmacia Uppsala, Sweden). Purification may be evaluated, e.g., by silver stained SDS-PAGE.

5 V. Preparation of antibodies against IL-173

Inbred Balb/c mice are immunized intraperitoneally, e.g., with 1 ml of purified human IL-173-FLAG emulsified in Freund's complete adjuvant on day 0, and in Freund's incomplete adjuvant on days 15 and 22. The mice are boosted with 0.5 ml of

10 purified human IL-173 administered intravenously.

Polyclonal antiserum is collected. The serum can be purified to antibodies. The antibodies can be further processed, e.g., to Fab, Fab2, Fv, or similar fragments.

Hybridomas are created using, e.g., the non-secreting
15 myeloma cells line SP2/0-Ag8 and polyethylene glycol 1000 (Sigma, St. Louis, MO) as the fusing agent. Hybridoma cells are placed in a 96-well Falcon tissue culture plate (Becton Dickinson, NJ) and fed with DMEM F12 (Gibco, Gaithersburg, MD) supplemented with 80 μ g/ml gentamycin, 2 mM glutamine, 10%
20 horse serum (Gibco, Gaithersburg, MD), 1% ADCM (CRTS, Lyon, France) 10^{-5} M azaserine (Sigma, St. Louis, MO) and 5×10^{-5} M hypoxanthine. Hybridoma supernatants are screened for antibody production against human IL-173 by immunocytochemistry (ICC) using acetone fixed human IL-173 transfected COS-7 cells and by
25 ELISA using human IL-173-FLAG purified from COS-7 supernatants as a coating antigen. Aliquots of positive cell clones are expanded for 6 days and cryopreserved as well as propagated in ascites from pristane (2,6,10,14-teramethylpentadecane, Sigma, St. Louis, MO) treated Balb/c mice who had received on
30 intraperitoneal injection of pristane 15 days before. Typically, about 10^5 hybridoma cells in 1 ml of PBS are given intraperitoneally, and 10 days later, ascites are collected from each mouse.

After centrifugation of the ascites, the antibody fraction
35 is isolated by ammonium sulfate precipitation and anion-exchange chromatography on a Zephyr-D silicium column (IBF Sepracor) equilibrated with 20 mM Tris pH 8.0. Proteins are eluted with a NaCl gradient (ranging from 0 to 1 M NaCl). 2 ml fractions are collected and tested by ELISA for the presence of

anti-IL-173 antibody. The fractions containing specific anti-IL-173 activity are pooled, dialyzed, and frozen. Aliquots of the purified monoclonal antibodies may be peroxidase labeled.

Antibody preparations, polyclonal or monoclonal, may be cross absorbed, depleted, or combined to create reagents which exhibit desired combinations of selectivities and specificities. Defined specific antigens can be immobilized to a solid matrix and used to selectively deplete or select for desired binding capacities.

10

VI. Quantification of human IL-173

Among the antibodies specific for IL-173, appropriate clonal isolates are selected to quantitate levels of human IL-173 using a sandwich assay. Purified antibodies are diluted, e.g., at 2 $\mu\text{g/ml}$ in coating buffer (carbonate buffer, pH 9.6, 15 mM Na_2CO_3 , 35 mM NaHCO_3). This diluted solution is coated onto the wells of a 96-well ELISA plate (Immunoplate Maxisorp F96 certified, NUNC, Denmark) overnight at room temperature. The plates are then washed manually, e.g., with a washing buffer consisting of Phosphate Buffered Saline and 0.05% Tween 20 (Technicon Diagnostics, USA). 110 μl of purified human CTLA-8 diluted in TBS-B-T buffer [20 mM Tris, 150 mM NaCl, 1% BSA (Sigma, St. Louis, MO), and 0.05% Tween 20] is added to each well. After 3 hours of incubation at 37° C, the plates are washed once. 100 μl of peroxidase labeled Ab diluted to 5 $\mu\text{g/ml}$ in TBS-B-T buffer is added to each well, and incubated for 2 hours at 37° C. The wells are then washed three times in washing buffer. 100 μl of peroxidase substrate, 2.2' Azino-bis(3 ethylbenzthiazoline-6-sulfonic acid) (ABTS), diluted to 1 mg/ml in citrate/phosphate buffer, is added to each well, and the colorimetric reaction read at 405 nm.

25
30

VII. Distribution of IL-170 genes

The human IL-173 was identified from sequence derived from a cDNA library from an epileptic brain frontal cortex. The rat IL-173 was derived from a cDNA library from cochlea, brain, cerebellum, eye, lung, and kidney. Again, the genes appear to be quite rare, which suggests the expression distributions would be highly restricted.

35

The mouse IL-174 was identified from sequence derived from a cDNA library derived from a mouse embryo. The gene appears to be quite rare, which suggests the expression distribution would be highly restricted.

- 5 The human IL-171 was identified from a sequence derived from an apoptotic T cell. The gene appears to be quite rare, which suggests the expression distribution would be highly restricted.

- 10 The human IL-172 was identified from sequences derived from human fetal heart, liver and spleen, thymus, thymus tumor, and total fetus. Mouse was derived from sequences derived from mouse, embryo, mammary gland, and pooled organs. Both genes appear to be quite rare, which suggests their expression distribution would be highly restricted.

- 15 The human IL-175 was identified from a sequence derived from a 12 h thiouridine activated T cell. The gene appears to be quite rare, which suggests the expression distribution would be highly restricted.

20 VIII. Chromosome mapping of IL-170 genes

An isolated cDNA encoding the appropriate IL-170 gene is used. Chromosome mapping is a standard technique. See, e.g., BIOS Laboratories (New Haven, CT) and methods for using a mouse somatic cell hybrid panel with PCR.

- 25 The human IL-173 gene maps to human chromosome 13q11.

IX. Isolating IL-170 Homologues

- 30 A binding composition, e.g., antibody, is used for screening of an expression library made from a cell line which expresses an IL-170 protein. Standard staining techniques are used to detect or sort intracellular or surface expressed antigen, or surface expressing transformed cells are screened by panning. Screening of intracellular expression is performed by various staining or
35 immunofluorescence procedures. See also McMahan, et al. (1991) EMBO J. 10:2821-2832.

Similar methods are applicable to isolate either species or allelic variants. Species variants are isolated using cross-species hybridization techniques based upon a full

length isolate or fragment from one species as a probe, or appropriate species.

X. Isolating receptors for IL-170

- 5 Methods are available for screening of an expression library made from a cell line which expresses potential IL-170 receptors. A labeled IL-170 ligand is produced, as described above. Standard staining techniques are used to detect or sort surface expressed receptor, or surface
10 expressing transformed cells are screened by panning. See also McMahan, et al. (1991) EMBO J. 10:2821-2832.

For example, on day 0, precoat 2-chamber permanox slides with 1 ml per chamber of fibronectin, 10 ng/ml in PBS, for 30 min at room temperature. Rinse once with PBS. Then plate
15 COS cells at $2-3 \times 10^5$ cells per chamber in 1.5 ml of growth media. Incubate overnight at 37° C.

On day 1 for each sample, prepare 0.5 ml of a solution of 66 µg/ml DEAE-dextran, 66 µM chloroquine, and 4 µg DNA in serum free DME. For each set, a positive control is
20 prepared, e.g., of huIL-170-FLAG cDNA at 1 and 1/200 dilution, and a negative mock. Rinse cells with serum free DME. Add the DNA solution and incubate 5 hr at 37° C. Remove the medium and add 0.5 ml 10% DMSO in DME for 2.5 min. Remove and wash once with DME. Add 1.5 ml growth medium and
25 incubate overnight.

On day 2, change the medium. On days 3 or 4, the cells are fixed and stained. Rinse the cells twice with Hank's Buffered Saline Solution (HBSS) and fix in 4% paraformaldehyde (PFA)/glucose for 5 min. Wash 3X with HBSS.
30 The slides may be stored at -80° C after all liquid is removed. For each chamber, 0.5 ml incubations are performed as follows. Add HBSS/saponin (0.1%) with 32 µl/ml of 1 M NaN₃ for 20 min. Cells are then washed with HBSS/saponin 1X. Soluble antibody is added to cells and incubate for 30 min.
35 Wash cells twice with HBSS/saponin. Add second antibody, e.g., Vector anti-mouse antibody, at 1/200 dilution, and incubate for 30 min. Prepare ELISA solution, e.g., Vector Elite ABC horseradish peroxidase solution, and preincubate for 30 min. Use, e.g., 1 drop of solution A (avidin) and 1

- drop solution B (biotin) per 2.5 ml HBSS/saponin. Wash cells twice with HBSS/saponin. Add ABC HRP solution and incubate for 30 min. Wash cells twice with HBSS, second wash for 2 min, which closes cells. Then add Vector diaminobenzoic acid (DAB) for 5 to 10 min. Use 2 drops of buffer plus 4 drops DAB plus 2 drops of H₂O₂ per 5 ml of glass distilled water. Carefully remove chamber and rinse slide in water. Air dry for a few minutes, then add 1 drop of Crystal Mount and a cover slip. Bake for 5 min at 85-90° C.
- 10 Alternatively, the labeled ligand is used to affinity purify or sort out cells expressing the receptor. See, e.g., Sambrook, et al. or Ausubel, et al.

- 15 All references cited herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

- 20 Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

WHAT IS CLAIMED IS:

1. An isolated or recombinant polynucleotide comprising sequence selected from the group consisting of:

- 5 a) a mammalian IL-173 sequence which:
- i) encodes at least 8 contiguous amino acids of mature SEQ ID NO: 6, 8, 10, or or 12;
 - ii) encodes at least two distinct segments of at least 5 contiguous amino acids of mature SEQ ID NO: 6, 8, 10, or 12; or
 - 10 iii) comprises one or more segments at least 21 contiguous nucleotides of SEQ ID NO: 5, 7, 9, or 11;
- b) a mammalian IL-174 sequence which:
- 15 i) encodes at least 8 contiguous amino acids of mature SEQ ID NO: 14, 16, or 18;
 - ii) encodes at least two distinct segments of at least 5 contiguous amino acids of mature SEQ ID NO: 14, 16, or 18; or
 - 20 iii) comprises one or more segments at least 21 contiguous nucleotides of SEQ ID NO: 14, 16, or 18;
- c) a mammalian IL-176 sequence which:
- i) encodes at least 8 contiguous amino acids of mature SEQ ID NO: 28;
 - 25 ii) encodes at least two distinct segments of at least 5 contiguous amino acids of mature SEQ ID NO: 28; or
 - iii) comprises one or more segments at least 21 contiguous nucleotides of SEQ ID NO: 27; and
- d) a mammalian IL-177 sequence which:
- 30 i) encodes at least 8 contiguous amino acids of mature SEQ ID NO: 30;
 - ii) encodes at least two distinct segments of at least 5 contiguous amino acids of mature SEQ ID NO: 30; or
 - 35 iii) comprises one or more segments at least 21 contiguous nucleotides of SEQ ID NO: 29.

2. The polynucleotide of Claim 1 in an expression vector, comprising a sequence selected from the group consisting of:

- a) an IL-173 sequence which:
- i) encodes at least 12 contiguous amino acids of SEQ ID NO: 6, 8, 10, or 12;
 - 5 ii) encodes at least two distinct segments of at least 7 and 10 contiguous amino acids of SEQ ID NO: 6, 8, 10, or 12; or
 - iii) comprises at least 27 contiguous nucleotides of SEQ ID NO: 5, 7, 9, or 11;
- b) an IL-174 sequence which:
- 10 i) encodes at least 12 contiguous amino acids of SEQ ID NO: 14, 16, or 18;
 - ii) encodes at least two distinct segments of at least 7 and 10 contiguous amino acids of SEQ ID NO: 14, 16, or 18; or
 - 15 iii) comprises at least 27 contiguous nucleotides of SEQ ID NO: 13, 15, or 17;
- c) an IL-176 sequence which:
- i) encodes at least 12 contiguous amino acids of SEQ ID NO: 28;
 - 20 ii) encodes at least two distinct segments of at least 7 and 10 contiguous amino acids of SEQ ID NO: 28; or
 - iii) comprises at least 27 contiguous nucleotides of SEQ ID NO: 27; and
- d) an IL-177 sequence which:
- 25 i) encodes at least 12 contiguous amino acids of SEQ ID NO: 30;
 - ii) encodes at least two distinct segments of at least 7 and 10 contiguous amino acids of SEQ ID NO: 30; or
 - 30 iii) comprises at least 27 contiguous nucleotides of SEQ ID NO: 29.

3. The polynucleotide of Claim 2 selected from the group consisting of:

- a) an IL-173 sequence which:
- 35 i) encodes at least 16 contiguous amino acid residues of mature SEQ ID NO: 6, 8, 10, or 12;
 - ii) encodes at least two distinct segments of at least 10 and 13 contiguous amino acid residues of mature SEQ ID NO: 6, 8, 10, or 12;

- iii) comprises at least 33 contiguous nucleotides of SEQ ID NO: 5, 7, 9, or 11; or
- iv) comprises the entire mature coding portion of SEQ ID NO: 5, 7, 9, or 11;
- 5 b) an IL-174 sequence which:
 - i) encodes at least 16 contiguous amino acid residues of mature SEQ ID NO: 14, 16, or 18;
 - ii) encodes at least two distinct segments of at least 10 and 13 contiguous amino acid residues of mature SEQ ID NO: 14, 16, or 18; or
 - 10 iii) comprises at least 33 contiguous nucleotides of SEQ ID NO: 13, 15, or 17; or
 - iv) comprises the entire mature coding portion of SEQ ID NO: 13, 15, or 17;
- 15 c) an IL-176 sequence which:
 - i) encodes at least 16 contiguous amino acids of mature SEQ ID NO: 28;
 - ii) encodes at least two distinct segments of at least 10 and 14 contiguous amino acid residues of mature SEQ ID NO: 28;
 - 20 iii) comprises at least 33 contiguous nucleotides of SEQ ID NO: 27; or
 - iv) comprises the entire mature coding portion of SEQ ID NO: 27; and
- 25 d) an IL-177 sequence which:
 - i) encodes at least 16 contiguous amino acids of mature SEQ ID NO: 30;
 - ii) encodes at least two distinct segments of at least 10 and 14 contiguous amino acid residues of mature SEQ ID NO: 30;
 - 30 iii) comprises at least 33 contiguous nucleotides of SEQ ID NO: 29; or
 - iv) comprises the entire mature coding portion of SEQ ID NO: 29.

4. A method of making:
- a) a polypeptide comprising expressing said expression vector of Claim 2, thereby producing said polypeptide;
 - 5 b) a duplex nucleic acid comprising contacting a polynucleotide of Claim 2 with a complementary nucleic acid, thereby resulting in production of said duplex nucleic acid; or
 - 10 c) a polynucleotide of Claim 2 comprising amplifying using a PCR method.
5. An isolated or recombinant polynucleotide which hybridizes under stringent wash conditions of at least 55° C and less than 400 mM salt to:
- 15 a) the (IL-173) polynucleotide of Claim 3 which consists of the mature coding portions of SEQ ID NO: 5, 7, 9, or 11;
 - b) the (IL-174) polynucleotide of Claim 3 which consists of the mature coding portions of SEQ ID NO: 13, 15, 20 or 17; or
 - c) the (IL-176) polynucleotide of Claim 3 which consists of the mature coding portions of SEQ ID NO: 27; or
 - d) the (IL-177) polynucleotide of Claim 3 which consists of the mature coding portions of SEQ ID NO: 29.
- 25 6. A polynucleotide of Claim 5:
- a) wherein said wash conditions are at least 65° C and less than 300 mM salt; or
 - 30 b) which comprises at least 50 contiguous nucleotides of the mature coding portion of:
 - i) SEQ ID NO: 5, 7, 9, or 11 (IL-173);
 - ii) SEQ ID NO: 13, 15, or 17 (IL-174);
 - iii) SEQ ID NO: 27 (IL-176); or
 - 35 iv) SEQ ID NO: 29 (IL-177).
7. A kit comprising said polynucleotide of Claim 6, and
- a) instructions for the use of said polynucleotide for detection;

- b) instructions for the disposal of said polynucleotide or other reagents of said kit; or
- c) both a and b.

5 8. A cell containing said expression vector of Claim 3, wherein said cell is:

- a) a prokaryotic cell;
- b) a eukaryotic cell;
- c) a bacterial cell;
- 10 d) a yeast cell;
- e) an insect cell;
- f) a mammalian cell;
- g) a mouse cell;
- h) a primate cell; or
- 15 i) a human cell.

9. An isolated or recombinant antigenic polypeptide:

- a) (IL-173) comprising at least:
 - i) one segment of 8 identical contiguous amino acids from
20 the mature coding portions of SEQ ID NO: 6, 8, 10, or 12; or
 - ii) two distinct segments of at least 5 contiguous amino acids from the mature coding portions of SEQ ID NO: 6, 8, 10, or 12; or
- 25 b) (IL-174) comprising at least:
 - i) one segment of 8 identical contiguous amino acids from the mature coding portions of SEQ ID NO: 14, 16, or 18; or
 - ii) two distinct segments of at least 5 contiguous amino
30 acids from the mature coding portions of SEQ ID NO: 14, 16, or 18.
- c) (IL-176) comprising at least:
 - i) one segment of 8 identical contiguous amino acids from the mature coding portions of SEQ ID NO: 28; or
 - 35 ii) two distinct segments of at least 5 contiguous amino acids from the mature coding portions of SEQ ID NO: 28;

- d) (IL-177) comprising at least:
- i) one segment of 8 identical contiguous amino acids from the mature coding portions of SEQ ID NO: 30; or
 - ii) two distinct segments of at least 5 contiguous amino acids from the mature coding portions of SEQ ID NO: 30.
10. The polypeptide of Claim 9, wherein:
- a) said segment of 8 identical contiguous amino acids is at least 14 contiguous amino acids; or
 - b) one of said segments of at least 5 contiguous amino acids comprises at least 7 contiguous amino acids.
11. The polypeptide of Claim 9, wherein:
- 15 A) (IL-173) said polypeptide:
- a) comprises SEQ ID NO: 6, 8, 10, or 12;
 - b) binds with selectivity to a polyclonal antibody generated against an immunogen of the mature SEQ ID NO: 6, 8, 10, or 12;
 - 20 c) comprises a plurality of distinct polypeptide segments of 10 contiguous amino acids of the mature SEQ ID NO: 6, 8, 10, or 12;
 - d) is a natural allelic variant of SEQ ID NO: 8 or 12;
 - e) has a length at least 30 amino acids; or
 - 25 f) exhibits at least two non-overlapping epitopes which are selective for the mature SEQ ID NO: 6, 8, 10, or 12;
- B) (IL-174) said polypeptide:
- a) comprises the mature SEQ ID NO: 14, 16, or 18;
 - 30 b) binds with selectivity to a polyclonal antibody generated against an immunogen of the mature SEQ ID NO: 14, 16, or 18;
 - c) comprises a plurality of distinct polypeptide segments of 10 contiguous amino acids of the mature SEQ ID NO: 14, 16, or 18;
 - 35 d) is a natural allelic variant of SEQ ID NO: 14 or 18;
 - e) has a length at least 30 amino acids; or

- f) exhibits at least two non-overlapping epitopes which are selective for primate protein of the mature SEQ ID NO: 14, 16, or 18;
- C) (IL-176) said polypeptide:
- 5 a) comprises a mature sequence of SEQ ID NO: 28;
- b) binds with selectivity to a polyclonal antibody generated against an immunogen of the mature SEQ ID NO: 28;
- 10 c) comprises a plurality of distinct polypeptide segments of 10 contiguous amino acids of the mature SEQ ID NO: 28;
- d) is a natural allelic variant of SEQ ID NO: 28;
- e) has a length at least 30 amino acids; or
- 15 f) exhibits at least two non-overlapping epitopes which are selective for the mature SEQ ID NO: 28; or
- D) (IL-177) said polypeptide:
- a) comprises a mature sequence of SEQ ID NO: 30;
- b) binds with selectivity to a polyclonal antibody generated against an immunogen of the mature SEQ ID NO: 30;
- 20 c) comprises a plurality of distinct polypeptide segments of 10 contiguous amino acids of the mature SEQ ID NO: 30;
- d) is a natural allelic variant of SEQ ID NO: 30;
- 25 e) has a length at least 30 amino acids; or
- f) exhibits at least two non-overlapping epitopes which are selective for the mature SEQ ID NO: 30.
12. The polypeptide of Claim 11, which:
- 30 a) is in a sterile composition;
- b) is not glycosylated;
- c) is denatured;
- d) is a synthetic polypeptide;
- e) is attached to a solid substrate;
- 35 f) is a fusion protein with a detection or purification tag;
- g) is a 5-fold or less substitution from a natural sequence; or

- h) is a deletion or insertion variant from a natural sequence.

13. A method using said polypeptide of Claim 9:

- 5 a) to label said polypeptide, comprising labeling said polypeptide with a radioactive label;
- b) to separate said polypeptide from another polypeptide in a mixture, comprising running said mixture on a chromatography matrix, thereby separating said
- 10 polypeptides;
- c) to identify a compound that binds selectively to said polypeptide, comprising incubating said compound with said polypeptide under appropriate conditions; thereby causing said compound to bind to said
- 15 polypeptide; or
- d) to conjugate said polypeptide to a matrix, comprising derivatizing said polypeptide with a reactive reagent, and conjugating said polypeptide to said matrix.
- 20

14. A binding compound comprising an antigen binding portion from an antibody which binds with selectivity to said polypeptide of Claim 11, wherein said polypeptide:

- 25 a) (IL-173) comprises the mature SEQ ID NO 6, 8, 10, or 12; or
- b) (IL-174) comprises the mature SEQ ID NO 14, 16, or 18;
- c) (IL-176) comprises the mature SEQ ID NO 28; or
- d) (IL-177) comprises the mature SEQ ID NO 30.

30 15. The binding compound of Claim 14, wherein said antibody is a polyclonal antibody which is raised against:

- a) (IL-173) SEQ ID NO: 6, 8, 10, or 12; or
- b) (IL-174) SEQ ID NO: 14, 16, or 18;
- c) (IL-176) SEQ ID NO: 28; or
- 35 d) (IL-177) SEQ ID NO: 30.

16. The binding compound of Claim 14, wherein said:

a) antibody:

- i) is immunoselected;
- ii) binds to a denatured protein; or
- 5 iii) exhibits a K_d to said polypeptide of at least 30 mM; or

b) said binding compound:

- i) is attached to a solid substrate, including a bead or plastic membrane;
- 10 ii) is in a sterile composition; or
- iii) is detectably labeled, including a radioactive or fluorescent label.

17. A method of producing an antigen:antibody complex, comprising contacting a polypeptide comprising sequence from SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 28, or 30 with a binding compound of Claim 14 under conditions which allow said complex to form.

18. The method of Claim 17, wherein said binding compound is an antibody, and said polypeptide is in a biological sample.

19. A kit comprising said binding compound of Claim 14 and:

- 25 a) a polypeptide of the mature SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 28, or 30;
- b) instructions for the use of said binding compound for detection; or
- c) instructions for the disposal of said binding compound or other reagents of said kit.
- 30

20. A method of evaluating the selectivity of binding of an antibody to a protein of the mature SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 28, or 30, comprising contacting said antibody to said protein and to another cytokine; and comparing binding of said antibody to said protein and said cytokine.

35

SEQUENCE LISTING

SEQ ID NO: 1 is primate IL-172 nucleic acid sequence.
SEQ ID NO: 2 is primate IL-172 polypeptide sequence.
SEQ ID NO: 3 is murine IL-172 nucleic acid sequence.
SEQ ID NO: 4 is murine IL-172 polypeptide sequence.
SEQ ID NO: 5 is primate IL-173 nucleic acid sequence.
SEQ ID NO: 6 is primate IL-173 polypeptide sequence.
SEQ ID NO: 7 is supplementary primate IL-173 nucleic acid sequence.
SEQ ID NO: 8 is supplementary primate IL-173 polypeptide sequence.
SEQ ID NO: 9 is murine IL-173 nucleic acid sequence.
SEQ ID NO: 10 is murine IL-173 polypeptide sequence.
SEQ ID NO: 11 is supplementary murine IL-173 nucleic acid sequence.
SEQ ID NO: 12 is supplementary murine IL-173 polypeptide sequence.
SEQ ID NO: 13 is primate IL-174 nucleic acid sequence.
SEQ ID NO: 14 is primate IL-174 polypeptide sequence.
SEQ ID NO: 15 is murine IL-174 nucleic acid sequence.
SEQ ID NO: 16 is murine IL-174 polypeptide sequence.
SEQ ID NO: 17 is supplementary murine IL-174 nucleic acid sequence.
SEQ ID NO: 18 is supplementary murine IL-174 polypeptide sequence.
SEQ ID NO: 19 is primate IL-171 IUPAC nucleic acid sequence.
SEQ ID NO: 20 is primate IL-171 nucleic acid sequence.
SEQ ID NO: 21 is primate IL-171 polypeptide sequence.
SEQ ID NO: 22 is supplementary primate IL-171 nucleic acid sequence.
SEQ ID NO: 23 is supplementary primate IL-171 polypeptide sequence.
SEQ ID NO: 24 is primate IL-175 IUPAC nucleic acid sequence.
SEQ ID NO: 25 is primate IL-175 nucleic acid sequence.
SEQ ID NO: 26 is primate IL-175 polypeptide sequence.
SEQ ID NO: 27 is primate IL-176 nucleic acid sequence.
SEQ ID NO: 28 is primate IL-176 polypeptide sequence.
SEQ ID NO: 29 is primate IL-177 nucleic acid sequence.
SEQ ID NO: 30 is primate IL-177 polypeptide sequence.
SEQ ID NO: 31 is rat CTLA-8 polypeptide sequence.
SEQ ID NO: 32 is mouse CTLA-8 polypeptide sequence.
SEQ ID NO: 33 is primate CTLA-8 polypeptide sequence.
SEQ ID NO: 34 is viral CTLA-8 polypeptide sequence.

<110> Schering Corporation

<120> Purified Mammalian Cytokines; Related Reagents and Methods

<130> DX0917K

<140>

<141>

<150> USSN 09/228,822

<151> 1999-01-11

<160> 34

<170> PatentIn Ver. 2.1

<210> 1

<211> 543

<212> DNA

<213> primate

<220>

<221> CDS

<222> (1)..(540)

<220>

<221> mat_peptide

<222> (61)..(540)

<400> 1

```

atg gac tgg cct cac aac ctg ctg ttt ctt ctt acc att tcc atc ttc 48
Met Asp Trp Pro His Asn Leu Leu Phe Leu Leu Thr Ile Ser Ile Phe
-20 -15 -10 -5

ctg ggg ctg ggc cag ccc agg agc ccc aaa agc aag agg aag ggg caa 96
Leu Gly Leu Gly Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln
-1 1 5 10

ggg cgg cct ggg ccc ctg gtc cct ggc cct cac cag gtg cca ctg gac 144
Gly Arg Pro Gly Pro Leu Val Pro Gly Pro His Gln Val Pro Leu Asp
15 20 25

ctg gtg tca cgg atg aaa ccg tat gcc cgc atg gag gag tat gag agg 192
Leu Val Ser Arg Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg
30 35 40

aac atc gag gag atg gtg gcc cag ctg agg aac agc tca gag ctg gcc 240
Asn Ile Glu Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala
45 50 55 60

cag aga aag tgt gag gtc aac ttg cag ctg tgg atg tcc aac aag agg 288
Gln Arg Lys Cys Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg
65 70 75

agc ctg tct ccc tgg ggc tac agc atc aac cac gac ccc agc cgt atc 336
Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile
80 85 90

ccc gtg gac ctg ccg gag gca cgg tgc ctg tgt ctg ggc tgt gtg aac 384
Pro Val Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn
95 100 105

ccc ttc acc atg cag gag gac cgc agc atg gtg agc gtg ccg gtg ttc 432
Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe
110 115 120

agc cag gtt cct gtg cgc cgc cgc ctc tgc ccg cca ccg ccc cgc aca 480
Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr
125 130 135 140

ggg cct tgc cgc cag cgc gca gtc atg gag acc atc gct gtg ggc tgc 528
Gly Pro Cys Arg Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys
145 150 155

acc tgc atc ttc tga 543
Thr Cys Ile Phe
160

```

<210> 2

<211> 180

<212> PRT

<213> primate

<400> 2

Met Asp Trp Pro His Asn Leu Leu Phe Leu Leu Thr Ile Ser Ile Phe
 -20 -15 -10 -5

Leu Gly Leu Gly Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln
 -1 1 5 10

Gly Arg Pro Gly Pro Leu Val Pro Gly Pro His Gln Val Pro Leu Asp
 15 20 25

Leu Val Ser Arg Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg
 30 35 40

Asn Ile Glu Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala
 45 50 55 60

Gln Arg Lys Cys Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg
 65 70 75

Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile
 80 85 90

Pro Val Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn
 95 100 105

Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe
 110 115 120

Ser Gln Val Pro Val Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr
 125 130 135 140

Gly Pro Cys Arg Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys
 145 150 155

Thr Cys Ile Phe
 160

<210> 3

<211> 543

<212> DNA

<213> rodent

<220>

<221> CDS

<222> (1)..(540)

<220>

<221> mat_peptide

<222> (67)..(540)

<400> 3

atg gac tgg ccg cac agc ctg ctc ttc ctc ctg gcc atc tcc atc ttc 48
 Met Asp Trp Pro His Ser Leu Leu Phe Leu Leu Ala Ile Ser Ile Phe
 -20 -15 -10

ctg gcg cca agc cac ccc cgg aac acc aaa ggc aaa aga aaa ggg caa 96
 Leu Ala Pro Ser His Pro Arg Asn Thr Lys Gly Lys Arg Lys Gly Gln
 -5 -1 1 5 10

```

ggg agg ccc agt ccc ttg gcc cct ggg cct cat cag gtg ccg ctg gac 144
(Gly Arg Pro Ser Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp
      15                20                25

ctg gtg tct cga gta aag ccc tac gct cga atg gaa gag tat gag cgg 192
Leu Val Ser Arg Val Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg
      30                35                40

aac ctt ggg gag atg gtg gcc cag ctg agg aac agc tcc gag cca gcc 240
Asn Leu Gly Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Pro Ala
      45                50                55

aag aag aaa tgt gaa gtc aat cta cag ctg tgg ttg tcc aac aag agg 288
Lys Lys Lys Cys Glu Val Asn Leu Gln Leu Trp Leu Ser Asn Lys Arg
      60                65                70

agc ctg tcc cca tgg ggc tac agc atc aac cac gac ccc agc cgc atc 336
Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile
      75                80                85                90

cct gcg gac ttg ccc gag gcg cgg tgc cta tgt ttg ggt tgc gtg aat 384
Pro Ala Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn
      95                100                105

ccc ttc acc atg cag gag gac cgt agc atg gtg agc gtg cca gtg ttc 432
Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe
      110                115                120

agc cag gtg ccg gtg cgc cgc cgc ctc tgt cct caa cct cct cgc cct 480
Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro Gln Pro Pro Arg Pro
      125                130                135

ggg ccc tgc cgc cag cgt gtc gtc atg gag acc atc gct gtg ggt tgc 528
Gly Pro Cys Arg Gln Arg Val Val Met Glu Thr Ile Ala Val Gly Cys
      140                145                150

acc tgc atc ttc tga 543
Thr Cys Ile Phe
155

<210> 4
<211> 180
<212> PRT
<213> rodent

<400> 4
Met Asp Trp Pro His Ser Leu Leu Phe Leu Leu Ala Ile Ser Ile Phe
      -20                -15                -10

Leu Ala Pro Ser His Pro Arg Asn Thr Lys Gly Lys Arg Lys Gly Gln
      -5                -1 1                5                10

Gly Arg Pro Ser Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp
      15                20                25

Leu Val Ser Arg Val Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg
      30                35                40

Asn Leu Gly Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Pro Ala

```

45 50 55
 Lys Lys Lys Cys Glu Val Asn Leu Gln Leu Trp Leu Ser Asn Lys Arg
 60 65 70
 Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile
 75 80 85 90
 Pro Ala Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn
 95 100 105
 Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe
 110 115 120
 Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro Gln Pro Pro Arg Pro
 125 130 135
 Gly Pro Cys Arg Gln Arg Val Val Met Glu Thr Ile Ala Val Gly Cys
 140 145 150
 Thr Cys Ile Phe
 155

<210> 5
 <211> 454
 <212> DNA
 <213> primate

<220>
 <221> CDS
 <222> (1)..(453)

<400> 5
 tgc gcg gac cgg ccg gag gag cta ctg gag cag ctg tac ggg cgc ctg 48
 Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu
 1 5 10 15
 gcg gcc ggc gtg ctc agt gcc ttc cac cac acg ctg cag ctg ggg ccg 96
 Ala Ala Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro
 20 25 30
 cgt gag cag gcg cgc aac gcg agc tgc ccg gca ggg ggc agg ccc gcc 144
 Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Gly Arg Pro Ala
 35 40 45
 gac cgc cgc ttc cgg acg ccc acc aac ctg cgc agc gtg tcg ccc tgg 192
 Asp Arg Arg Phe Arg Thr Pro Thr Asn Leu Arg Ser Val Ser Pro Trp
 50 55 60
 gcc tac aga atc tcc tac gac ccg gcg agg tac ccc agg tac ctg cct 240
 Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro
 65 70 75 80
 gaa gcc tac tgc ctg tgc cgg ggc tgc ctg acc ggg ctg ttc ggc gag 288
 Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu
 85 90 95
 gag gac gtg cgc ttc cgc agc gcc cct gtc tac atg ccc acc gtc gtc 336
 Glu Asp Val Arg Phe Arg Ser Ala Pro Val Tyr Met Pro Thr Val Val
 100 105 110

ctg cgc cgc acc ccc gcc tgc gcc ggc ggc cgt tcc gtc tac acc gag 384
 Leu Arg Arg Thr Pro Ala Cys Ala Gly Gly Arg Ser Val Tyr Thr Glu
 115 120 125

gcc tac gtc acc atc ccc gtg ggc tgc acc tgc gtc ccc gag ccg gag 432
 Ala Tyr Val Thr Ile Pro Val Gly Cys Thr Cys Val Pro Glu Pro Glu
 130 135 140

aag gac gca gac agc atc aac t 454
 Lys Asp Ala Asp Ser Ile Asn
 145 150

<210> 6
 <211> 151
 <212> PRT
 <213> primate

<400> 6
 Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu
 1 5 10 15

Ala Ala Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro
 20 25 30

Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Gly Arg Pro Ala
 35 40 45

Asp Arg Arg Phe Arg Thr Pro Thr Asn Leu Arg Ser Val Ser Pro Trp
 50 55 60

Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro
 65 70 75 80

Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu
 85 90 95

Glu Asp Val Arg Phe Arg Ser Ala Pro Val Tyr Met Pro Thr Val Val
 100 105 110

Leu Arg Arg Thr Pro Ala Cys Ala Gly Gly Arg Ser Val Tyr Thr Glu
 115 120 125

Ala Tyr Val Thr Ile Pro Val Gly Cys Thr Cys Val Pro Glu Pro Glu
 130 135 140

Lys Asp Ala Asp Ser Ile Asn
 145 150

<210> 7
 <211> 1385
 <212> DNA
 <213> primate

<220>
 <221> CDS
 <222> (59)..(664)

<220>

<221> mat_peptide
 <222> (110)..(664)

<400> 7

```

gcccgggcag gtggcgacct cgctcagtcg gcttctcggt ccaagtcgcc gggctctgg 58

atg ctg gta gcc gcc ttc ctg ctg gcg ctg ccg ccg agc tgg gcc gcg 106
Met Leu Val Ala Gly Phe Leu Leu Ala Leu Pro Pro Ser Trp Ala Ala
      -15              -10              -5

ggc gcc ccg agg gcg gcc agg cgc ccc gcg cgg ccg ccg gcc tgc gcg 154
Gly Ala Pro Arg Ala Gly Arg Arg Pro Ala Arg Pro Arg Gly Cys Ala
      -1   1           5           10           15

gac cgg ccg gag gag cta ctg gag cag ctg tac ggg cgc ctg gcg gcc 202
Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu Ala Ala
              20              25              30

ggc gtg ctc agt gcc ttc cac cac acg ctg cag ctg ggg ccg cgt gag 250
Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro Arg Glu
              35              40              45

cag gcg cgc aac gcg agc tgc ccg gca ggg gcc agg ccc gcc gac cgc 298
Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Gly Arg Pro Ala Asp Arg
              50              55              60

cgc ttc ccg ccg ccc acc aac ctg cgc agc gtg tgc ccc tgg gcc tac 346
Arg Phe Arg Pro Pro Thr Asn Leu Arg Ser Val Ser Pro Trp Ala Tyr
              65              70              75

aga atc tcc tac gac ccg gcg agg tac ccc agg tac ctg cct gaa gcc 394
Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro Glu Ala
      80              85              90              95

tac tgc ctg tgc ccg gcc tgc ctg acc ggg ctg ttc gcc gag gag gac 442
Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu Glu Asp
              100              105              110

gtg cgc ttc cgc agc gcc cct gtc tac atg ccc acc gtc gtc ctg cgc 490
Val Arg Phe Arg Ser Ala Pro Val Tyr Met Pro Thr Val Val Leu Arg
              115              120              125

cgc acc ccc gcc tgc gcc gcc gcc cgt tcc gtc tac acc gag gcc tac 538
Arg Thr Pro Ala Cys Ala Gly Gly Arg Ser Val Tyr Thr Glu Ala Tyr
              130              135              140

gtc acc atc ccc gtg gcc tgc acc tgc gtc ccc gag ccg gag aag gac 586
Val Thr Ile Pro Val Gly Cys Thr Cys Val Pro Glu Pro Glu Lys Asp
      145              150              155

gca gac agc atc aac tcc agc atc gac aaa cag gcc gcc aag ctc ctg 634
Ala Asp Ser Ile Asn Ser Ser Ile Asp Lys Gln Gly Ala Lys Leu Leu
      160              165              170              175

ctg gcc ccc aac gac gcg ccc gct gcc ccc tgaggccggt cctgccccgg 684
Leu Gly Pro Asn Asp Ala Pro Ala Gly Pro
              180              185

gaggtctccc cggccccgat cccgaggcgc ccaagctgga gccgcttga gggctcggtc 744

ggcgacctct gaagagagtg caccgagcaa accaagtgcc ggagcaccag cgccgccttt 804

```

ccatggagac tcgtaagcag cttcatctga cacgggcac cctggcttgc ttttagctac 864
aagcaagcag cgtggctgga agctgatggg aaacgacccg gcacgggcat cctgtgtgcg 924
gcccgcatgg agggtttgga aaagttcacg gaggtccctt gaggagcctc tcagatcggc 984
tgctgcgggg gcagggcgtg actcaccgct gggtgcttgc caaagagata gggacgcata 1044
tgctttttta agcaatctaa aaataataat aagtatagcg actatatacc tactttttaa 1104
atcaactggt ttgaatagag gcagagctat tttatattat caaatgagag ctactctggt 1164
acattttctt acatataaac atcggttttt acttcttctg gtagaatttt ttaaagcata 1224
attggaatcc ttgataaat tttgtagctg gtacactctg gcctgggtct ctgaattcag 1284
cctgtcaccg atggctgact gatgaaatgg acacgtctca tctgacccac tcttccttcc 1344
actgaaggtc ttcacgggcc tccaggcctc gtgccgaatt c 1385

<210> 8
<211> 202
<212> PRT
<213> primate

<400> 8
Met Leu Val Ala Gly Phe Leu Leu Ala Leu Pro Pro Ser Trp Ala Ala
-15 -10 -5
Gly Ala Pro Arg Ala Gly Arg Arg Pro Ala Arg Pro Arg Gly Cys Ala
-1 1 5 10 15
Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu Ala Ala
20 25 30
Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro Arg Glu
35 40 45
Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Gly Arg Pro Ala Asp Arg
50 55 60
Arg Phe Arg Pro Pro Thr Asn Leu Arg Ser Val Ser Pro Trp Ala Tyr
65 70 75
Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro Glu Ala
80 85 90 95
Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu Glu Asp
100 105 110
Val Arg Phe Arg Ser Ala Pro Val Tyr Met Pro Thr Val Val Leu Arg
115 120 125
Arg Thr Pro Ala Cys Ala Gly Gly Arg Ser Val Tyr Thr Glu Ala Tyr
130 135 140
Val Thr Ile Pro Val Gly Cys Thr Cys Val Pro Glu Pro Glu Lys Asp
145 150 155
Ala Asp Ser Ile Asn Ser Ser Ile Asp Lys Gln Gly Ala Lys Leu Leu

<400> 11
atg ttg ggg aca ctg gtc tgg atg ctc ctc gtc ggc ttc ctg ctg gca 48
Met Leu Gly Thr Leu Val Trp Met Leu Leu Val Gly Phe Leu Leu Ala

| | -20 | -15 | -10 | |
|-------------------------------------------------------------------|-----|------|---------|-----|
| ctg gcg ccg ggc cgc gcg gcg ggc gcg ctg agg acc ggg agg cgc ccg | | | | 96 |
| Leu Ala Pro Gly Arg Ala Ala Gly Ala Leu Arg Thr Gly Arg Arg Pro | | | | |
| | -5 | -1 1 | 5 | |
| gcg ccg ccg cgg gac tgc gcg gac cgg cca gag gag ctc ctg gag cag | | | | 144 |
| Ala Arg Pro Arg Asp Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln | | | | |
| | 10 | 15 | 20 | |
| ctg tac ggg cgg ctg gcg gcc ggc gtg ctc agc gcc ttc cac cac acg | | | | 192 |
| Leu Tyr Gly Arg Leu Ala Ala Gly Val Leu Ser Ala Phe His His Thr | | | | |
| | 25 | 30 | 35 40 | |
| ctg cag ctc ggg ccg cgc gag cag gcg cgc aat gcc agc tgc ccg gcc | | | | 240 |
| Leu Gln Leu Gly Pro Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala | | | | |
| | 45 | 50 | 55 | |
| ggg ggc agg gcc gcc gac cgc cgc ttc cgg cca ccc acc aac ctg cgc | | | | 288 |
| Gly Gly Arg Ala Ala Asp Arg Arg Phe Arg Pro Pro Thr Asn Leu Arg | | | | |
| | 60 | 65 | 70 | |
| agc gtg tcg ccc tgg gcg tac agg att tcc tac gac cct gct cgc ttt | | | | 336 |
| Ser Val Ser Pro Trp Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Phe | | | | |
| | 75 | 80 | 85 | |
| ccg agg tac ctg ccc gaa gcc tac tgc ctg tgc cga ggc tgc ctg acc | | | | 384 |
| Pro Arg Tyr Leu Pro Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr | | | | |
| | 90 | 95 | 100 | |
| ggg ctc tac ggg gag gag gac ttc cgc ttt cgc agc aca ccc gtc ttc | | | | 432 |
| Gly Leu Tyr Gly Glu Glu Asp Phe Arg Phe Arg Ser Thr Pro Val Phe | | | | |
| | 105 | 110 | 115 120 | |
| tct cca gcc gtg gtg ctg cgg cgc aca gcg gcc tgc gcg ggc ggc cgc | | | | 480 |
| Ser Pro Ala Val Val Leu Arg Arg Thr Ala Ala Cys Ala Gly Gly Arg | | | | |
| | 125 | 130 | 135 | |
| tct gtg tac gcc gaa cac tac atc acc atc ccg gtg ggc tgc acc tgc | | | | 528 |
| Ser Val Tyr Ala Glu His Tyr Ile Thr Ile Pro Val Gly Cys Thr Cys | | | | |
| | 140 | 145 | 150 | |
| gtg ccc gag ccg gac aag tcc gcg gac agt gcg aac tcc agc atg gac | | | | 576 |
| Val Pro Glu Pro Asp Lys Ser Ala Asp Ser Ala Asn Ser Ser Met Asp | | | | |
| | 155 | 160 | 165 | |
| aag ctg ctg ctg ggg ccc gcc gac agg cct gcg ggg cgc tgatgccggg | | | | 625 |
| Lys Leu Leu Leu Gly Pro Ala Asp Arg Pro Ala Gly Arg | | | | |
| | 170 | 175 | 180 | |
| gactgccgc catggccag cttcctgcat gcatcaggtc ccctggccct gacaaaaccc | | | | 685 |
| accccatgat ccctggccgc tgcctaattt ttccaaaagg acagctacat aagcttttaa | | | | 745 |
| tatatatttc aaagtagaca ctacatatct acaactattt tgaatagtgg cagaaactat | | | | 805 |
| tttcatatta gtaatttaga gcaagcatgt tgttttttaa cttctttgat atacaagcac | | | | 865 |
| atcacacaca tcccgttttc ctctagtagg attcttgagt gcataattgt agtgctcaga | | | | 925 |
| tgaacttct tctgctgcac tgtgccctgt ccctgagtct ctctgtggc ccaagcttac | | | | 985 |

taagggtgata atgagtgctc cggatctggg cacctaaggt ctccaggtcc ctggagaggg 1045
 agggatgtgg gggggctagg aaccaagcgc cctttgttc tttagcttat ggatggtctt 1105
 aactttataa agattaaagt ttttggtgtt attctttc 1143

<210> 12
 <211> 205
 <212> PRT
 <213> rodent

<400> 12
 Met Leu Gly Thr Leu Val Trp Met Leu Leu Val Gly Phe Leu Leu Ala
 -20 -15 -10
 Leu Ala Pro Gly Arg Ala Ala Gly Ala Leu Arg Thr Gly Arg Arg Pro
 -5 -1 1 5
 Ala Arg Pro Arg Asp Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln
 10 15 20
 Leu Tyr Gly Arg Leu Ala Ala Gly Val Leu Ser Ala Phe His His Thr
 25 30 35 40
 Leu Gln Leu Gly Pro Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala
 45 50 55
 Gly Gly Arg Ala Ala Asp Arg Arg Phe Arg Pro Pro Thr Asn Leu Arg
 60 65 70
 Ser Val Ser Pro Trp Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Phe
 75 80 85
 Pro Arg Tyr Leu Pro Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr
 90 95 100
 Gly Leu Tyr Gly Glu Glu Asp Phe Arg Phe Arg Ser Thr Pro Val Phe
 105 110 115 120
 Ser Pro Ala Val Val Leu Arg Arg Thr Ala Ala Cys Ala Gly Gly Arg
 125 130 135
 Ser Val Tyr Ala Glu His Tyr Ile Thr Ile Pro Val Gly Cys Thr Cys
 140 145 150
 Val Pro Glu Pro Asp Lys Ser Ala Asp Ser Ala Asn Ser Ser Met Asp
 155 160 165
 Lys Leu Leu Leu Gly Pro Ala Asp Arg Pro Ala Gly Arg
 170 175 180

<210> 13
 <211> 504
 <212> DNA
 <213> primate

<220>
 <221> CDS

<222> (19)..(501)

<220>

<221> mat_peptide

<222> (67)..(501)

<400> 13

| | | | | | | | | | | | | | |
|------------|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| tgagtgtgca | gtgccagc | atg | tac | cag | gtg | gtt | gca | ttc | ttg | gca | atg | gtc | 51 |
| | | Met | Tyr | Gln | Val | Val | Ala | Phe | Leu | Ala | Met | Val | |
| | | -15 | | | | | | -10 | | | | | |
| atg | gga | acc | cac | acc | tac | agc | cac | tgg | ccc | agc | tgc | tgc | ccc |
| Met | Gly | Thr | His | Thr | Ser | His | Trp | Pro | Ser | Cys | Cys | Pro | Ser |
| -5 | | | -1 | 1 | | | | 5 | | | | 10 | 99 |
| ggg | cag | gac | acc | tct | gag | gag | ctg | ctg | agg | tgg | agc | act | gtg |
| Gly | Gln | Asp | Thr | Ser | Glu | Glu | Leu | Leu | Arg | Trp | Ser | Thr | Val |
| | | 15 | | | | | 20 | | | | | 25 | 147 |
| cct | ccc | cta | gag | cct | gct | agg | ccc | aac | cgc | cac | cca | gag | tcc |
| Pro | Pro | Leu | Glu | Pro | Ala | Arg | Pro | Asn | Arg | His | Pro | Glu | Ser |
| | | 30 | | | | | 35 | | | | 40 | | 195 |
| gcc | agt | gaa | gat | gga | ccc | ctc | aac | agc | agg | gcc | atc | tcc | ccc |
| Ala | Ser | Glu | Asp | Gly | Pro | Leu | Asn | Ser | Arg | Ala | Ile | Ser | Pro |
| 45 | | | | | | 50 | | | | 55 | | | 243 |
| tat | gag | ttg | gac | aga | gac | ttg | aac | cgg | ctc | ccc | cag | gac | ctg |
| Tyr | Glu | Leu | Asp | Arg | Asp | Leu | Asn | Arg | Leu | Pro | Gln | Asp | Leu |
| 60 | | | | | 65 | | | | 70 | | | | 75 |
| gcc | cgt | tgc | ctg | tgc | ccg | cac | tgc | gtc | agc | cta | cag | aca | ggc |
| Ala | Arg | Cys | Leu | Cys | Pro | His | Cys | Val | Ser | Leu | Gln | Thr | Gly |
| | | | 80 | | | | | 85 | | | | | 90 |
| atg | gac | ccc | cgg | ggc | aac | tcg | gag | ctg | ctc | tac | cac | aac | cag |
| Met | Asp | Pro | Arg | Gly | Asn | Ser | Glu | Leu | Leu | Tyr | His | Asn | Gln |
| | | | 95 | | | | 100 | | | | | 105 | |
| ttc | tac | cgg | cgg | cca | tgc | cat | ggc | gag | aag | ggc | acc | cac | aag |
| Phe | Tyr | Arg | Arg | Pro | Cys | His | Gly | Glu | Lys | Gly | Thr | His | Lys |
| | | 110 | | | | | 115 | | | | | 120 | |
| tgc | ctg | gag | cgc | agg | ctg | tac | cgt | gtt | tcc | tta | gct | tgt | gtg |
| Cys | Leu | Glu | Arg | Arg | Leu | Tyr | Arg | Val | Ser | Leu | Ala | Cys | Val |
| 125 | | | | | 130 | | | | 135 | | | | |
| cgg | ccc | cgt | gtg | atg | ggc | tag | | | | | | | |
| Arg | Pro | Arg | Val | Met | Gly | | | | | | | | |
| 140 | | | | 145 | | | | | | | | | 504 |

<210> 14

<211> 161

<212> PRT

<213> primate

<400> 14

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Tyr | Gln | Val | Val | Ala | Phe | Leu | Ala | Met | Val | Met | Gly | Thr | His | Thr |
| -15 | | | | | | -10 | | | | | -5 | | | | -1 |

Tyr Ser His Trp Pro Ser Cys Cys Pro Ser Lys Gly Gln Asp Thr Ser
 1 5 10 15
 Glu Glu Leu Leu Arg Trp Ser Thr Val Pro Val Pro Pro Leu Glu Pro
 20 25 30
 Ala Arg Pro Asn Arg His Pro Glu Ser Cys Arg Ala Ser Glu Asp Gly
 35 40 45
 Pro Leu Asn Ser Arg Ala Ile Ser Pro Trp Arg Tyr Glu Leu Asp Arg
 50 55 60
 Asp Leu Asn Arg Leu Pro Gln Asp Leu Tyr His Ala Arg Cys Leu Cys
 65 70 75 80
 Pro His Cys Val Ser Leu Gln Thr Gly Ser His Met Asp Pro Arg Gly
 85 90 95
 Asn Ser Glu Leu Leu Tyr His Asn Gln Thr Val Phe Tyr Arg Arg Pro
 100 105 110
 Cys His Gly Glu Lys Gly Thr His Lys Gly Tyr Cys Leu Glu Arg Arg
 115 120 125
 Leu Tyr Arg Val Ser Leu Ala Cys Val Cys Val Arg Pro Arg Val Met
 130 135 140
 Gly
 145

<210> 15
 <211> 620
 <212> DNA
 <213> rodent

<220>
 <221> CDS
 <222> (1)..(432)

<400> 15
 CGG CAC AGG CGG CAC AAA GCC CGG AGA GTG GCT GAA GTG GAG CTC TGC 48
 Arg His Arg Arg His Lys Ala Arg Arg Val Ala Glu Val Glu Leu Cys
 1 5 10 15
 ATC TGT ATC CCC CCC AGA GCC TCT GAG CCA CAC CCA CCA CGC AGA ATC 96
 Ile Cys Ile Pro Pro Arg Ala Ser Glu Pro His Pro Pro Arg Arg Ile
 20 25 30
 CTG CAG GGC CAG CAA GGA TGG CCT CTC AAC AGC AGG GCC ATC TCT CCT 144
 Leu Gln Gly Gln Gln Gly Trp Pro Leu Asn Ser Arg Ala Ile Ser Pro
 35 40 45
 TGG AGC TAT GAG TTG GAC AGG GAC TTG AAT CGG GTC CCC CAG GAC TGG 192
 Trp Ser Tyr Glu Leu Asp Arg Asp Leu Asn Arg Val Pro Gln Asp Trp
 50 55 60
 TAC CAC GCT CGA TGC CTG TGC CCA CAC TGC GTC ACG CTA CAG ACA GGC 240
 Tyr His Ala Arg Cys Leu Cys Pro His Cys Val Thr Leu Gln Thr Gly
 65 70 75 80

TCC CAC ATG GAC CCG CTG GGC AAC TCC GTC CCA CTT TAC CAC AAC CAG 288
 Ser His Met Asp Pro Leu Gly Asn Ser Val Pro Leu Tyr His Asn Gln
 85 90 95

ACG GTC TTC TAC CGG CGG CCA TGC ATG GCG AGG AAG GTA CCC ATC GCC 336
 Thr Val Phe Tyr Arg Arg Pro Cys Met Ala Arg Lys Val Pro Ile Ala
 100 105 110

GCT ACT GCT TGG AGC GCA GGT CTA CCG AGT CTC CTT GGC TTG TGT GTG 384
 Ala Thr Ala Trp Ser Ala Gly Leu Pro Ser Leu Leu Gly Leu Cys Val
 115 120 125

TGT GCG GCC CCG GGT CAT GGC TTA GTC ATG CTC ACC ATC TGC CTG AGG 432
 Cys Ala Ala Pro Gly His Gly Leu Val Met Leu Thr Ile Cys Leu Arg
 130 135 140

TGAATGCCGG GTGGGAGAGA GGGCCAGGTG TACATCACCT GCCAATGCGG GCCGGGTTCA 492

AGCCTGCAAA GCCTACCTGA AGCAGCAGGT CCCGGGACAG GATGGAGACT TGGGGAGAAA 552

TCTGACTTTT GCACTTTTGT GAGCATTTTG GGAAGAGCAG GTTCGCTTGT GCTGTAGAGA 612

TGCTGTTG 620

<210> 16
 <211> 144
 <212> PRT
 <213> rodent

<400> 16
 Arg His Arg Arg His Lys Ala Arg Arg Val Ala Glu Val Glu Leu Cys
 1 5 10 15

Ile Cys Ile Pro Pro Arg Ala Ser Glu Pro His Pro Pro Arg Arg Ile
 20 25 30

Leu Gln Gly Gln Gln Gly Trp Pro Leu Asn Ser Arg Ala Ile Ser Pro
 35 40 45

Trp Ser Tyr Glu Leu Asp Arg Asp Leu Asn Arg Val Pro Gln Asp Trp
 50 55 60

Tyr His Ala Arg Cys Leu Cys Pro His Cys Val Thr Leu Gln Thr Gly
 65 70 75 80

Ser His Met Asp Pro Leu Gly Asn Ser Val Pro Leu Tyr His Asn Gln
 85 90 95

Thr Val Phe Tyr Arg Arg Pro Cys Met Ala Arg Lys Val Pro Ile Ala
 100 105 110

Ala Thr Ala Trp Ser Ala Gly Leu Pro Ser Leu Leu Gly Leu Cys Val
 115 120 125

Cys Ala Ala Pro Gly His Gly Leu Val Met Leu Thr Ile Cys Leu Arg
 130 135 140

<210> 17
 <211> 985

<212> DNA
<213> rodent

<220>
<221> CDS
<222> (1)..(507)

<220>
<221> mat_peptide
<222> (49)..(507)

<400> 17
atg tac cag gct gtt gca ttc ttg gca atg atc gtg gga acc cac acc 48
Met Tyr Gln Ala Val Ala Phe Leu Ala Met Ile Val Gly Thr His Thr
-15 -10 -5 -1

gtc agc ttg cgg atc cag gag ggc tgc agt cac ttg ccc agc tgc tgc 96
Val Ser Leu Arg Ile Gln Glu Gly Cys Ser His Leu Pro Ser Cys Cys
1 5 10 15

ccc agc aaa gag caa gaa ccc ccg gag gag tgg ctg aag tgg agc tct 144
Pro Ser Lys Glu Gln Glu Pro Pro Glu Glu Trp Leu Lys Trp Ser Ser
20 25 30

gca tct gtg tcc ccc cca gag cct ctg agc cac acc cac cac gca gaa 192
Ala Ser Val Ser Pro Pro Glu Pro Leu Ser His Thr His His Ala Glu
35 40 45

tcc tgc agg gcc agc aag gat ggc ccc ctc aac agc agg gcc atc tct 240
Ser Cys Arg Ala Ser Lys Asp Gly Pro Leu Asn Ser Arg Ala Ile Ser
50 55 60

cct tgg agc tat gag ttg gac agg gac ttg aat cgg gtc ccc cag gac 288
Pro Trp Ser Tyr Glu Leu Asp Arg Asp Leu Asn Arg Val Pro Gln Asp
65 70 75 80

ctg tac cac gct cga tgc ctg tgc cca cac tgc gtc agc cta cag aca 336
Leu Tyr His Ala Arg Cys Leu Cys Pro His Cys Val Ser Leu Gln Thr
85 90 95

ggc tcc cac atg gac ccg ctg ggc aac tcc gtc cca ctt tac cac aac 384
Gly Ser His Met Asp Pro Leu Gly Asn Ser Val Pro Leu Tyr His Asn
100 105 110

cag acg gtc ttc tac cgg cgg cca tgc cat ggt gag gaa ggt acc cat 432
Gln Thr Val Phe Tyr Arg Arg Pro Cys His Gly Glu Glu Gly Thr His
115 120 125

cgc cgc tac tgc ttg gag cgc agg ctc tac cga gtc tcc ttg gct tgt 480
Arg Arg Tyr Cys Leu Glu Arg Arg Leu Tyr Arg Val Ser Leu Ala Cys
130 135 140

gtg tgt gtg cgg ccc ccg gtc atg gct tagtcatgct caccacctgc 527
Val Cys Val Arg Pro Arg Val Met Ala
145 150

ctgaggctga tgcccgttg ggagagaggg ccagggtgtac aatcaccttg ccaatgcggg 587

ccgggttcaa gccctccaaa gccctacctg aagcagcagg ctcccgggac aagatggagg 647

acttggggag aaactctgac ttttgcaactt tttggaagca cttttgggaa ggagcagggt 707

ccgcttggtgc tgctagagga tgctgttggtg gcattttctac tcaggaacgg actccaaagg 767
cctgctgacc ctggaagcca tactcctggc tcctttcccc tgaatcccc aactcctggc 827
acaggcactt tctccacctc tccccctttg ccttttggtg tgtttgttg tgcatgccaa 887
ctctgcgtgc agccaggtgt aattgccttg aaggatggtt ctgaggtgaa agctgttacc 947
gaaagtgaag agatttatcc aaataaacat ctgtgttt 985

<210> 18
<211> 169
<212> PRT
<213> rodent

<400> 18

Met Tyr Gln Ala Val Ala Phe Leu Ala Met Ile Val Gly Thr His Thr
-15 -10 -5 -1

Val Ser Leu Arg Ile Gln Glu Gly Cys Ser His Leu Pro Ser Cys Cys
1 5 10 15

Pro Ser Lys Glu Gln Glu Pro Pro Glu Glu Trp Leu Lys Trp Ser Ser
20 25 30

Ala Ser Val Ser Pro Pro Glu Pro Leu Ser His Thr His His Ala Glu
35 40 45

Ser Cys Arg Ala Ser Lys Asp Gly Pro Leu Asn Ser Arg Ala Ile Ser
50 55 60

Pro Trp Ser Tyr Glu Leu Asp Arg Asp Leu Asn Arg Val Pro Gln Asp
65 70 75 80

Leu Tyr His Ala Arg Cys Leu Cys Pro His Cys Val Ser Leu Gln Thr
85 90 95

Gly Ser His Met Asp Pro Leu Gly Asn Ser Val Pro Leu Tyr His Asn
100 105 110

Gln Thr Val Phe Tyr Arg Arg Pro Cys His Gly Glu Glu Gly Thr His
115 120 125

Arg Arg Tyr Cys Leu Glu Arg Arg Leu Tyr Arg Val Ser Leu Ala Cys
130 135 140

Val Cys Val Arg Pro Arg Val Met Ala
145 150

<210> 19
<211> 521
<212> DNA
<213> primate

<220>
<221> misc_feature
<222> (1)..(521)
<223> note= "n may be a, c, g, or t"

```

<400> 19
gacacggatg aggaccgcta tccacagaag ctggccttcg ccgagtgcct gtgcagaggc 60
tgtatcgatg cacggacggg ccgcgagaca gctgcgtcga actccgtgcg gctgctccag 120
agcctgctgg tgctgcgccg ccggccctgc tcccgcgacg gctcggggct cccacacact 180
ggggcctttg ccttccacac cgagttcatc cacgtccccg tcggctgcac ctgctgtgctg 240
ccccgttcaa gtgtgaccgc caaggccgtg gggcccttag ntgacaccgt gtgctcccca 300
gagggacccc tatttatggg aattatggta ttatatgctt cccacatact tggggctggc 360
atcccngct gagacagccc cctgttctat tcagctatat ggggagaaga gtagactttc 420
agctaagtga aaagtgnaac gtgctgactg tctgctgtcg tntactnat gctagcccga 480
gtgttcactc tgagcctgtt aaatataggc gggtatgtac c 521

```

```

<210> 20
<211> 521
<212> DNA
<213> primate

```

```

<220>
<221> CDS
<222> (1)..(369)

```

```

<220>
<221> misc_feature
<222> (281)
<223> note= "nucleotides 281, 367, 437, 462, and 468 are
            indicated c; each may alternatively be a, g, or t;
            translated amino acid depends on genetic code"

```

```

<400> 20
gac acg gat gag gac cgc tat cca cag aag ctg gcc ttc gcc gag tgc 48
Asp Thr Asp Glu Asp Arg Tyr Pro Gln Lys Leu Ala Phe Ala Glu Cys
 1          5          10          15

ctg tgc aga ggc tgt atc gat gca cgg acg ggc cgc gag aca gct gcg 96
Leu Cys Arg Gly Cys Ile Asp Ala Arg Thr Gly Arg Glu Thr Ala Ala
 20          25          30

ctc aac tcc gtg cgg ctg ctc cag agc ctg ctg gtg ctg cgc cgc cgg 144
Leu Asn Ser Val Arg Leu Leu Gln Ser Leu Leu Val Leu Arg Arg Arg
 35          40          45

ccc tgc tcc cgc gac ggc tcg ggg ctc ccc aca cct ggg gcc ttt gcc 192
Pro Cys Ser Arg Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala
 50          55          60

ttc cac acc gag ttc atc cac gtc ccc gtc ggc tgc acc tgc gtg ctg 240
Phe His Thr Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val Leu
 65          70          75          80

ccc cgt tca agt gtg acc gcc aag gcc gtg ggg ccc tta gct gac acc 288
Pro Arg Ser Ser Val Thr Ala Lys Ala Val Gly Pro Leu Ala Asp Thr
 85          90          95

gtg tgc tcc cca gag gga ccc cta ttt atg gga att atg gta tta tat 336
Val Cys Ser Pro Glu Gly Pro Leu Phe Met Gly Ile Met Val Leu Tyr
100          105          110

gct tcc cac ata ctt ggg gct ggc atc ccg cgc tgagacagcc ccctgttcta 389
Ala Ser His Ile Leu Gly Ala Gly Ile Pro Arg
115          120

```

ttcagctata tggggagaag agtagacttt cagctaagtg aaaagtgcaa cgtgctgact 449
 gtctgctgtc gtcctactca tgctagcccg agtggttcaact ctgagcctgt taaatatagg 509
 cggttatgta cc 521

<210> 21
 <211> 123
 <212> PRT
 <213> primate

<400> 21
 Asp Thr Asp Glu Asp Arg Tyr Pro Gln Lys Leu Ala Phe Ala Glu Cys
 1 5 10 15
 Leu Cys Arg Gly Cys Ile Asp Ala Arg Thr Gly Arg Glu Thr Ala Ala
 20 25 30
 Leu Asn Ser Val Arg Leu Leu Gln Ser Leu Leu Val Leu Arg Arg Arg
 35 40 45
 Pro Cys Ser Arg Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala
 50 55 60
 Phe His Thr Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val Leu
 65 70 75 80
 Pro Arg Ser Ser Val Thr Ala Lys Ala Val Gly Pro Leu Ala Asp Thr
 85 90 95
 Val Cys Ser Pro Glu Gly Pro Leu Phe Met Gly Ile Met Val Leu Tyr
 100 105 110
 Ala Ser His Ile Leu Gly Ala Gly Ile Pro Arg
 115 120

<210> 22
 <211> 1107
 <212> DNA
 <213> primate

<220>
 <221> CDS
 <222> (115)..(705)

<220>
 <221> mat_peptide
 <222> (166)..(705)

<400> 22
 gtgtggcctc aggtataaga gcggctgctg ccaggtgcat ggccaggtgc acctgtggga 60
 ttgccgccag gtgtgcaggc cgctccaagc ccagcctgcc ccgctgccgc cacc atg 117
 Met
 acg ctc ctc ccc ggc ctc ctg ttt ctg acc tgg ctg cac aca tgc ctg 165
 Thr Leu Leu Pro Gly Leu Leu Phe Leu Thr Trp Leu His Thr Cys Leu
 -15 -10 -5 -1

gcc cac cat gac ccc tcc ctc agg ggg cac ccc cac agt cac ggt acc 213
 Ala His His Asp Pro Ser Leu Arg Gly His Pro His Ser His Gly Thr
 1 5 10 15

cca cac tgc tac tgc gct gag gaa ctg ccc ctc ggc cag gcc ccc cca 261
 Pro His Cys Tyr Ser Ala Glu Glu Leu Pro Leu Gly Gln Ala Pro Pro
 20 25 30

cac ctg ctg gct cga ggt gcc aag tgg ggg cag gct ttg cct gta gcc 309
 His Leu Leu Ala Arg Gly Ala Lys Trp Gly Gln Ala Leu Pro Val Ala
 35 40 45

ctg gtg tcc agc ctg gag gca gca agc cac agg ggg agg cac gag agg 357
 Leu Val Ser Ser Leu Glu Ala Ala Ser His Arg Gly Arg His Glu Arg
 50 55 60

ccc tca gct acg acc cag tgc ccg gtg ctg cgg ccg gag gag gtg ttg 405
 Pro Ser Ala Thr Thr Gln Cys Pro Val Leu Arg Pro Glu Glu Val Leu
 65 70 75 80

gag gca gac acc cac cag cgc tcc atc tca ccc tgg aga tac cgt gtg 453
 Glu Ala Asp Thr His Gln Arg Ser Ile Ser Pro Trp Arg Tyr Arg Val
 85 90 95

gac acg gat gag gac cgc tat cca cag aag ctg gcc ttc gcc gag tgc 501
 Asp Thr Asp Glu Asp Arg Tyr Pro Gln Lys Leu Ala Phe Ala Glu Cys
 100 105 110

ctg tgc aga ggc tgt atc gat gca cgg acg ggc cgc gag aca gct gcg 549
 Leu Cys Arg Gly Cys Ile Asp Ala Arg Thr Gly Arg Glu Thr Ala Ala
 115 120 125

ctc aac tcc gtg cgg ctg ctc cag agc ctg ctg gtg ctg cgc cgc cgg 597
 Leu Asn Ser Val Arg Leu Leu Gln Ser Leu Leu Val Leu Arg Arg Arg
 130 135 140

ccc tgc tcc cgc gac ggc tgc ggg ctc ccc aca cct ggg gcc ttt gcc 645
 Pro Cys Ser Arg Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala
 145 150 155 160

ttc cac acc gag ttc atc cac gtc ccc gtc ggc tgc acc tgc gtg ctg 693
 Phe His Thr Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val Leu
 165 170 175

ccc cgt tca gtg tgaccgccga ggccgtgggg cccctagact ggacacgtgt 745
 Pro Arg Ser Val
 180

gctccccaga gggcaccccc tatttatgtg tatttattgg tatttatatg cctcccccaa 805

cactaccctt ggggtctggg cattccccgt gtctggagga cagccccca ctgttctcct 865

catctccagc ctcatgtgtt gggggtagaa ggagctcagc acctcttcca gcccttaaag 925

ctgcagaaaa ggtgtcacac ggctgctgt accttggtc cctgtcctgc tccggcttc 985

ccttacccta tcaactggct caggcccccg caggtgcct ctcccaacc tcttggaag 1045

taccctgtt tcttaacaa ttatttaagt gtacgtgtat tattaaactg atgaacacat 1105

cc

1107

<210> 23
 <211> 197
 <212> PRT
 <213> primate

<400> 23
 Met Thr Leu Leu Pro Gly Leu Leu Phe Leu Thr Trp Leu His Thr Cys
 -15 -10 -5
 Leu Ala His His Asp Pro Ser Leu Arg Gly His Pro His Ser His Gly
 -1 1 5 10 15
 Thr Pro His Cys Tyr Ser Ala Glu Glu Leu Pro Leu Gly Gln Ala Pro
 20 25 30
 Pro His Leu Leu Ala Arg Gly Ala Lys Trp Gly Gln Ala Leu Pro Val
 35 40 45
 Ala Leu Val Ser Ser Leu Glu Ala Ala Ser His Arg Gly Arg His Glu
 50 55 60
 Arg Pro Ser Ala Thr Thr Gln Cys Pro Val Leu Arg Pro Glu Glu Val
 65 70 75
 Leu Glu Ala Asp Thr His Gln Arg Ser Ile Ser Pro Trp Arg Tyr Arg
 80 85 90 95
 Val Asp Thr Asp Glu Asp Arg Tyr Pro Gln Lys Leu Ala Phe Ala Glu
 100 105 110
 Cys Leu Cys Arg Gly Cys Ile Asp Ala Arg Thr Gly Arg Glu Thr Ala
 115 120 125
 Ala Leu Asn Ser Val Arg Leu Leu Gln Ser Leu Leu Val Leu Arg Arg
 130 135 140
 Arg Pro Cys Ser Arg Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe
 145 150 155
 Ala Phe His Thr Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val
 160 165 170 175
 Leu Pro Arg Ser Val
 180

<210> 24
 <211> 403
 <212> DNA
 <213> primate

<220>
 <221> misc_feature
 <222> (1)..(403)
 <223> note= "n may be a, c, g, or t"

<400> 24
 gagaaagagc ttctctgcaca aagtaagcca ccagcgcaac atgacagtga agaccctgca 60

```

tggcccagcc atggtcaagt acttgctgct gtcgatattg gggcttgcc ttttgagtga 120
ggcggcagct cggaaaatcc ccaaagtagg acatactttt ttccaaaagc ctgagagttg 180
cccgccctgtg ccaggaggta gtatgaagct tgacattggc atcatcaatg aaaaccagcg 240
cgtttccatg tcacgtaaca tcgagagccg ctccacctcc ccctggaatt acaactgtcac 300
ttgggacccc aaccggtacc cctcgaagtt gtacaggccc aagtgtagga acttgggctg 360
tatcaatgct caaggaaagg aagacatctn catgaattcc gtc 403

```

<210> 25

<211> 403

<212> DNA

<213> primate

<220>

<221> CDS

<222> (71)..(403)

<220>

<221> mat_peptide

<222> (131)..(403)

<220>

<221> misc_feature

<222> (1)..(403)

<223> note= "n may be a, c, g, or t; translated amino acid depends on genetic code"

<400> 25

gagaaagagc ttcctgcaca aagtaagcca ccagcgcaac atgacagtga agaccctgca 60

```

tggcccagcc atg gtc aag tac ttg ctg ctg tcg ata ttg ggg ctt gcc 109
Met Val Lys Tyr Leu Leu Leu Ser Ile Leu Gly Leu Ala
-20 -15 -10

```

```

ttt ctg agt gag gcg gca gct cgg aaa atc ccc aaa gta gga cat act 157
Phe Leu Ser Glu Ala Ala Ala Arg Lys Ile Pro Lys Val Gly His Thr
-5 -1 1 5

```

```

ttt ttc caa aag cct gag agt tgc ccg cct gtg cca gga ggt agt atg 205
Phe Phe Gln Lys Pro Glu Ser Cys Pro Pro Val Pro Gly Gly Ser Met
10 15 20 25

```

```

aag ctt gac att ggc atc atc aat gaa aac cag cgc gtt tcc atg tca 253
Lys Leu Asp Ile Gly Ile Ile Asn Glu Asn Gln Arg Val Ser Met Ser
30 35 40

```

```

cgt aac atc gag agc cgc tcc acc tcc ccc tgg aat tac act gtc act 301
Arg Asn Ile Glu Ser Arg Ser Thr Ser Pro Trp Asn Tyr Thr Val Thr
45 50 55

```

```

tgg gac ccc aac cgg tac ccc tcg aag ttg tac agg ccc aag tgt agg 349
Trp Asp Pro Asn Arg Tyr Pro Ser Lys Leu Tyr Arg Pro Lys Cys Arg
60 65 70

```

```

aac ttg ggc tgt atc aat gct caa gga aag gaa gac atc tnc atg aat 397
Asn Leu Gly Cys Ile Asn Ala Gln Gly Lys Glu Asp Ile Xaa Met Asn
75 80 85

```

```

tcc gtc 403
Ser Val
90

```


<210> 26
 <211> 111
 <212> PRT
 <213> primate

<400> 26
 Met Val Lys Tyr Leu Leu Ser Ile Leu Gly Leu Ala Phe Leu Ser
 -20 -15 -10 -5
 Glu Ala Ala Ala Arg Lys Ile Pro Lys Val Gly His Thr Phe Phe Gln
 -1 1 5 10
 Lys Pro Glu Ser Cys Pro Pro Val Pro Gly Gly Ser Met Lys Leu Asp
 15 20 25
 Ile Gly Ile Ile Asn Glu Asn Gln Arg Val Ser Met Ser Arg Asn Ile
 30 35 40
 Glu Ser Arg Ser Thr Ser Pro Trp Asn Tyr Thr Val Thr Trp Asp Pro
 45 50 55 60
 Asn Arg Tyr Pro Ser Lys Leu Tyr Arg Pro Lys Cys Arg Asn Leu Gly
 65 70 75
 Cys Ile Asn Ala Gln Gly Lys Glu Asp Ile Xaa Met Asn Ser Val
 80 85 90

<210> 27
 <211> 784
 <212> DNA
 <213> primate

<220>
 <221> CDS
 <222> (3)..(281)

<400> 27
 tc gtg ccg tat ctt ttt aaa aaa att att ctt cac ttt ttt gcc tcc 47
 Val Pro Tyr Leu Phe Lys Lys Ile Ile Leu His Phe Phe Ala Ser
 1 5 10 15
 tat tac ttg tta ggg aga ccc aat ggt agt ttt att cct tgg gga tac 95
 Tyr Tyr Leu Leu Gly Arg Pro Asn Gly Ser Phe Ile Pro Trp Gly Tyr
 20 25 30
 ata gta aat act tca tta aag tcg agt aca gaa ttt gat gaa aag tgt 143
 Ile Val Asn Thr Ser Leu Lys Ser Ser Thr Glu Phe Asp Glu Lys Cys
 35 40 45
 gga tgt gtg gga tgt act gcc gcc ttc aga agt cca cac act gcc tgg 191
 Gly Cys Val Gly Cys Thr Ala Ala Phe Arg Ser Pro His Thr Ala Trp
 50 55 60
 agg gag aga act gct gtt tat tca ctg att aag cat ttg ctg tgt acc 239
 Arg Glu Arg Thr Ala Val Tyr Ser Leu Ile Lys His Leu Leu Cys Thr
 65 70 75
 aac tac ttt tca tgt ctt atc tta att ctc ata aca gtc att 281

Asn Tyr Phe Ser Cys Leu Ile Leu Ile Leu Ile Thr Val Ile
80 85 90

tgatatttta aaaaacccca gaaatctgag aaagagataa agtgggttgc tcaaggttat 341
agaacagact accatgtggt gtatttcaga ttttaattca tgtttgctg attttaagtt 401
ttgttcgctt gccagggtac ccacaaaaa tgccaggcag ggcattttca tgatgcactt 461
gagatacctg aaatgacagg gtagcatcac acctgagagg ggtaaaggat gggaacctac 521
cttccatggc cgctgcttgg cagtctcttg ctgcatgcta gcagagccac tgtatatgtg 581
ccgaggctct gagaattaac tgcttaaaga actgccttct ggagggagaa gagcacaaga 641
tcacaattaa ccatatacac atcttactgt gcgagggtcat tgagcaatac aggagggatt 701
ttatacatat tagcaactat cttcaaaacc tgagctatag ttgtattctg ccccttct 761
ctgggcaaaa gtgtaaaagt ttg 784

<210> 28
<211> 93
<212> PRT
<213> primate

<400> 28
Val Pro Tyr Leu Phe Lys Lys Ile Ile Leu His Phe Phe Ala Ser Tyr
1 5 10 15
Tyr Leu Leu Gly Arg Pro Asn Gly Ser Phe Ile Pro Trp Gly Tyr Ile
20 25 30
Val Asn Thr Ser Leu Lys Ser Ser Thr Glu Phe Asp Glu Lys Cys Gly
35 40 45
Cys Val Gly Cys Thr Ala Ala Phe Arg Ser Pro His Thr Ala Trp Arg
50 55 60
Glu Arg Thr Ala Val Tyr Ser Leu Ile Lys His Leu Leu Cys Thr Asn
65 70 75 80
Tyr Phe Ser Cys Leu Ile Leu Ile Leu Ile Thr Val Ile
85 90

<210> 29
<211> 460
<212> DNA
<213> primate

<220>
<221> CDS
<222> (1)..(189)

<400> 29
gtg act gta ttg tgg gga cag gaa gca caa att ccc atg tgg atc act 48
Val Thr Val Leu Trp Gly Gln Glu Ala Gln Ile Pro Met Trp Ile Thr
1 5 10 15

agg aga gat aat aag tgg ggt cat ttc acc cct tgg tcc cct gct tcc 96
 Arg Arg Asp Asn Lys Trp Gly His Phe Thr Pro Trp Ser Pro Ala Ser
 20 25 30

aga ccc aaa gag gcc tac atg gca ttg tgc ttc ctt ctt agt tgt agg 144
 Arg Pro Lys Glu Ala Tyr Met Ala Leu Cys Phe Leu Leu Ser Cys Arg
 35 40 45

agg tgt gag ata caa tca ttt gcc tct gac ttt gag ggt tgg tcc 189
 Arg Cys Glu Ile Gln Ser Phe Ala Ser Asp Phe Glu Gly Trp Ser
 50 55 60

tagcatgcc ctgaccagta gcccttaaa tacttcattg atatggaagg tctctgaatc 249

ttcgtgggct taatctacca ctctctgaag ttcttatgtc tttcaaaggc ctctaaaatc 309

tctgccatgt cttgctcatc cagttgttag catgatgtca ttgatacagt ggactttgga 369

atctaagtgg ggagacactg gtaagtgacc aattacttca cctgtggtgt gcaagccaga 429

tcaggaagcc tctacctgca cgacaacaca t 460

<210> 30
 <211> 63
 <212> PRT
 <213> primate

<400> 30
 Val Thr Val Leu Trp Gly Gln Glu Ala Gln Ile Pro Met Trp Ile Thr
 1 5 10 15

Arg Arg Asp Asn Lys Trp Gly His Phe Thr Pro Trp Ser Pro Ala Ser
 20 25 30

Arg Pro Lys Glu Ala Tyr Met Ala Leu Cys Phe Leu Leu Ser Cys Arg
 35 40 45

Arg Cys Glu Ile Gln Ser Phe Ala Ser Asp Phe Glu Gly Trp Ser
 50 55 60

<210> 31
 <211> 150
 <212> PRT
 <213> rodent

<400> 31
 Met Cys Leu Met Leu Leu Leu Leu Leu Asn Leu Glu Ala Thr Val Lys
 1 5 10 15

Ala Ala Val Leu Ile Pro Gln Ser Ser Val Cys Pro Asn Ala Glu Ala
 20 25 30

Asn Asn Phe Leu Gln Asn Val Lys Val Asn Leu Lys Val Ile Asn Ser
 35 40 45

Leu Ser Ser Lys Ala Ser Ser Arg Arg Pro Ser Asp Tyr Leu Asn Arg
 50 55 60

Ser Thr Ser Pro Trp Thr Leu Ser Arg Asn Glu Asp Pro Asp Arg Tyr

65 70 75 80
 Pro Ser Val Ile Trp Glu Ala Gln Cys Arg His Gln Arg Cys Val Asn
 85 90 95
 Ala Glu Gly Lys Leu Asp His His Met Asn Ser Val Leu Ile Gln Gln
 100 105 110
 Glu Ile Leu Val Leu Lys Arg Glu Pro Glu Lys Cys Pro Phe Thr Phe
 115 120 125
 Arg Val Glu Lys Met Leu Val Gly Val Gly Cys Thr Cys Val Ser Ser
 130 135 140
 Ile Val Arg His Ala Ser
 145 150

<210> 32
 <211> 147
 <212> PRT
 <213> rodent

<400> 32
 Met Leu Leu Leu Leu Leu Ser Leu Ala Ala Thr Val Lys Ala Ala Ala
 1 5 10 15
 Ile Ile Pro Gln Ser Ser Ala Cys Pro Asn Thr Glu Ala Lys Asp Phe
 20 25 30
 Leu Gln Asn Val Lys Val Asn Leu Lys Val Phe Asn Ser Leu Gly Ala
 35 40 45
 Lys Val Ser Ser Arg Arg Pro Ser Asp Tyr Leu Asn Arg Ser Thr Ser
 50 55 60
 Pro Trp Thr Leu His Arg Asn Glu Asp Pro Asp Arg Tyr Pro Ser Val
 65 70 75 80
 Ile Trp Glu Ala Gln Cys Arg His Gln Arg Cys Val Asn Ala Glu Gly
 85 90 95
 Lys Leu Asp His His Met Asn Ser Val Leu Ile Gln Gln Glu Ile Leu
 100 105 110
 Val Leu Lys Arg Glu Pro Glu Ser Cys Pro Phe Thr Phe Arg Val Glu
 115 120 125
 Lys Met Leu Val Gly Val Gly Cys Thr Cys Val Ala Ser Ile Val Arg
 130 135 140
 Gln Ala Ala
 145

<210> 33
 <211> 155
 <212> PRT
 <213> primate

<400> 33

Met Thr Pro Gly Lys Thr Ser Leu Val Ser Leu Leu Leu Leu Ser
 1 5 10 15
 Leu Glu Ala Ile Val Lys Ala Gly Ile Thr Ile Pro Arg Asn Pro Gly
 20 25 30
 Cys Pro Asn Ser Glu Asp Lys Asn Phe Pro Arg Thr Val Met Val Asn
 35 40 45
 Leu Asn Ile His Asn Arg Asn Thr Asn Thr Asn Pro Lys Arg Ser Ser
 50 55 60
 Asp Tyr Tyr Asn Arg Ser Thr Ser Pro Trp Asn Leu His Arg Asn Glu
 65 70 75 80
 Asp Pro Glu Arg Tyr Pro Ser Val Ile Trp Glu Ala Lys Cys Arg His
 85 90 95
 Leu Gly Cys Ile Asn Ala Asp Gly Asn Val Asp Tyr His Met Asn Ser
 100 105 110
 Val Pro Ile Gln Gln Glu Ile Leu Val Leu Arg Arg Glu Pro Pro His
 115 120 125
 Cys Pro Asn Ser Phe Arg Leu Glu Lys Ile Leu Val Ser Val Gly Cys
 130 135 140
 Thr Cys Val Thr Pro Ile Val His His Val Ala
 145 150 155

<210> 34
 <211> 151
 <212> PRT
 <213> viral

<400> 34

Met Thr Phe Arg Lys Thr Ser Leu Val Leu Leu Leu Leu Ser Ile
 1 5 10 15
 Asp Cys Ile Val Lys Ser Glu Ile Thr Ser Ala Gln Thr Pro Arg Cys
 20 25 30
 Leu Ala Ala Asn Asn Ser Phe Pro Arg Ser Val Met Val Thr Leu Ser
 35 40 45
 Ile Arg Asn Trp Asn Thr Ser Ser Lys Arg Ala Ser Asp Tyr Tyr Asn
 50 55 60
 Arg Ser Thr Ser Pro Trp Thr Leu His Arg Asn Glu Asp Gln Asp Arg
 65 70 75 80
 Tyr Pro Ser Val Ile Trp Glu Ala Lys Cys Arg Tyr Leu Gly Cys Val
 85 90 95
 Asn Ala Asp Gly Asn Val Asp Tyr His Met Asn Ser Val Pro Ile Gln
 100 105 110
 Gln Glu Ile Leu Val Val Arg Lys Gly His Gln Pro Cys Pro Asn Ser
 115 120 125

Phe Arg Leu Glu Lys Met Leu Val Thr Val Gly Cys Thr Cys Val Thr
130 135 140

Pro Ile Val His Asn Val Asp
145 150